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Magnesium and calcium transport in the kidney
Magnesium (Mg2+) and calcium (Ca2+) are essential ions for life. Careful maintenance 
of the levels of these ions in the body is paramount for proper functioning and 
survival. Adequate Mg2+ and Ca2+ homeostasis in the body is maintained by the 
uptake of these ions by the intestines, resorption in bone and excretion by the 
kidneys.1 The focus of this thesis will be on the kidney, which is essential for the 
careful management of ion concentrations in the blood.2 A kidney consists of 
approximately 1 million nephrons, which are the functional units that facilitate (ion) 
reabsorption (Figure 1). Every nephron consists of a glomerular filter and tubule, 
where metabolic waste products, ions and water are pushed into the luminal space 
of the tubule, leaving proteins and other large molecules behind in the bloodstream. 
The kidney is responsible for the recovery of 95-99% of the filtered Mg2+ and Ca2+ 
ions.1 The nephron is divided into several segments, each with unique properties for 
the reabsorption of ions and water. The segments most important for the uptake of 
Mg2+ and Ca2+ are the proximal tubule (PT), thick ascending limb of Henle’s loop (TAL), 
distal convoluted tubule (DCT) and connecting tubule (CNT) (Figure 1).
Proximal Tubule
In the first segment called the PT, 60-70% of the filtered Ca2+ is reabsorbed.3 The Na+- 
driven water uptake taking place in the proximal tubule causes an increase in the 
luminal concentration of Ca2+, subsequently driving passive diffusion through tight 
junctions between epithelial cells (Figure 1) and ending in the renal interstitium.4 
Only 10-25% of Mg2+ is reabsorbed in the proximal tubule via the same pathway.5, 6
Thick ascending limb of Henle’s loop
By combined action of the paracellular and transcellular transport process, the TAL is 
responsible for uptake of large amounts of Ca2+ (20-25%) and Mg2+ (50-70%).3, 7 
Paracellular transport means that ions are transported between cells, whereas 
transcellular transport takes ions through cells. The TAL is divided into two distinct 
segments, namely the medullary TAL (mTAL) and cortical TAL (cTAL). The mTAL is 
mostly responsible for the paracellular uptake of Na+ without the reabsorption of 
water.8 The decreased concentration of Na+ at the luminal side of the mTAL is 
hypothesized to facilitate the back leak of Na+ in the following segment the cTAL.9 
A strong lumen-positive voltage (+10mV) facilitates passive paracellular transport, 
which is promoted by the activity of the Na+-K+-2Cl- co-transporter (NKCC2) and the 
extrusion of K+ via the K+-channel ROMK at the apical membrane (Figure 2).3, 10 
Divalent cation reabsorption is mainly executed in the cTAL, which largely depends on 
tight junction permeability.11 Tight junctions in the TAL are occupied by a modular 
array of claudin proteins, an extensive gene family consisting of 24 members. The claudins 
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specific for the TAL are Claudin3, 10, 11, 14, 16, & 19. Depending on the configuration 
of claudins in the tight junction, the barrier is more permeable for cations versus 
anions and even changes the permeability for divalent versus monovalent cations.12 
The tight junction in the cTAL consists of Claudin3, 16 & 19 and is highly selective for 
the paracellular uptake of Mg2+ and Ca2+, whereas the tight junctions in the mTAL 
Figure 1 | Ca2+ and Mg2+ reabsorption along the nephron
Along the nephron 95-99% of Ca2+ and Mg2+ is reabsorbed. Bulk uptake of 60-70% of Ca2+ takes 
place along the whole proximal tubule (PT), whereas only 10-25% of Mg2+ is taken up in the late 
proximal tubule. In the thick ascending limb of Henle’s loop (TAL) 50-70% of Mg2+ is taken up 
by paracellular transport through the tight junctions between the TAL cells. A large part of the 
remaining Ca2+ 20-25% is taken up in the TAL as well. In the distal convoluted tubule (DCT) the 
remaining 10% of Mg2+ is taken up. No Mg2+ is taken up past this segment. The late DCT and 
connecting tubule (CNT) are responsible for another 5-10% of Ca2+ transport. Any remaining 
Ca2+ that requires to be reabsorbed (1-2%) is taken up in the collecting duct (CD). The remaining 
Ca2+ and Mg2+ are excreted via the urine.
   DCT     Ca2+  1-10%
             Mg2+ 1-10%
   CNT   Ca2+  1-10%
   
    CD   Ca2+  1-2%
   
   TAL  Ca2+  20-25%
      Mg2+  50-70%
    PT Ca2+  60-70%
   Mg2+ 10-25%
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mostly consist of Claudin10b and are highly selective for Na+ (Figure 2).8 Recent 
studies show that increased plasma Mg2+ and Ca2+ lead to changes in the configuration 
of the cTAL tight junctions by the addition of Claudin14 into the junction.13, 14 This 
shifts the preference of the tight junction from divalent cations, like Mg2+ and Ca2+, to 
monovalent ions like Na+, restricting Mg2+ and Ca2+ uptake into the bloodstream. This 
change in tight junction permeability is regulated by the calcium-sensing receptor 
(CaSR) (Figure 2).14, 15 
The distal convoluted tubule
The DCT is the last segment of the nephron that absorbs Mg2+.16 Contrary to upstream 
segments, the DCT actively reabsorbs Mg2+ via the apical Mg2+ ion channel transient 
receptor potential cation channel subfamily M, member 6 (TRPM6).17 Unlike Ca2+, 
there is no sufficient chemical gradient for Mg2+ to cross the plasma membrane, since 
luminal concentrations hover around 0.2-0.7 mM and intracellular concentrations 
vary between 0.5-1.0 mM. Therefore, Mg2+ reabsorption via TRPM6 relies on a 
negative membrane potential (-5mV).1 The maintenance of this negative membrane 
potential is highly reliant on K+ extrusion via either the Kv1.1 or ROMK channel and 
uptake of Na+ via the thiazide-sensitive Na-Cl-cotransporter (NCC) (Figure 3).18-20 The 
mechanism behind Mg2+ extrusion from the basolateral side of the DCT is still 
unknown. Several proteins are suggested to transport Mg2+ across the basolateral 
membrane. Recent studies implicate solute carrier family 41 member 1 (SLC41A1), 
which has been previously identified as a Na+-driven Mg2+ extruder.21 Others 
identified solute carrier family 41 member 3 (SLC41A3) as the potential basolateral 
Mg2+ extruder, since it was significantly increased in the DCTs of mice that were fed a 
low Mg2+-diet and loss of SLC41A3 in zebrafish resulted in renal Mg2+ wasting.22, 23 
However, it is still unclear whether SLC41A1 or SLC41A3 are expressed at the 
basolateral side of the DCT and how they function on the physiological level. Although 
the exact means of Mg2+ transport here are unknown, a negative membrane potential 
is essential to provide Mg2+ with an electrochemical driving force to cross the 
basolateral membrane. This membrane potential is maintained by the continuous 
recycling of K+, which is extruded by the Kir4.1/Kir5.1 inward rectifying K+ channel and 
taken up and exchanged for Na+ by the basolateral Na+-K+-adenosine triphosphatase 
(Na+-K+-ATPase) (Figure 3).24-26 This ensures that Mg2+ can be efficiently extruded 
across the basolateral membrane.
The connecting tubule
The final fraction of Ca2+ is reabsorbed actively in the late DCT and CNT (Figure 1) via 
the epithelial Ca2+ channel transient receptor potential vanilloid 5 (TRPV5) and 
extruded by the Na+-Ca2+ exchanger (NCX1) and the plasma membrane Ca2+-ATPase 
(PMCA1b).3, 27 The remaining Mg2+ and Ca2+ (1-2%) is excreted by the kidney.28  
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Figure 2 | Mechanisms of Ca2+ and Mg2+ transport in the TAL
The Claudin3/16/19 tight junction complex facilitates the reabsorption of Ca2+ and Mg2+ from 
the pro-urine. The Na+-K+-2Cl- cotransporter and the K+-channel ROMK maintain a positive 
membrane potential, which promotes the paracelllular transport of Ca2+ and Mg2+ in the tight 
junctions. An abundance of Ca2+ and Mg2+ at the basolateral side of the cell will activate the G 
protein-coupled Ca2+-sensing receptor (CaSR) by the binding of Ca2+ and Mg2+ to the receptor. 
Activation of the CaSR will increase intracellular Ca2+ concentrations, which then acts as a 
signaling molecule, and causes downregulation of microRNAs (miRNA) Mir-9 and Mir-374b 
expression levels in the nucleus. Downregulation of these miRNAs will increase the production 
of Claudin14 protein, which in turn will be incorporated into the Claudin3/16/19 complex. 
Inclusion of the Claudin14 protein in the tight junction complex shifts the ion permeability 
towards monovalent cations like Na+ instead of divalent cations, decreasing the reabsorption 
of Ca2+ and Mg2+ in the TAL.
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Figure 3 | Mechanisms of Ca2+ and Mg2+ transport in the DCT
In the DCT, TRPM6 facilitates Mg2+ uptake from the pro-urine. This is dependent on the voltage 
gated back leak of K+ via the ROMK K+-channel and the uptake of Na+ and Cl- via the Na+-Cl- 
cotransporter (NCC). At the basolateral membrane an as of yet unknown Mg2+ transporter 
extrudes Mg2+ outside the cell. This process is highly reliant on a positive Na+ gradient, which 
is maintained by the Na+-K+-ATPase. Na+-K+-ATPase activity is in turn dependent on the 
continuous recycling of K+ via the Kir4.1/Kir5.1 potassium channel. This process in turn also 
facilitates the extrusion of Cl- via the Chloride channel protein Kb (ClC-Kb). Transcription factor 
HNF1β is a known transcriptional regulator of the FXYD domain containing ion transport 
regulator 2 (FXYD2) gene, which encodes for the y-subunit of the Na+-K+-ATPase. Activation of 
the epidermal growth factor receptor (EGFR) and insulin receptor (IR) by their respective 
signaling molecules results in an intracellular signaling cascade, which results in increased 
TRPM6 membrane expression. Additionally, estrogens stimulate TRPM6 mRNA expression.
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Mg2+ and Ca2+ electrolyte disorders in the thick  
ascending limb of Henle’s loop
Over the decades, various gene mutations have been described that resulted in 
disturbed Mg2+ and Ca2+ reabsorption in the TAL. In this segment, the most common 
genetic disturbances of ion reabsorption will be described.
Bartter syndrome
The most common electrolyte disorder is Bartter syndrome, which is characterized 
by hypokalemic alkalosis, elevated renin and aldosterone levels, and low blood 
pressure.29 Bartter syndrome is caused by a mutation in either solute carrier family 
12 member 1 (SLC12A1) encoding for NKCC2 (Bartter syndrome type 1; OMIM: 601678), 
ATP-sensitive inward rectifier potassium channel 1 (KCNJ1) (Bartter syndrome, type 2; 
OMIM: 600359) encoding for ROMK, Chloride channel protein ClC-Kb (CIC-Kb) (Bartter 
syndrome, type 3; OMIM: 602023), Barttin (Bartter syndrome, type 4; OMIM: 606412) 
and the CaSR (Bartter syndrome, type 5; OMIM: 601199).30-33 Bartter’s syndrome 
type 5 is accompanied with hypocalcemia, hypercalciuria and hypomagnesemia due 
to activating mutations in the CaSR. Increased activation of the CASR is known to 
inhibit the activity of the ROMK channel in rats, which explains the Bartter’s syndrome 
symptoms observed in these CaSR patients.34
Autosomal dominant hypocalcemia and familial hypocalciuric 
hypercalcemia
Mutations in the CaSR can be activating or inactivating, depending on the nature of 
the mutation, which leads to opposing phenotypes.35, 36 Heterozygous gain-of-function 
mutations cause autosomal dominant hypocalcemia (ADH: OMIM 601198). These 
patients suffer from renal Mg2+ wasting, hypomagnesemia, renal Ca2+ wasting and 
hypocalcemia often combined with hypoparathyroidism.37 In around 50% of the 
cases the resulting hypocalcemia and hypomagnesemia is mild and asymptomatic, 
the other 50% experiences paresthesias, carpopedal spasm, and seizures. 10% of 
patients also develop nephrocalcinosis, fully mimicking the FHHNC type 1 phenotype 
at the renal level. In 35% of patients, additional ectopic and basal ganglia calcifications 
have been found.38 Loss-of-function mutations in the CaSR cause familial hypocalciuric 
hypercalcemia (FHH: OMIM 145980), which results in the hyperabsorption of Ca2+ 
and Mg2+ and subsequent low levels in the urine. Additional nephrolithiasis and 
peptic ulcers are relatively uncommon. Since most patients are asymptotic, the disorder 
is considered mostly benign.39 
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Familial hypomagnesemia with hypocalcuria and nephrocalcinosis  
type 1 & 2
Several mutations directly disturb the tight junctions in the TAL. Mutations in Claudin16 
(CLDN16) are known to cause familial hypomagnesemia with hypocalcuria and 
nephro calcinosis Type I (FHHNC type 1; OMIM: 248250).40 Patients with mutations 
in CLDN16 suffer from renal Mg2+ wasting, hypomagnesemia, renal Ca2+ wasting, 
nephro calcinosis and renal failure. Other segments like the DCT and CNT cannot 
compensate for the loss of Mg2+ and Ca2+ reabsorption in the TAL. Treatment with 
Mg2+ supplementation is not able to restore Mg2+ levels or alleviating other symptoms 
in patients.41 Several dozen mutations in CLDN16 have been described and all are 
characterized by a recessive mode of inheritance.42 Similarly, mutations in CLDN19 
are also known to cause familial hypomagnesemia with hypocalcuria and nephrocal-
cinosis (FHHNC type 2; OMIM: 248250). These patients suffer from a severe hypo-
magnesemia combined with hypercalciuria and nephrocalcinosis. Additionally, patients 
develop ocular defects as claudin19 is expressed in the retina.43 Furthermore, FHHNC 
type 2 patients seem to be more prone to developing chronic kidney disease (CKD) 
and develop this disease earlier in life than FHHNC type 1 patients.42 As with FHHNC 
type 1, oral Mg2+ supplementation or use of thiazide diuretics does not significantly 
improve serum Mg2+ levels.42 As described earlier Claudin16 and Claudin19 are the 
main components for the Mg2+ and Ca2+ selective tight junction pore. Mutations in 
either CLDN16 or CLDN19 cause a reduction in the tight junction selectivity for Ca2+ 
and Mg2+, decreasing the influx of Mg2+ and Ca2+ through the tight junction pore.9 
Depending on the nature of the mutation misfolding of the claudin protein can also 
occur relegating it to the endoplasmatic reticulum (ER), which changes the claudin 
configuration in the tight junctions in the TAL.44, 45 
Mg2+ and Ca2+ electrolyte disorders in the distal  
convoluted tubule
Disturbed Mg2+ reabsorption in the DCT typically leads to renal Mg2+ wasting and 
subsequent hypomagnesemia, since the DCT is the final point for Mg2+ reabsorption 
in the renal tubule. Several genetic disorders that cause Mg2+ disorders are due to 
defects in the DCT. 
Mutations in the epithelial Mg2+ channel TRPM6
Autosomal-recessive mutations in Mg2+ channel TRPM6 are known to cause severe 
hypomagnesemia (0.1-0.3 mmol/L) and secondary hypocalcemia (HSH, OMIM: 
602014), resulting in severe muscular and neurological complications including 
seizures and mental retardation.46, 47 Since TRPM6 is expressed in both the intestines 
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and kidney defects result in reduced intestinal reabsorption and renal Mg2+ wasting, 
explaining the severity of the phenotype.17 Mg2+ supplementation does improve 
serum Mg2+ levels, but in general do not recover to normal levels.48 In mice, knocking 
out Trpm6 results in early neonatal lethality, however heterozygous Trpm6 knockout 
(KO) mice already display decreased Mg2+ reabsorption and wasting.49 
Mutations in regulators of TRPM6 result in hypomagnesemia  
and renal Mg2+ wasting
An important stimulator of TRPM6 function is the epidermal growth factor (EGF) 
hormone. A mutation in EGF was reported to cause isolated autosomal recessive 
hypomagnesemia (IRH, OMIM: 611718).50 The patients suffered from epileptic 
seizures and psychomotor retardation. Plasma renin activity, plasma aldosterone, 
and parathyroid hormone concentrations were normal. The patient mutation leads to 
impaired basolateral sorting of EGF, which hampers to induce the signaling cascade 
required for TRPM6 activation.51, 52 Injecting wildtype mice with EGF receptor (EGFR) 
inhibitor erlotinib does indeed cause a small but significant decrease in serum Mg2+ 
levels.53 Furthermore, colorectal cancer patients that were treated with EGFR 
antagonist cetuximab develop hypomagnesemia. It is therefore no suprise that a 
patient with a mutation in the EGFR also developed hypomagnesemia.54 This provides 
additional evidence that EGF is an important signaling hormone for maintaining Mg2+ 
homeostasis.51 
Gitelman syndrome
Defects in solute carrier family 12 member 3 (SLC12A3) encoding for NCC cause 
Gitelman syndrome (OMIM: 263800), a disorder characterized by Dr. Gitelman in 
1966.55 Patients present with hypomagnesemia, hypokalemia, hypocalciuria and 
metabolic alkalosis, which is in some occasions associated with mild hypotension. 
Patients are generally treated with Mg2+ supplementation.56 In some cases this 
resulted in restored K+ levels showing that the hypokalemia is likely secondary to the 
hypomagnesemia.57 NCC KO mice confirm this hypothesis, since they are 
hypomagnesemic but present with normal K+ levels under basal conditions.58 
Interestingly, NCC KO mice have significantly reduced TRPM6 expression levels, which 
would explain the observed hypomagnesemia.59 However, it is as of yet unclear why 
a loss in NCC function results in decreased TRPM6 expression. Although it has been 
suggested that atrophy of the DCT segment could in part explain this phenomenon.60 
SeSAME-EAST syndrome
Mutations in ATP-sensitive inward rectifier potassium channel 10 (KCNJ10) encoding 
for the Kir4.1 inward rectifying K+ channel lead to Seizures, Sensorineural deafness, 
Ataxia, Mental retardation and Electrolyte imbalance or Epilepsy, Ataxia, Sensorineural 
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deafness, Tubulopathy (SeSAME-EAST, OMIM: 612780).26, 61, 62 Patients have marked 
electrolyte abnormalities reminiscent of Gitelman syndrome, including severe 
hypomagnesemia, hypokalemia and metabolic alkalosis. In some patients’ high renin, 
aldosterone levels, salt craving and polyuria were observed. K+ channel subunit Kir4.1 
together with the ATP-sensitive inward rectifier potassium channel 16 (KCNJ16) 
encoding for the Kir5.1 K+-channel subunit are responsible for maintaining the 
basolateral membrane potential in the DCT (Figure 3). Any defects in Kir4.1 functioning 
lead to decreased K+ availability, which decreases Na+-K+-ATPase activity. It is 
hypothesized that decreased activity of the Na+-K+-ATPase will depolarize the 
basolateral membrane potential. In turn this will hamper the extrusion of CI- by the 
CIC-Kb channel. A rise in intracellular CI- inhibits NCC activity, which in turn is required 
for Mg2+ reabsorption by TRPM6. Indeed, kidney-specific Kir4.1 KO mice showed 
decreased NCC activity and expression. These mice exhibited hypochloremic 
metabolic alkalosis with hypokalemia and urinary Na+, K+ and Mg2+ wasting.63 No 
TRPM6 activity or expression levels were measured to assess the direct effect of 
Kcnj10 loss on TRPM6 functioning. To compensate for the loss of Na+ in the DCT by 
decreased NCC functioning, epithelial Na+-channel (ENaC) activity in the CNT and CD 
is increased at the expense of increased K+ extrusion via ROMK. Therefore, 
SeSAME-EAST patients suffer from both hypomagnesemia and hypokalemia. 
Treatment usually involves Mg2+ and K+ supplementation in combination with 
aldosterone antagonists or ENaC inhibitors.24 Additionally Kir4.1 patients suffer from 
severe seizures, cerebellar ataxia and hearing loss, due to the loss of Kir4.1 functioning 
in neurons and glial cells.64
Na+-K+-ATPase у-subunit
Direct disturbances in Na+-K+-ATPase functioning in the DCT can be attributed to 
missense mutations in the FXYD domain containing ion transport regulator 2 (FXYD2) 
encoding for the у-subunit of the Na+-K+-ATPase. The c.121G>A mutation in FXYD2 
results in a p.Gly41Arg missense mutation, which causes misrouting of the у-subunit 
to the membrane, decreasing the activity of the Na+-K+-ATPase.65, 66 Curiously, this 
did not result in a SeSAME-EAST-like phenotype. Patients diagnosed with dominant 
isolated hypomagnesemia (IDH, OMIM: 154020) suffer from a severe renal Mg2+ 
wasting and hypomagnesemia (0.4 mmol/L) lacking any other electrolyte disturbances 
except for a slight loss of Ca2+ in the urine. The exact role of the у-subunit remains 
unclear. It is hypothesized to stabilize the alpha and beta-subunit of the Na+-K+-ATPase 
at the membrane. Other reports show that the у-subunit might function as an inward 
rectifier channel on its own.67 Although, this seems unlikely, since there is no evidence 
for the existence of such a channel in vivo.
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Autosomal Dominant Tubulointersitial Kidney Disease (HNF1β)
Deletions or mutations in hepatocyte nuclear factor 1 homeobox β (HNF1β), encoding 
for the transcription factor HNF1β, cause autosomal dominant tubulo-interstitial 
kidney disease (ADTKD-HNF1β, OMIM: 137920). HNF1β is a transcription factor 
important for regulating gene expression in kidney development.68 Patients suffer 
from a heterogeneous phenotype, which is characterized by renal cysts and maturity 
onset diabetes of the young (MODY).69-74 Around 50% of the patients are affected by a 
whole-gene deletion at the 17q12 position in the genome, which contains around ~10 
genes including HNF1β. The remaining cases consist of point mutations along the 
entire coding sequence.69, 75 An extensive meta-analysis of HNF1β patients with point 
mutations or whole-gene deletions demonstrated that there were no phenotypical 
differences with regard to the kidney or MODY defects.76 However, 40% of 17q12 
patients exhibited a neurodevelopmental disorder compared to the intragenic mutations, 
which is possibly caused by one of the other genes missing in these patients.77 HNF1β 
patients are also known to present with a wide variety of renal and extra-renal 
symptoms like, genital tract malformation (CAKUT),78, 79 abnormal liver function,80 
pancreatic hypoplasia,81 hyperparathyroidism and electrolyte disturbances.69, 82, 83 
De novo mutations in the HNF1β gene are encountered in 30-50% of new cases, 
which might explain the high phenotypical heterogeneity observed in patients.84 
The electrolyte disorder is characterized by a hypomagnesemia, hypokalemia, 
hypocalcuria and metabolic alkalosis mimicking both Gitelman and SeSAME-EAST 
syndrome. Renal cysts are reported in ~70% of patients, MODY in ~50% and 
hypomagnesemia in ~45%.69
Hyperphenylalaninemia, BH4-deficient, D
Patients with mutations in pterin-4a-carbinolamine dehydratase/dimerization factor 
(PCBD1) were diagnosed with hypomagnesemia, renal Mg2+ loss and in two cases 
MODY (Hyperphenylalaninemia, BH4-deficient, D; OMIM: 126090).85 This was 
attributed to the fact that PCBD1 is a crucial binding factor and coactivator of HNF1α 
and HNF1β, which explains the commonalities between ADTKD-HNF1β and the PCBD1 
patient phenotypes.86, 87 
Kenny-Caffey syndrome type 2 (FAM111a)
Although ubiquitously expressed throughout the body, mutations in FAM111a gives 
rise to a rather specific disease phenotype. Patients suffer from a severe short stature, 
gracile bones, severe bouts of hypocalcemia, low levels of parathyroid hormone 
(PTH) and hypomagnesemia.88-91 The most commonly found mutation c.1706G>A 
(p.Arg569His) results in a milder phenotype known as Kenny-Caffey syndrome type 2 
(KCS, OMIM: 244460), whereas mutations and deletions at or surrounding the 
c.1026_1028delTTC (p.Ser342del) develop osteocraniostenosis (OCS, OMIM: 
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602361).88, 92 The difference between both syndromes is mainly severity. Whereas 
KCS patients can survive well into adulthood, OCS patients usually do not survive 
beyond the neonatal period. KCS type 2 patients are often treated with Ca2+ and 
vitamin D supplementation, although this often does not sufficiently correct Ca2+, 
Mg2+ and PTH deficiencies.92 Mg2+ supplementation tends to correct the Ca2+ and 
PTH deficiency much more effectively.88 This has led to the hypothesis that the Mg2+ 
deficiency could be the primary defect in KCS type 2. However, little is known about 
FAM111as’ function. Over the years FAM111a has been mainly implicated as an 
inhibitor of SV40 and adenovirus replication.93 Recently FAM111a was identified as a 
binding partner of the proliferating cell nuclear antigen (PCNA).94 PCNA is a key 
docking protein involved in the mitotic replication process, where it recruits other 
proteins involved in the replication process. It is hypothesized that FAM111a facilitates 
this docking process by binding PCNA and stabilizing it on both DNA strands.94 It 
remains however unclear how an electrolyte disorder with such specific symptoms as 
Kenney-Caffey syndrome type 2 is caused by a general defect in DNA replication. As 
of yet there are no FAM111a KO models to study the pathophysiology of Kenney-Caffey 
syndrome type 2.  
Regulatory mechanisms of ion transport
Paracrine regulation
The rate-limiting factor for a kidney cell to transport Ca2+ or Mg2+ across the plasma 
membrane is determined by the amount of Ca2+ or Mg2+ ions that can enter through 
a single channel or transporter and the amount of channels or transporters that are 
located at the membrane at any given moment (Figure 4, #1). There are several 
cellular processes at various levels that regulate either the activity or abundance of 
ion channels. Post-translational modification of ion channels and transporter like 
phosphorylation or glycosylation can dramatically alter transport dynamics at the 
cell-surface (Figure 4, #6).95, 96 A fast regulatory mechanism is the insertion and 
retrieval of channels from the cell surface, which enables a rapid cellular response to 
fast ion fluxes. Upon retrieval, channels can either be degraded or re-enter into the 
plasma membrane (Figure 4, #4,5). In the DCT, EGF facilitates such a response by 
quickly recruiting TRPM6 to the apical membrane by initiating an intracellular 
signaling cascade.51 Another crucial regulator is insulin, which can directly affect 
TRPM6 activity through cyclin-dependent kinase 5 (cdk5)-dependent phosphoryla-
tion of the channel (Figure 3).95 An important signaling molecule for regulating Ca2+ 
and Mg2+ transport is adenosine triphosphate (ATP). ATP acts as an autocrine and 
paracrine signalling molecule modulating ion transport processes in the kidney and 
intestine.97, 98 High amounts of ATP (25-100 µmol/L) are released in response to 
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Figure 4 |  Regulatory mechanisms involved in the expression of ion channels at  
the plasma membrane.
1) Autocrine release of adenosine triphosphate (ATP) stimulates purinergic channels to increase Ca2+ 
uptake into the cell. Binding of Ca2+ and Mg2+ activates a G protein-coupled protein receptor, 
which initiates an intracellular pathway that results in the release of intracellular Ca2+ from the 
endoplasmatic reticulum (ER). 2) The increase in intracellular Ca2+ changes transcription factor 
(TF) binding to specific sites in the promoter. 3) Post-transcriptional modifications like miRNA 
binding to the 3’-UTR reduces mRNA levels and facilitates gene silencing. 4) Translation. 5) Post- 
translation; Vesicular insertion and retrieval. 6) Post-translational modification; Phosphorylation 
and glycosylation.
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various stimuli like flow and neuronal activation.99 Extracellular ATP activates 
purinergic receptors, like P2X and P2Y receptors, to facilitate or inhibit the 
non-selective influx of cations (Figure 4, #1).97 For example, extracellular ATP release 
is known to inhibit ENaC mediated Na+ uptake in the collecting duct.100 In the DCT, 
P2X4 and P2X6 are the most abundant purinergic receptors and recently it has been 
shown that P2X4 inhibits TRPM6 mediated Mg2+ uptake.101 However more research 
is needed to elucidate how purinergic signaling is influencing TRPM6 activity.
Mg2+ and Ca2+ sensing 
The CaSR is a G-protein coupled receptor (GCPR) expressed on the basolateral side of 
the TAL.102 Both Ca2+ and Mg2+ can bind and activate the receptor to regulate 
reabsorption of Ca2+ and Mg2+.103 Although, a five-fold higher concentration of Mg2+ 
then Ca2+ is needed to elicit the same CaSR-mediated intracellular Ca2+ response. 
Investigations in microperfused rat cTAL, show that acute inhibition of the CaSR 
increases the permeability to Ca2+ of the paracellular pathway instead of altering 
NaCl reabsorption or change the transepithelial potential difference.104 CaSR 
stimulation activates a transcriptional pathway to decrease the transcript levels of 
two microRNAs (miRNA), Mir-9 and Mir-374.13, 15, 105 MiRNAs are single-stranded, 
non-coding RNAs of 19-25 nucleotides. MiRNAs can bind the 3’-untranslated region 
(3’-UTR) of messenger RNAs (mRNA) and result in the degradation of the targeted 
mRNA. In this way miRNAs control the amount of mRNA that is translated into protein 
(Figure 4, #3).106 Mir-9 and Mir-374 are known to target the 3’-UTR of CLDN14. 
Activation of the CaSR decreases the amount of available Mir-9 and Mir-374. In turn, 
this facilitates CLDN14 mRNA translation into protein and targeting to the tight 
junction decreasing Mg2+ and Ca2+ reabsorption in the TAL (Figure 2).13 In case of an 
activating CaSR mutation, the CaSR signaling pathway is overactive resulting in an 
increase in claudin14 in the mTAL tight junctions, which hampers the uptake of Ca2+ 
and Mg2+. Injecting wild-type mice with CaSR agonist cinacalcet did indeed increase 
Claudin14 expression and a subsequent decrease in Ca2+ and Mg2+ uptake. In contrast, 
injections with CaSR antagonist NPS-2143 resulted in the opposite effect.15 Taken 
together, this data adequately explains what occurs in patients that suffer from 
activating (ADH) or inactivating (FHH) CaSR mutations.
Transcriptional regulation
Transcriptional regulation is responsible for the long-term control of ion channel 
abundance at the cell surface. Activation of GCPRs, Ca2+-channels, or the diffusion of 
lipophillic hormones into the intracellular compartment can initiate signaling cascades 
that stimulate various transcription factors.15, 107-110 Transcription factors bind to the 
responsive elements within proximal promoters of target genes and modulate the 
recruitment of the transcriptional machinery needed to start transcription at the 
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transcription start site (TSS) (Figure 4, #2). Downstream, upstream or intronic 
enhancer and silencer sites regulate gene transcription by providing binding elements/
sequences for regulatory proteins that affect promoter activity. These sequence 
motifs are specific to an enhancer-transcription factor and often highly conserved 
between species. Additionally, the level of chromatin packing can significantly alter 
the levels of transcription. The last layer of regulation appears at the post-transcrip-
tional level, splicing, 5’-methyl capping, polyadenylation and cleavage initiated by 
small RNAs are determining whether mature RNA is degraded or translated in 
ribosomes. MiRNAs silence target mRNAs through translational repression affecting 
the rate of protein synthesis and eventually the number of ion channels available at 
the plasma membrane (Figure 4, #4,5,6). Along the nephron, a pattern of seg-
ment-specific and more ubiquitous transcription factors has been identified.111 
However, the transcriptional targets of these transcription factors remain elusive and 
therefore also their effect on electrolyte reabsorption. It has been shown that Mg2+ 
depletion increases human CLDN16 promoter activity and the addition of Mg2+ 
decreased its activity in transfected human embryonic kidney (HEK293) cells.112 
Although as of yet, no Mg2+ responsive element was identified that affects the 
promoter activity of CLDN16. Similar experiments found that the addition of 
1,25- dihydroxyvitamin D3 (1,25(OH)2D3) inhibits CLDN16 promoter activity in 
HEK293.113 Adding transiently transfected CaSR significantly increased the inhibitory 
effect, which was explained as a compensatory mechanism for 1,25(OH)2VitD3- 
mediated intestinal uptake. Although, experiments in mice show that activation of 
the CaSR regulates expression of CLDN14 via a nuclear factor of activated T-cells 
(NFAT)-mediated pathway. In contrast, the expression levels of Claudin16 and 
Claudin19 were unaffected.15 In DCT, the transcriptional regulation of Mg2+ and Ca2+ 
transport has been studied in a limited capacity. A KO mouse model of potassium 
channel subunit Kir4.1 demonstrated a decrease in NCC expression levels in the 
DCT.63 Furthermore, it is known that TRPM6 expression levels are modulated by 
estrogen in wild-type mice.50 EGF-induced modulation of TRMP6 mRNA levels was 
identified to be mediated via an ERK/AP-1-dependent pathway. As mutations in the 
binding sites of AP-1 in the promoter sequence of TRPM6 abolished the EGF-induced 
increase in TRPM6 mRNA levels.109 It is however in general unclear, which transcrip-
tional elements are involved and what their exact transcriptional targets are in the 
DCT (Figure 3). 
Transcriptional regulation by HNF1β: a master regulator of 
Mg2+ transport
An important player in the transcriptional regulation of Mg2+ transport is HNF1β. 
HNF1β is part of the homeodomain-containing transcription factors. It binds to DNA 
through a typical POU-region and an atypical POU homeodomain (POUH), which 
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specifically recognize the consensus sequence 5’-RGTTAATNATTAAC-3’ (R: purine, N: 
unspecified nucleotide;). HNF1β forms homodimers or heterodimers with the related 
HNF1α through its dimerization domain and requires dimerization factor pterin-4-al-
pha-carbinolamine dehydratase (PCBD1) to facilitate this dimerization.85, 86 HNF1β is 
ChIP-seq (BOX1) 
In general, transcription factors have thousands of bindings sites in the genome. 
All of which can potentially contribute to the transcription of target genes. The 
classic binding site for a transcription factor is located in the proximal promoter 
directly upstream of the TSS.121 In silico analysis can reveal predicted binding sites 
that match with a motif specific for a transcription factor in the target promoter. 
However, numerous downsides are that only one target promoter is analyzed and 
predicted binding sites in silico are not necessarily real in vitro. Additionally, 
potential binding sites upstream or downstream of that promoter can be missed. 
Therefore, chromatin immunoprecipitation and sequencing (ChIP-seq) has been 
developed for genome-wide assessment of all protein-DNA interactions for a 
single transcription factor or histone modification.122 Nuclei are extracted from 
the cell or tissue sample and all chromatin is crosslinked, ensuring that all 
DNA-bound proteins remain fixed. The crosslinked chromatin is than sheared into 
smaller fragments; around the 200-600 base pair (bp) range, either by sonication 
or through an enzymatic process. Now a highly specific antibody against the 
transcription factor or histone modification of interest is used to immunoprecipi-
tate the protein-DNA complex from the chromatin sample. After decrosslinking, 
these samples are sequenced using a next generation sequencing platform. 
Between 100-400 million reads are generated in a single run of which ~60-80% 
can be aligned uniquely to the genome. The resulting dataset consists of a 
genome-wide map of all binding sites of the transcription factor specific to the 
used cell or tissue type. There are however certain downsides to ChIP-seq that 
have to be considered. For example, antibody quality is very important to generate 
specific and low-noise data. If such a ChIP-grade antibody is not available then 
ChIP-seq can either result in low quality data or could be no option at all. 
Furthermore, sample quantity can be a limiting factor. The average ChIP-seq 
experiment requires ~106-107 cells and between 10-100ng of DNA. Although 
advances in ChIP protocols and sequencing techniques means that nowadays 
ChIP-seq experiments can be performed with as little as ~104-105 cells.121, 123 It is, 
therefore, possible to perform ChIP-seq on rare cell populations or valuable 
tissues.
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RNA-seq (BOX2) 
In general, mRNA levels in various cell and tissue types are assessed by real-time 
quantitative PCR (RT-qPCR). Although this method is extremely sensitive and 
precise, it comes with a large drawback. As it is only feasible to investigate the 
transcriptional levels of a relatively small sample of target genes and that these 
targets have to be determined a priori based on previous knowledge. To investigate 
the effect of a treatment on a specific cell and tissue type it is often preferable to 
proceed with an unbiased approach and assess the complete transcriptional 
profile. This is possible with RNA-sequencing, which is a next generation sequencing 
method that allows for the genome-wide assessement of the complete transcriptome 
in a given sample. RNA-seq sets out to determine all species of transcript, including 
mRNAs, non-coding RNAs and small RNAs. In addition, it provides information on 
the transcriptional structure of genes, in terms of their 5’ and 3’ ends, start sites, 
splicing patterns and other post-transcriptional modifications. Furthemore, RNA-seq 
allows for the quantification of changing expression levels of each transcript over 
time and under various conditions. In general, RNA is isolated from a cell or tissue 
type of interest and then converted to a library of cDNA fragments with adaptors 
on one or both ends, which are used as an identifiying tag for the library. This 
RNA-seq library is then often amplified (depending on the sequencing platform) 
and sequenced in a high-throughput manner to obtain short sequences from one 
end (single-end sequencing) or both ends (pair-end sequencing). The sequenced 
reads tend to be between 30-400 bp in length depending on the sequencing 
platform. After sequencing, the reads are aligned to either a reference genome or 
reference transcripts to provide a genome-wide map for transcription that 
contains the information on both expression levels and transcriptional structure.124 
RNA-seq has a couple of distinct advantages over micro-array based techniques. 
For example, RNA-seq is not limited to the detection of sequences that correspond 
to known genomic transcripts allowing for transcriptome analysis in non-model 
organisms. Furthermore, RNA-seq is incredibly sensitive allowing for the reveal of 
transcript boundaries at single base resolution. Additionally, short reads give 
information on the connectivity between two exons, whereas longer reads can 
span multiple exons, which allows for more complex transcriptome analysis. This 
combined with the low background signal of RNA-seq, as reads can be unambigously 
mapped to unique regions in the genome and no upper limit for quantification, 
whereas micro-arrays lose sensitivity for low and highly expressed genes. It makes 
RNA-seq the first sequencing-based technique to provide complete coverage of 
the transcriptome in a high-throughput and quantitative manner. There are some 
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a key transcription factor in embryogenesis, as it is involved in the development of 
tubular structures in the kidney, liver, pancreas and the genital tract.114 In the adult 
kidney, HNF1β is expressed throughout the epithelial cells of the nephron. Known 
targets of HNF1β are PKHD1, UMOD, KIF12 and PKD2, which are all cystic disease 
genes.115-118 PKHD1, KIF12 and PKD2 are ubiquitously expressed in the epithelial cells 
of the nephron. Uromodulin (UMOD) is highly expressed in TAL, although lower 
expression levels have been reported in DCT. It is unknown whether the DCT 
expression has any functional relevance. Loss of HNF1β decreases the expression of 
all three proteins, which induce proliferation of renal epithelial cells causing cyst 
formation during nephrogenesis. FXYD2a is a transcriptional target of HNF1β that has 
been hypothesized to contribute to hypomagnesemia and hypokalemia observed in 
ADTKD-HNF1β.25 However, HNF1β only regulates the ya-subunit of the Na+-K+-ATPase, 
which is not expressed in the DCT.119, 120 It is therefore unlikely that the loss of HNF1β 
has an effect on Na+-K+-ATPase activity via this pathway. It can, therefore, not be 
excluded that HNF1β additionally regulates other DCT genes, contributing to the 
electrolyte disturbances observed in ADTKD-HNF1β. It has also been shown that 
mutations in PCBD1 decreased the promoter activity of Fxyd2 when co-expressed 
with HNF1β. Furthermore, wildtype mice that were fed a low Mg2+ diet displayed 
significant upregulation of Pcbd1 expression in the DCT.22 These findings confirm that 
PCBD1 is an important factor in regulating Mg2+ reabsorption together with HNF1β. 
Although it is unclear, which downstream targets of HNF1β are affected.
Outline of this thesis
The aim of this thesis was to increase our understanding of the transcriptional 
regulation of Mg2+ and Ca2+ transporters in the kidney. Although much is known 
about the biochemical and molecular basis of Mg2+ and Ca2+ transport pathways and 
its regulatory networks, there is little knowledge on how Mg2+ and Ca2+ reabsorption 
disadvantages to RNA-seq that should be considered. Library construction requires 
fragmentation of the RNA, which introduces certain biases that favor the transcript 
body compared to the transcript ends. Additionally, most RNA-seq platforms 
require an amplification step during library preparation and this can introduce a 
bias towards highly available sequences, skewing quantification results.124 
However this can be easily checked by RT-qPCR. Despite these small drawbacks, 
RNA-seq has enabled the generation of a complete picture of the transcriptome 
and its organization in different cell types and species.
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is regulated at the transcriptional level. Chapter 2 provides a genome-wide 
assessment of all binding sites of transcription factor HNF1β in the DCT. The potassium 
channel subunit Kir5.1 was identified as a target of HNF1β. Luciferase assays, siRNA 
knockdown expriments, and a HNF1β renal knockout mouse was used to confirm the 
regulation of Kir5.1 by HNF1β. These results contribute to a increased understanding 
of the transcriptional regulation behind Mg2+ handling in the DCT. In chapter 3 the CaSR 
was identified as a novel target gene of HNF1β in the TAL. Additional luciferase assays 
and siRNA knockdown experiments were performed to confirm the transcriptional 
regulation of HNF1β on the CaSR. This study revealed HNF1β as a novel transcriptional 
activator of Mg2+ and Ca2+ transport in the TAL. Chapter 4 investigates the function 
of nuclear protein FAM111a in renal Mg2+ transport. Both RNA-sequencing and 
GFP-pulldown experiments were used to identify transcriptional targets and binding 
partners. These findings contribute to a better understanding of the renal electrolyte 
phenotype in FAM111a patients and could lead to potential new treatments for 
Kenney-Caffey syndrome type 2 patients. In chapter 5 P2x6 KO mouse were 
characterized to investigate its potential renal electrolyte phenotype by performing 
metabolic cage experiments and subsequent screening of magnesiotropic genes with 
real-time quantitative-PCR (RT-qPCR). In chapter 6 the findings of this thesis are 
summarized and further discussed by placing them in the context of current 
knowledge on the transcriptional regulation behind Ca2+ and Mg2+ transport in the 
TAL and DCT. 
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Abstract
HNF1β is an essential transcription factor for the development and functioning of 
the kidney. Mutations in HNF1β cause autosomal dominant tubulointerstitial kidney 
disease (ADTKD-HNF1β), which is characterized by renal cysts and maturity-onset 
diabetes of the young (MODY). Moreover, patients suffer from a severe electrolyte 
phenotype consisting of hypomagnesemia and hypokalemia. Until now, genes that 
are regulated by HNF1β are only partially known and do not fully explain the 
phenotype of the patients. Therefore, we conducted chIP-seq in immortalized mouse 
kidney cells (mpkDCT) to identify HNF1β binding sites at a genome-wide scale. 
 In total 7,421 HNF1β binding sites were identified, including several genes involved 
in electrolyte transport and diabetes. A highly specific and conserved HNF1β site was 
identified in the promoter of Kcnj16, encoding the potassium channel Kir5.1. Luciferase- 
promoter assays showed a 2.2 fold increase in Kcnj16 expression when HNF1β was 
present. Expression of the Hnf1β p.Lys156Glu mutant that was previously identified 
in a ADTKD-HNF1β patient, did not activate Kcnj16 expression. Knock down of Hnf1β 
in mpkDCT cells significantly reduced the expression of Kcnj16 (Kir5.1) and Kcnj10 
(Kir4.1) by 38% and 37%, respectively. These results were confirmed in a HNF1β renal 
knockout mouse, exhibiting downregulation of Kcnj16, Kcnj10 and Slc12a3 transcripts 
in the kidney by 78%, 83% and 76%, respectively, compared to HNF1β wild-type mice.
 In conclusion, HNF1β has been identified as a transcriptional activator of Kcnj16. 
Consequently patients with HNF1β mutations may have a reduced Kir5.1 activity in 
the kidney, resulting in hypokalemia and hypomagnesemia.
Keywords: HNF1β, Kir4.1, Kir5.1, ADTKD-HNF1β, hypomagnesemia, potassium, 
magnesium, chIP-seq
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Introduction
Heterozygous deletion or mutation of hepatocyte nuclear factor 1 homeobox B 
(HNF1β) causes autosomal dominant tubulointerstitial kidney disease (ADTKD-HNF1β, 
OMIM: 137920),1 comprising a wide variety of renal and extra-renal disorders. 
Although the symptoms have incomplete penetrance, the most common clinical 
phenotype is renal malformation combined with maturity-onset diabetes of the young 
(MODY5).1-5 However, patients can also present with genital tract malformations,6, 7 
pancreatic hypoplasia,8 abnormal liver functioning,9 electrolyte disturbances,4, 10 
and hyperparathyroidism.11 This makes ADTKD-HNF1β a multi-systemic disorder with 
a highly heterogeneous phenotype that is difficult to diagnose in the clinic.
 Careful phenotyping of the electrolyte disturbances observed in ADTKD-HNF1β 
patients led several clinicians to conclude that the phenotype is reminiscent of 
Gitelman syndrome (OMIM: 263800). The shared symptoms include hypomagnesemia 
and hypokalemia, although hypocalciuria and metabolic alkalosis are less frequently 
observed.4, 5, 10, 12 In Gitelman syndrome, inactivating mutations in the sodium- 
chloride-cotransporter (NCC) decrease Na+ and Mg2+ transport in the DCT and increase 
K+ secretion further downstream.13, 14 Similarly, in SeSAME/EAST syndrome (OMIM: 
612780) loss of function mutations in the Kir4.1/Kir5.1 inward-rectifying K+ channel 
are causative for hypomagnesemia and hypokalemia.15-17 Whether mutations in 
HNF1β affect NCC or Kir4.1/Kir5.1 remains to be elucidated.
 Over the last decade, several transcriptional targets of HNF1β have been identified, 
including UMOD, PKHD1 and FXYD2.18-20 Specifically FXYD2 has been implicated in 
the electrolyte disturbances observed in ADTKD-HNF1β. FXYD2 encodes for the 
γ-subunit of the Na+-K+-ATPase and as such regulates the basolateral membrane 
potential.4, 20 Indeed, heterozygous mutations in FXYD2 are known to cause autosomal 
dominant hypomagnesemia with hypocalciuria (OMIM: 154020).21, 22 Whether the 
regulation of FXYD2 by HNF1β is sufficient to explain the symptoms in ADTKD-HNF1β 
is being questioned.23 Current studies on HNF1β binding sites depend mainly on bio-
informatical identification of the HNF1β recognition sequence in gene promoters. 
The complete genome-wide spectrum of HNF1β binding sites in the distal convoluted 
tubule (DCT) is not known.
 The aim of our study was to elucidate the role of HNF1β in DCT electrolyte 
reabsorption. To this end, a genome-wide DNA binding profile for HNF1β was acquired 
by performing a chromatin immunoprecipitation followed by next generation sequencing 
(chIP-seq). Kir5.1 was identified as a prime candidate and its regulation by HNF1β was 
characterized by luciferase promoter assays and siRNA knock down experiments. 
Moreover, using renal-specific HNF1β knockout mice, the transcriptional effects of 
HNF1β were examined in the kidney.
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Results
HNF1β is expressed in the distal convoluted tubule
Immunohistochemistry of mouse kidney was performed to examine the HNF1β 
localization and expression. HNF1β was located to the nuclei of tubular cells (Figure 1), 
and was absent in the interstitium and glomerulus. HNF1β is expressed with DCT marker 
Parvalbumin in the distal convoluted tubule. 
HNF1β chIP-seq binding sites are specific for the HNF1β motif 
Genome-wide HNF1β binding sites were identified by performing chromatin-immu-
noprecipitation and sequencing (chIP-seq) on mpkDCT cells. Chromatin was isolated, 
cross-linked and immunoprecipitated with an anti-HNF1β antibody. After de-cross-
Figure 1 |  HNF1β is expressed in the distal convoluted tubule
Immunohistochemical stainings of mouse kidney sections were co-stained with anti-HNF1β in 
green (top right), anti-Parvalbumin in red, (lower left) and 4’, 6-diamidino-2-phenylindole 
(DAPI) in blue (top left). A merged image is shown in the lower right. Scale bar: 100 µm. 
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linking, samples underwent next-generation sequencing. Binding sites were found by 
comparing enriched immunoprecipitated genomic sequences to an untreated input 
control (genomic background). In total, 7421 HNF1β binding sites were significantly 
enriched over background (false discovery rate (FDR); q<0.001). Of which 4530 genes 
contained an HNF1β peak within 50kb of their respective transcription start sites 
(TSS). To determine whether these binding sites are near actively transcribed genes, 
a chIP-seq with an antibody against histone 3 lysine 4 trimethyl (H3K4me3) was 
performed. Of note: H3K4me3 is a histone marker for active TSS 24. 43.5% of all 
HNF1β binding sites could be assigned to actively transcribed genes, determined by 
the presence of H3K4 trimethylation. 28.5% of HNF1β binding peaks were linked to 
H3K4me3 negative genes and the remaining 28% were located to intergene regions 
(Figure 2A). The nucleotide sequence of HNF1β binding sites in our analysis 
corresponds to the database motif nRTTAATnATTAACn for HNF1β binding (JASPAR 
database ID: MA0153.2), showing high specificity and sensitivity of the chIP-seq 
(Figure 2B-D). Furthermore, HNF1β bindings sites were identified in promoters of 
several known targets of HNF1β, for example Pkhd1 and Pcbd1 (Figure 2E). 
HNF1β peaks are significantly enriched in putative promoter regions
Cis-regulatory element annotation system (CEAS) was used to quantify peak 
distribution along the genome (Figure 3A). This method assesses the percentage of 
Hnf1β binding sites found in upstream promoters, distal sites or the gene body 25. 
A significant 1.78 fold (p<0.001) enrichment in HNF1β peaks was observed in a range 
of 3 kb upstream from the TSS of putative promoter regions, compared to genomic 
background (Figure 3A). No enrichment was found in regions <3 kb distal from the 
TSS. HNF1β peak enrichment was significantly lower in the gene body, which consists 
of the coding exons, introns, 5’UTR and 3’UTR. Hierarchical clustering with Euclidean 
distance metric was performed to assess the amount of overlap of HNF1β peaks with 
H3K4me3 peaks. Within a window of ±10 kb surrounding H3K4me3 peaks, most 
HNF1β binding sites were located either upstream or more distal from enriched H3K4 
trimethylation binding sites indicating limited overlap with H3K4 trimethylation 
positive promoter regions (Figure 3B). 
HNF1β shows enrichment of the MODY and type II diabetes pathways 
Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis was performed 
on genes positive for HNF1β binding sites.26 A significant enrichment for MODY and 
type II diabetes pathway was detected (Figure 4A). Interestingly, HNF1β peaks were 
located near the transcription start sites of genes related to diabetes, including 
Hnf1α, Irs1 and Irs2 (Figure 5). Subsequent gene ontology (GO) analysis showed 
enrichment of ‘ion binding’ (GO:0043167), ‘calcium’ (GO:0005509) and ‘magnesium 
ion binding’ (GO:0000287) GO-terms (Figure 5B). 
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Figure 2 |  HNF1β chIP-seq binding sites are specific for the HNF1β motif and  
known HNF1β target genes
A) Pie chart showing HNF1β peaks assigned to genes in a 50 kb window around the TSS. In total 
7421 peaks were called (q<0.001). The percentage of H3K4me3 positive genes is depicted in 
black, H3K4me3 negative genes are shown in white and peaks that could not be assigned to a 
gene are portrayed in the grey segment. B) Left, sequence logo of the HNF1β motif found with 
the GimmeMotifs algorithm in our chIP-seq dataset. Right, HNF1β sequence logo acquired 
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Figure 3 |  HNF1β peaks are significantly enriched in putative promoter regions
A) Distribution of HNF1β peak location relative to RefSeq genes. Promoter indicates all HNF1β 
peaks that are <3 kb upstream from the TSS. Downstream refers to enrichment of HNF1β peaks 
over genomic background in <3 kb downstream from the TSS. A significantly lower enrichment 
of HNF1β peaks over genomic background is shown in the gene body. The gene body includes 
all exons, introns, 5’ UTR and 3’ UTR. One-sided binominal test *, p<0.01. B) Heatmap of HNF1β 
and H3K4me3 chIP-seq signal in a 10 kb window around HNF1β peak regions using hierarchical 
clustering with Euclidean distance metric. Rows in the heatmap represent individual peak 
regions. Left, all HNF1β peaks are centered in the middle of the map. Most HNF1β peaks are 
located >10 kb upstream or distal locations from H3K4me3 positive promoters.
from the JASPAR database (ID: MA0153.2). C) Histogram showing the HNF1β motif specificity 
score in relation to HNF1β peak height. Peaks were sorted by peak height in descending order 
and divided into quartiles (q1-4). Data (n=1855 per quartile) represent the mean ± SEM HNF1β 
motif specificity score. One-way ANOVA with Holm-Sidak correction, *, p<0.05. D) Positional 
preference plot indicates HNF1β peak frequency in relation to the motif position. The x-axis is 
the relative distance to the central position of the analyzed motif. E) HNF1β and H3K4me3 
binding profile for two known targets of HNF1β, respectively Pkhd1 (left) and Pcbd1 (right).
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Figure 4 |  HNF1β chIP-seq shows enrichment of the MODY and type II diabetes 
pathways and has novel bindings sites in known cystic and diabetes genes
A) KEGG pathway analysis was performed on genes with a HNF1β binding site in a window of 
50 kb surrounding the TSS. The x-axis shows the –log q-value for each identified KEGG pathway. 
The q-value is adjusted with a FDR correction. B) GO-term molecular function analysis was 
performed on genes that had an Hnf1β peak in a window of 50 kb surrounding the TSS. The x-axis 
shows the –log q-value for each significant pathway. The q-value is adjusted for multiple 
comparisons with a FDR correction.
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Figure 5 |  Novel HNF1β binding sites are found in known diabetes genes 
A-C) Screenshots of the UCSC genome browser for Hnf1α, Irs1 and Irs2 reveals HNF1β binding 
sites (upper track) near the H3K4me3 enriched transcription start sites (bottom track) of these 
genes.
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Figure 6 |  HNF1β enhances activation of the Kcnj16 promoter
A) HNF1β binding profile for Kir5.1 in mpkDCT cells. Underneath displays a linear representation 
of the location of the promoter, HNF1β binding site and H3K4 trimethylation site in relation to 
the exons of Kir5.1 for both mouse and human. A black rectangle denotes the HNF1β binding 
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HNF1β enhances activation of the Kcnj16 promoter
Since patients with ADTKD-HNF1β suffer from a Gitelman-like phenotype, genes 
involved in Mg2+, Na+ and K+ reabsorption were specifically analyzed. A highly enriched 
peak was located in the promoter of Kcnj16 (Kir5.1), which is an important subunit of 
the Kir4.1/Kir5.1 inward rectifying K+ channel (Figure 6A). The peak was found 60 base 
pairs (bp) in front of the TSS and displays high nucleotide conservation (Figure 6B). 
Furthermore, it shows relatively high motif conservation with a motif specificity score 
of 5.26, obtained by the ‘screen motif’ algorithm.27 Placing this binding site in the 
15% of HNF1β peaks (n=7421) with the highest motif specificity scores (Supplemental 
table 1). To confirm the reproducibility of HNF1β binding, the binding site was 
validated separately with chromatin immunoprecipitation and real time quantitative 
Figure 7 |  The novel HNF1β binding site in the Kcnj16 promoter is significantly 
enriched in mpkDCT cells
HNF1β chIP samples of mpkDCT samples were used to verify the HNF1β binding site in the 
Kcnj16 promoter. The Pkhd1 binding site was used as a positive control. Samples were measured 
by quantitative RT-PCR. Data represent mean ± SEM and are expressed as fold enrichment over 
background. The cutoff for sufficient enrichment of the binding site was set at 10 fold 
enrichment over background. The background signal was determined at genomic coordinates 
GRCm38 chr15:99578842-99579015.
site. B) Alignment of the HNF1β peak at -60 bp from the TSS of different species revealed a 
highly conserved binding site. C) HEK293 cells were transiently transfected with a luciferase 
construct carrying the Kcnj16 promoter with the HNF1β binding site. Luciferase constructs 
with Fxyd2a were transfected as a positive control and an empty vector was added as negative 
control. Promoter activity was tested with (white bars), without (black bars) or with mutant 
(striped bars) HNF1β stimulation. Data (n=3) represent mean ± SEM. *, p<0.05, compared with 
non-stimulated condition.
Kc
nj1
6
Pk
hd
1
0
10
20
30
Fo
ld
 e
nr
ic
hm
en
t 
(o
ve
r a
 c
on
tro
l r
eg
io
n)
521424-L-sub01-bw-Kompatscher
Processed on: 24-7-2018 PDF page: 46
46 | Chapter 2
PCR and demonstrated 15-fold enrichment over background (Figure 7). Subsequently, 
luciferase constructs containing the human promoter for KCNJ16 including the HNF1β 
binding site were expressed in Human Embryonic Kidney cells (HEK293). HNF1β 
increased KCNJ16 promoter activity 2.2-fold compared to mock transfected cells 
(Figure 6C). Subsequently, we examined the effect of a HNF1β p.Lys156Glu mutant 
that was previously reported in a patient with renal cysts and MODY.4, 28 HNF1β 
p.Lys156Glu did not raise KCNJ16 or FXYD2a promoter activity.
Figure 8 |  Knockdown of Hnf1β causes downregulation of Kcnj16 and Kcnj10
A-F) The mRNA expression levels of Hnf1β (A), Kcnj16 (B), Kcnj10 (C), Egfr (D), Fxyd2a  (E), Fxyd2b 
(F) in mpkDCT cells treated with either non-targeting (nt) (black bars) or Hnf1β targeting (white 
bars) siRNAs. Samples were measured by quantitative RT-PCR and normalized for Gapdh 
expression. Data (n=3) represent mean ± SEM and are expressed as the fold difference when 
compared to the expression in siRNA nt.
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Knockdown of HNF1β downregulates Kcnj16 and Kcnj10 
To further substantiate the transcriptional activation of Kcnj16 by HNF1β, mpkDCT 
cells were transfected with siRNA targeting Hnf1β. RT-PCR analysis demonstrated a 
significant 42±28% decrease in Hnf1β transcript compared to a non-targeting siRNA 
(Figure 8A). Kcnj16 mRNA levels were significantly decreased by 38±23%, (Figure 8B). 
Moreover, the expression of Kcnj10, encoding Kir4.1, and the EGF-receptor (Egfr) 
were downregulated with 37±13% and 36±23% respectively (Figure 8C and D). 
Transient receptor potential cation channel, subfamily M member 6 (Trpm6) and 
Epidermal growth factor (Egf) expression were not significantly altered (Figure 9). 
Fxyd2a was significantly downregulated by 60±20% in the absence of HNF1β, whereas 
Fxyd2b transcript levels were not affected (Figure 8E and F). Due too low Slc12a3 
transcript levels in the mpkDCT cells available to us, we were not able to reliably 
measure Slc12a3 transcript abundance. 
HNF1β regulates Kcnj16, Kcnj10 and Slc12a3 in a HNF1β 
mutant mouse model
To further substantiate that genes involved in electrolyte handling in the DCT are 
regulated by HNF1β, RT-PCR analysis for the expression of several genes was 
performed on RNA isolated from kidneys of Ksp-Cre;Hnf1βflox/flox mice (n=3). In these 
mice, Hnf1β is specifically inactivated in renal distal tubules.29 This kidney-specific 
inactivation of Hnf1β significantly (p<0.05) decreased the transcript expression of 
Figure 9 |  Knockdown of Hnf1β has no effect on the transcription of Trpm6 and Egf
A-B) The mRNA expression levels of Trpm6 (A) and Egf (B) in mpkDCT cells treated with either 
non-targeting (nt) (black bars) or Hnf1β targeting (white bars) siRNAs. Samples were measured 
by quantitative RT-PCR and normalized for Gapdh expression. Data (n=3) represent mean ± SEM 
and are expressed as the fold difference when compared to the expression in siRNA nt. 
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Kcnj16, Kcnj10 and Slc12a3 in the kidney by 78±30%, 83±30% and 76±22%, respectively 
(Figure 10A, B and C). The expression of well-know HNF1β target Pkhd1 was 
determined as a positive control and shown to be significantly reduced in HNF1βfl+/fl+ 
mice by 66±12% (Figure 10D). No significant reduction was observed for other DCT 
genes, including Trpm6 and the Egfr (Figure 10E and F). To exclude hypothrophy of 
Figure 10 |  Kcnj16, Kcnj10 and Slc12a3 transcripts are reduced in a HNF1β mutant 
mouse model
A-F) The mRNA expression levels of Hnf1β (A), Kcnj16 (B), Kcnj10 (C), Egfr (D), Fxyd2a (E), Fxyd2b 
(F) in Ksp-Cre;Hnf1βflox/flox mouse kidneys. The black bars represent Hnf1βfl-/fl- wild-type mice, 
while the white bars represent Hnf1βfl+/fl+ knockout mice. Samples were measured by 
quantitative RT-PCR and normalized for 18s ribosomal RNA expression. Data (n=3) represent 
mean ± SEM and are expressed as the fold difference when compared to the expression in 
Hnf1βfl-/fl- wild-type mice.
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the DCT as a cause for the decrease in transcript abundance, kidney slices from Ksp- 
Cre;Hnf1βflox/flox mice were stained for the DCT-specific marker parvalbumin. A qualitative 
assessment did not detect differences between Hnf1βfl-/fl- wild type and Hnf1βfl+/fl+ 
mutant mice (Figure 11). 
Figure 11 |  No difference in DCT marker Parvalbumin abundance and intensity 
between Hnf1βfl-/fl- wild type and Hnf1βfl+/fl+ knockout mice
Representative images are displayed of kidney slices derived from a Hnf1βfl-/fl- wild type (left) 
and a Hnf1βfl+/fl+ knockout mouse (right) at various magnifications 10x (top), 20x (middle) and 
40x (bottom). Parvalbumin is shown in green and DAPI in blue. Scale bars are respectively 150 
µm (top), 100 µm (middle) and 50 µm (bottom).
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Discussion
The present study provides a genome-wide screening of HNF1β binding sites in a 
mouse DCT cell line. Our results indicate that HNF1β induces transcription of Kcnj16 
(Kir5.1) and thereby regulates ion reabsorption in the DCT. This conclusion is based on 
the following findings: i) a highly enriched and conserved HNF1β-binding site was 
found in the promoter region of Kcnj16; ii) HNF1β, and not a HNF1β mutant, enhanced 
the promoter activity of Kcnj16 in a luciferase assay; iii) knock down of Hnf1β in 
mpkDCT cells resulted in decreased expression of Kcnj16 (Kir5.1) and Kcnj10 (Kir4.1); 
iv) reduced expression of Kcnj16 and Kcnj10 transcript in HNF1β renal knockout mice 
compared to wild-type mice. 
 ChIP-seq was used to elucidate HNF1β binding sites at a genome-wide scale 
allowing the identification of novel HNF1β-regulated genes in the kidney. In total 
~7400 binding sites were identified of which most were attributed to putative 
promoter regions. The strong overlap of the nucleotide binding sequence in our 
experiments with the signature HNF1β-binding sequence indicates the high specificity 
of the data set (JASPAR database ID: MA0153.2). Moreover, HNF1β-binding peaks 
were located near known HNF1β target genes Pkhd1 and Pcbd1.19, 30 Among others, 
MODY genes were enriched in the KEGG pathway analysis. Although our experiments 
were aimed at studying renal electrolyte transport, the genome-wide scale and high 
specificity of this dataset also allowed for the identification of HNF1β-binding sites 
near genes related to diabetes (e.g. Irs1, Irs2). The complete dataset is available via 
GEO (Accession: GSE77397).
 The main result of our study is the identification of Kir5.1 as a novel target of 
HNF1β-induced transcription. Kir5.1 was first cloned in 1994 and subsequently shown 
to form heteromeric complexes with Kir4.1 in the kidney, rendering the channel pH 
sensitive.31, 32 Kir5.1 has no channel properties per se and requires Kir4.x subunits for 
functioning.31 In kidney, Kir4.1-Kir5.1 complexes are expressed in the DCT and cortical 
collecting duct, where they regulate Na+-K+-ATPase activity by recycling K+ at the 
basolateral membrane.33, 34 
 The HNF1β binding site in the Kir5.1 promoter is highly conserved among species 
and is 15-fold enriched in our chIP-seq dataset. HNF1β clearly increased the Kir5.1 
promoter activity, indicating a direct transcriptional regulation of Kir5.1 in mpkDCT 
cells. Importantly, expression of the HNF1β-p.Lys156Glu mutant, that was identified 
in ADTKD-HNF1β patients, did not activate Kir5.1 transcription.11 It is likely that this 
point mutation, which is located in the DNA binding domain of HNF1β, causes a 
 dominant-interfering effect, hampering the binding of HNF1β to the DNA. In literature 
no evidence is reported for an altered phenotype between intragenic HNF1β 
mutations or whole-gene deletions, which would be consistent with haploinsufficiency 
as the underlying disease mechanism.35, 36 However, more recent data revealed that 
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patients with an intragenic HNF1β mutation suffer from significantly increased renal 
impairment and have a reduced glomerular filtration rate (GFR) compared to patients 
with a whole-gene deletion.37, 38 This indicates that in the case of intragenic HNF1β 
mutations, there might be an additional interfering effect of the mutant on the 
function of the HNF1β WT allele. The physiological effect of HNF1β binding to the 
Kir5.1 promoter was further investigated and confirmed in a HNF1β knockdown 
experiment. Kir5.1 expression decreased in mpkDCT cells after transfection with 
siRNA targeting Hnf1β. 
 To understand the physiological role of HNF1β-dependent regulation of Kir5.1 
mouse models are important tools. Our renal-specific HNF1β knockout animals 
confirmed the in vitro data, since Kcnj16 (Kir5.1) mRNA expression was reduced in 
HNF1β knockout mice in comparison to wild type mice. Given the early postnatal 
lethality of the animals, urinary measurements to examine physiological effects of 
Kir5.1 knockdown are not possible in the HNF1β mouse model.18 However, Kir5.1-/- 
mice were reported to suffer from urinary K+ and Mg2+ wasting, which was partially 
reflected in lower plasma K+.39 Although, a mechanism that explains urinary wasting 
of both Mg2+ and K+ in the Kir5.1-/- mouse remains elusive. Indeed, both urinary Mg2+ 
and K+ wasting are key features of ADTKD-HNF1β patients. 
 In addition to Kir5.1, HNF1β knockout animals also displayed reduced transcripts 
of Kir4.1 and NCC. These results suggest that the HNF1β phenotype is more extensive 
than Kir5.1 downregulation alone. Our results did not identify the cause for reduced 
Kir4.1 or NCC expression. The chIP-seq experiments showed that HNF1β binding sites 
are not present in or near the promoter region of Slc12a3 or Kcnj10 and therefore 
direct regulation of NCC and Kir4.1 expression by HNF1β seems unlikely. Reduced K+ 
channel Kir4.1/Kir5.1 expression may impair electrolyte transport at the basolateral 
membrane of the DCT, resulting in reduced NCC activity and transcription. This is in 
line with Kir4.1 knockout mice that demonstrate decreased abundance and 
functioning of NCC, altogether resulting in hypokalemia and renal Mg2+ wasting.40 
Furthermore, Kir4.1-deficient mice displayed a blunted response to hydrochlorothia-
zides confirming reduced NCC activity. Interestingly, ADTKD-HNF1β patients display a 
similar decreased response to hydrochlorothiazide,41 further pointing towards NCC 
involvement in HNF1β disease. From both the clinical and animal experiments, it 
cannot be excluded that DCT size is affected. However, histological analysis of the 
renal-specific HNF1β knockout animals demonstrates that morphological defects are 
mainly located in the renal medulla leaving the cortex largely unaffected.18 Moreover, 
Trpm6 expression is not significantly altered in the HNF1β knockout mice and no 
differences in DCT marker parvalbumin abundance or intensity was detected when 
comparing HNF1β wild type and knockout animals, suggesting normal DCT 
development (Figure 11). Decreased electrolyte reabsorption in DCT, caused by a 
decreased functioning of the Kir4.1/Kir5.1 potassium channel, could induce an 
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effacement of the basolateral membrane of the DCT, as observed in the renal biopsy 
of an EAST patient.15 It is, therefore, conceivable that aberrant Kir4.1/Kir5.1 channel 
functioning can cause changes in DCT morphology. Although this has, as of yet, not 
been reported in HNF1β patients. 
 The strength of our study is the genome-wide approach to identify novel HNF1β 
binding sites. Performing a chIP-seq assay allowed for a highly specific identification 
of all HNF1β binding sites within the DCT. Furthermore, by including a kidney-specific 
HNF1β knockout mouse model, our findings were confirmed in vivo, which further 
substantiated the in vitro findings. An important limitation of this study is the early 
postnatal lethality of the kidney-specific HNF1β knockout animals. DCT-specific 
knockout of HNF1β would be necessary to further examine the role of HNF1β in the 
DCT. However, these animals are currently not available.
 In conclusion, by using a genome-wide screen for HNF1β targets in a DCT specific 
cell line, a novel HNF1β binding site was identified in the Kcnj16 promoter. We 
established that HNF1β regulates Kcnj16 gene transcription in vitro and in vivo. 
Therefore, our findings provide valuable new insights inside the mechanism behind 
the electrolyte imbalance in ADTKD-HNF1β patients. 
Methods
Cell lines and animals
HEK293 cells were grown in Dulbecco’s modified Eagle’s medium (Lonza, Leusden, 
The Netherlands) containing 10% (v/v) fetal calf serum (FCS), 2 mM L-glutamine at 37 
°C in a humidity controlled incubator with 5% (v/v) CO2. MpkDCT4a were cultured as 
described previously.42 Distal tubule-specific inactivation of HNF1β was achieved 
using Cre/LoxP recombination by crossing Ksp-cadherin Cre mice with Hnf1βflox/flox.18 
Cre/LoxP activity varies along the nephron and ensures HNF1β inactivation for 27% in 
the proximal tubule, 99% in the thick ascending limb (TAL), 92% in the DCT/CNT and 
100% in the collecting duct.43 All animal procedures were performed in accordance 
with the guidelines of the Institutional Animal Care and Use Committees of the 
University of Texas Southwestern Medical Center and the University of Minnesota 
Medical School.
Immunohistochemistry (IHC)
Immunohistochemistry was performed as previously described.44 In short, stainings 
for Hnf1β were performed on 4 µm sections of formalin fixed and paraffin embedded 
mouse kidney samples. Sections were incubated for 16 hours at 4 °C in rabbit 
anti-HNF1β  (Santa Cruz Biotechnology, Santa Cruz, CA) 1:1000 and goat anti-Parval-
bumin 1:2000 (Santa Cruz Biotechnology, Santa Cruz, CA). For detection, samples 
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were incubated with an Alexa 594-conjugated donkey anti-goat antibody 1:300 
(Thermo Scientific, Amsterdam, The Netherlands) and a biotin-conjugated swine 
anti-rabbit antibody 1:2000. Subsequently, samples were incubated with streptavidin- 
HRP 1:100 and fluorescein-tyramide 1:50 using the TSA Fluorescein System 
(PerkinElmer, Groningen, The Netherlands). Cell nuclei were stained with DAPI 
(1:20,000) for 10 min at RT. Images were taken with an AxioCam MRm camera (Zeiss, 
Sliedrecht, The Netherlands). For the IHC in HNF1βflox/flox mice, kidneys were isolated 
at p14 and fixed in 4% paraformaldehyde and then embedded in paraffin. Sections 
were incubated for 16 hrs at 4 °C in goat anti-parvalbumin 1:50 (Santa Cruz 
Biotechnology, Santa Cruz, CA) and goat donkey-goat alexa 488 1:1000 (Invitrogen, 
Breda, The Netherlands) for 2 hrs at room temperature. Cell nuclei were mounted 
and stained with ProLong Gold antifade containing DAPI (Invitrogen). Slides were 
visualized under a Leica DM5500 B upright microscope with DFC7000 T camera 
(Leica).
ChIP-seq
Chromatin was isolated from mpkDCT4a cells by fixing with 1% (v/v) formaldehyde 
(Ultra-Pure) (Thermo scientific) for 15 min at RT. Cells were washed and permeabilized 
in 0.25% (v/v) triton-X-100 and 0.05% (v/v) SDS. Samples were sonicated in a 
Diagenode bioruptor (Diagenode, Ougrée, Belgium), 50 times 30 seconds on 30 
seconds off at high intensity. Chromatin samples were then immunoprecipitated with 
Protein A/G beads (Santa Cruz Biotechnology, Santa Cruz, CA) in either 5µg rabbit 
anti-Hnf1β (Santa Cruz Biotechnology, Santa Cruz, CA) or rabbit anti-H3K4me3 
(Abcam, Cambridge, UK) for 16 hours at 4 °C. Samples were de-crosslinked in 5 M 
NaCl at 65 °C for 5 hours. De-crosslinked samples were then purified with phe-
nol-chloroform. Sample preparation was performed according to the manufacturers 
protocol (Illumina, Eindhoven, The Netherlands). In short, adaptor sequences were 
linked to the generated chIP samples. The library was size selected (200-250 bp) and 
amplified by PCR.  Sequencing was completed on an Illumina HiSeq 2000 (Illumina, 
Eindhoven, The Netherlands). Peak calling was executed with Macs2, q-value (False 
discovery rate, FDR) 0.001. Hnf1β peak distribution within genomic features was 
accomplished with CEAS as a part of the Galaxy/Cistrome toolbox.25, 27 Promoters 
were defined as <3 kb regions upstream of the TSS. Whereas downstream regions 
were <3 kb downstream of the TSS. The gene body includes all exons, introns, 5’ UTR 
and 3’ UTR. Significant enrichment over background was tested with a one-sided 
binominal test. Hierarchical clustering with Euclidean distance metric was done for 
HNF1β and H3K4me3 sequence reads in a window of ±10 kb surrounding HNF1β 
peaks. Motif analysis was performed with the GimmeMotifs algorithm as described 
previously.45 All motifs found by the GimmeMotifs algorithm are described in Table 1. 
Motif specificity scores were obtained by performing a motif screen with the ‘screen 
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motif’ algorithm from the Galaxy/Cistrome toolbox. 27 All matching motifs underneath 
HNF1β peaks were given a specificity score based on the resemblance to the positional 
weight matrix of the HNF1β motif derived from the JASPAR database (ID: MA0153.2). 
27 As HNF1β has a tendency to bind ATAT repeats, some motifs besides the HNF1β 
motif were enriched. However these additional motifs had lower specificity scores, 
proving less significant than the HNF1β motif (Table 1). 
GO-term and KEGG pathway analysis
Gene set enrichment analysis (GSEA) software and the Molecular Signature Database 
(MSigDB) was used to obtain gene enrichment for both KEGG pathway and GO-term 
gene sets.46 A total of 2717 genes containing an HNF1β peak within 50 kb from their 
respective TSS were used in the analysis. Gene set overlap was calculated for KEGG 
pathway analysis and GO ‘molecular function’ gene sets. Statistical significance 
(q<0.05) was determined using hypergeometric testing with a FDR correction.
Cloning 
The human Kcnj16 promoter region (-998 bp upstream, +113 bp downstream from 
the TSS) containing the HNF1β binding site was amplified from a human BAC-clone 
(RPCI-11.c 79M2, Source biosciences, Nottingham, UK) using a high fidelity DNA 
polymerase (Phusion, Thermofisher, Amsterdam, The Netherlands). The PCR product 
was digested with restriction enzymes KpnI and XmaI (New England Biolabs Ltd, 
Leiden, The Netherlands). The sequence was than ligated into a pGL3b vector in 
front of the luciferase gene using T4 DNA ligase (New England Biolabs Ltd, Leiden, 
The Netherlands). Primers used were; forward 5’-TCTAACAACCGTCAAACAGCAAC-3’ 
and reverse 5’- GCTAGGTGCTTTCAGCTGGG-3’. Human HNF1β full-length cDNA was 
amplified by PCR from HNF1β pCMV-SPORT6 (clone IRATp970A0421D), ImaGenes), 
and subcloned into the pCINeo IRES GFP expression vector. HNF1β p.Lys156Glu was 
obtained by site-directed mutagenesis (Stratagene, La Jolla, USA).20 
Luciferase assay
HEK293 cells were transiently transfected with 700 ng of the promoter firefly 
luciferase constructs using polyethylenimine cationic polymer (PEI) (Invitrogen, Breda, 
The Netherlands) (ratio 1µg DNA to 6 µl PEI). Cells were transfected with a pGL3b- 
empty, pGL3b-hFXYD2a, pGL3b-hKCNJ16-promoter, or pGL3b-hKCNJ16-promoter- 
bindingsite construct. All four conditions were additionally transfected with 50 ng 
of the pCINEO-empty, pCINEO-hHNF1β, or pCINEO-hHNF1β p.Lys156Glu mutant construct. 
For standardization of the transfection efficiency, 20 ng of Renilla luciferase plasmid 
CMV-pRL was used as a reference in all conditions. Firefly and Renilla luciferase activities 
were measured with the Dual-Luciferase Reporter Assay (Promega, Fitchburg, MA). 
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Quantitative Real-Time Polymerase Chain Reaction 
MpkDCT cells were transiently transfected with 100 pmol of siRNA targeting Hnf1β 
mRNA (Dharmacon, Lafayette, USA).47 Cells were transfected using lipofectamine 
2000 (Invitrogen, Breda, The Netherlands) adding 3 µl for each condition. After 48 
hours, Total RNA isolation was performed with TRizol (Invitrogen, Breda, The 
Netherlands). 1.5 µg of RNA was used for reverse transcription using a M-MLV 
transcriptase protocol as described by the manufacturer (Invitrogen, Breda, The 
Netherlands). The cDNA was used to determine mRNA expression levels by CF96 
Real-Time PCR detection system (Bio-Rad, Veenendaal, The Netherlands) for target 
genes of interest and of the housekeeping gene glyceraldehyde 3-phosphate 
dehydrogenase (Gapdh), as an endogenous control. Real-Time PCR primers are 
reported in Table 2.
Real-time qPCR on Ksp-Cre;Hnf1βflox/flox kidneys. 
Total RNA from postnatal day 28 adult wild–type or HNF1β mutant mouse kidneys 
was extracted using the RNeasy Mini Kit (Qiagen, Germantown, MD) according to the 
manufacturer’s protocol. RNA was treated with DNAse (Invitrogen, Breda, The 
Netherlands) and cDNA was synthesized using superscript III first strand synthesis kit 
Table 2 |  Primer Sequences for RT-qPCR
Forward Reverse
18S RNA 5’- GTAACCCGTTGAACCCCATT-3’ 5’- CCATCCAATCGGTAGTAGCG-3’
Gapdh 5’-TAACATCAAATGGGGTGAGG-3’ 5’-GGTTCACACCCATCACAAAC-3’
Kcnj16 5’-GACTTCCGACCAAACCATGTG-3’ 5’-GTCATCCTCCCTTCACTGTC-3’
Kcnj10 5’- CCGCGATTTATCAGAGC-3’ 5’- AGATCCTTGAGGTAGAGGAA-3’
Egfr 5’- CAGAACTGGGCTTAGGGAAC-3’ 5’- GGACGATGTCCCTCCACTG-3’
Fxyd2a 5’- GAACAGTGGTGGCAGTGCCAAG-3’ 5’- GATCTGTCAGCGAACAGTG-3’
Fxyd2b 5’- GTACCTGGGTGGCAGTGCCAAG-3’ 5’- CTACCATGGACAGGTGGTA-3’
Trpm6 5’-AAAGCCATGCGAGTTATCAGC-3’ 5’-CTTCACAATGAAAACCTGCCC-3’
proEgf 5’-GAGTTGCCCTGACTCTACCG-3’ 5’-CCACCATTGAGGCAGTATCC-3’
Slc12a3 5’-CTTCGGCCACTGGCATTCTG-3’ 5’-GATGGCAAGGTAGGAGATGG-3’
18S RNA, 18S Ribosomal RNA; Gapdh, glyceraldehyde 3-phosphate dehydrogenase; Kcnj16, 
ATP-sensitive inward rectifier potassium channel 16; Kcnj10, ATP-sensitive inward rectifier 
potassium channel 10; Egfr, epidermal growth factor receptor; Fxyd2a-b, FXYD domain containing 
ion transport regulator 2a-b; Trpm6, transient receptor potential cation channel, subfamily M, 
member 6; Egf, epidermal growth factor; Slc12a3, solute carrier family 12, member 3.
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(Invitrogen, Breda, The Netherlands). cDNA was diluted 1:20 and 10 µl was used in the 
real time qPCR reaction. Real-time qPCR was performed with the iTAG Universal 
SYBER Green Supermix (Bio-Rad, Veenendaal, The Netherlands) using the CFX 
Connect Real-Time System (Bio-Rad, Veenendaal, The Netherlands). 18S ribosomal 
RNA was used as an endogenous control. Real-Time PCR primers are listed in Table 2. 
Data analysis
All results presented are based on at least three separate experiments. Values are 
expressed as mean ± SEM. Statistical significance (P<0.05) was determined using 
one-tailed Students T-test or one-way ANOVA with Holm-Sidak procedure. Data was 
deposited in NCBI GEO (Accession: GSE77397).
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Abstract
Mutations in HNF1β cause autosomal dominant tubulointerstitial kidney disease 
(ADTKD-HNF1β), and patients tend to develop renal cysts, maturity-onset diabetes of 
the young (MODY), and suffer from electrolyte disturbances, including hypo-
magnesemia, hypokalemia and hypocalciuria. Previous HNF1β research focused on 
the renal distal convoluted tubule (DCT) to elucidate the ADTKD-HNF1β electrolyte 
phenotype, although 70% of Mg2+ is reabsorbed in the thick ascending limb of Henle’s 
loop (TAL). An important regulator of Mg2+ reabsorption in the TAL is the calci-
um-sensing receptor (CaSR).
 This study used several methods to elucidate the role of HNF1β in electrolyte 
reabsorption in the TAL. HNF1β ChIP-seq data revealed a conserved HNF1β binding 
site in the second intron of the CaSR gene. Luciferase-promoter assays displayed a 5.8 
fold increase in CaSR expression when HNF1β was present. Expression of the HNF1β 
p.Lys156Glu mutant, which prevents DNA binding, abolished CaSR expression. Hnf1β 
knockdown in an immortalized TAL cell line (MKTAL) reduced expression of the CaSR 
and Cldn14 (Claudin14) by 56% and 48%, respectively, while Cldn10b expression was 
upregulated 5.0 fold. These results were confirmed in a kidney-specific HNF1β 
knockout mouse, which exhibited downregulation of the Casr by 81%. Cldn19 and 
Cldn10b expression levels were also decreased by 37% and 83%, respectively, whereas 
Cldn3 was upregulated by 4.6 fold. 
 In conclusion, HNF1β is a transcriptional activator of the CaSR. Consequently, 
patients with HNF1β mutations may have reduced CaSR activity in the kidney, which 
could explain cyst progression and hyperabsorption of Ca2+ and Mg2+ in the TAL 
resulting in hypocalciuria.
Keywords: kidney, calcium-sensing receptor, HNF1β, TAL, hypomagnesemia, 
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Introduction
Autosomal dominant tubulo-interstitial kidney disease (ADTKD-HNF1β, OMIM: 137920) 
is caused by the deletion of or heterozygous mutations in hepatocyte nuclear factor 1 
homeobox β (HNF1β).1, 2 Patients suffer from a complex and heterogeneous phenotype 
characterized by renal malformations and maturity onset diabetes of the young 
subtype 5 (MODY5).1-6 Interestingly, approximately 50% of ADTKD-HNF1β patients 
experience impaired renal electrolyte handling resulting in hypomagnesemia, hypo - 
kalemia and hypocalciuria.5, 7-9 
 HNF1β is ubiquitously expressed in the epithelial cells of all nephron segments.10 
In the distal convoluted tubule (DCT), HNF1β regulates the expression of the 
Kir4.1-Kir5.1 K+ channel and the γ-subunit of the Na+-K+-ATPase (FXYD2).11, 12 Kidney- 
specific (Ksp) Hnf1β knockout (KO) mice display reduced Kcnj10 (Kir4.1) and Kcnj16 
(Kir5.1) expression levels, resulting in lower Na+-Cl--cotransporter (NCC) transcript 
levels.13 These findings explain why ADTKD-HNF1β resembles Gitelman syndrome 
(OMIM: 263800), seizures, sensorineural deafness, ataxia, mental retardation, and 
electrolyte imbalance; or epilepsy, ataxia, sensorineural deafness, and renal tubulop-
athy;(SeSAME-EAST, OMIM: 612780) or isolated dominant hypomagnesemia (IDH, 
OMIM: 15040). These are caused by NCC, Kir4.1, and FXYD2 mutations, respectively.14-16 
 HNF1β is ubiquitously expressed along the nephron, including the thick ascending 
limb of Henle’s loop (TAL). Here, HNF1β regulates the expression of uromodulin (UMOD), 
which is a cystic disease gene responsible for ADTKD-UMOD (OMIM: 191845).17 The 
TAL plays a dominant role in Na+, Ca2+ and Mg2+ reabsorption.11, 18 In this segment, 
the furosemide-sensitive Na+-K+-2Cl--cotransporter (NKCC2) facilitates transcellular 
Na+ reabsorption. A strong lumen positive potential drives the paracellular transport 
of divalent cations, which is maintained by the paracellular backflow of Na+ and the 
recycling of K+ into the lumen by the renal outer medullary potassium channel 
(ROMK). A highly regulated tight junction complex consisting of claudins 3, 14, 16 and 
19 forms a pore to facilitate the paracellular reabsorption of Ca2+ and Mg2+. The ion 
permeability and selectivity of this tight junction complex depends on the particular 
expression of each of the claudin-subunits.19, 20 Whereas claudin16 and claudin19 are 
cation-permeable, claudin14 is generally considered cation-blocking, shifting the 
preference of the claudin16-19 pore to Na+ instead of Ca2+ and Mg2+. 
 Over the last few years, the calcium-sensing receptor (CaSR) was identified as 
regulator of the claudin complex.19, 21 Several studies described the role of the CaSR 
in electrolyte transport in the TAL.21, 22 Patients with gain-of function mutations in 
the CaSR develop autosomal dominant hypocalcemia (ADH, OMIM: 601198), and 
subsequently, renal Mg2+ wasting, hypomagnesemia, and hypocalcemia with hypo-
parathyroidism.23 Loss-of-function mutations cause familial hypocalciuric hyper -
calcemia (FHH, OMIM: 145980), which is characterized by hyperabsorption of Ca2+ 
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and Mg2+, and reduced levels of these ions in the urine.24 Recent research shows how 
CaSR activation regulates claudin expression, by initiating a cellular cascade that 
results in the decreased expression of two specific microRNAs, Mir-9 and Mir-374, 
which in turn raise claudin14 protein levels.19, 21, 25 As a consequence, Ca2+ and Mg2+ 
reabsorption in the TAL are decreased, which was observed in mice treated with the 
CaSR-agonist cinacalcet.21 
 Although HNF1β is highly expressed in the TAL, the role of HNF1β in electrolyte 
reabsorption in this segment has never been examined. The aim of the present study 
was to investigate the function of HNF1β in the TAL. The CaSR was identified as a 
prime candidate for HNF1β transcriptional regulation by screening HNF1β chromatin 
immunoprecipitation and sequencing (ChIP-seq) data. Transcriptional regulation of 
the CaSR by HNF1β was assessed by luciferase assays and siRNA knockdown 
experiments in mouse kidney TAL cells (MKTAL). Quantitative PCR analysis was 
performed on HNF1β mutant mice kidney tissue to determine differences in CaSR 
expression in vivo.
Results
Expression of HNF1β in the TAL
Immunohistochemistry was performed on mouse kidney slices to investigate HNF1β 
expression and localization in the TAL. HNF1β localizes to the nuclei of tubular cells 
and is co-expressed with the TAL-specific marker uromodulin (Figure 1).
HNF1β regulates the expression of the Calcium-sensing receptor
Analysis of previously published HNF1β chIP-seq data in an immortalized mouse DCT 
cell line revealed a highly enriched binding site for HNF1β in the second intron of 
the Casr gene (Figure 2A).11 The binding site is located +16,611 nucleotides from the 
Casr transcriptional start site (TSS), and displays elevated nucleotide conservation 
(Figure 2B). The binding site has a motif conservation score of 6.38 as calculated by 
the screen motif algorithm, indicating high conservation, and placing it in the top 5% 
of most conserved HNF1β peaks (n=7421) found in the HNF1β chIP-seq dataset.11, 26 
Reproducibility of this binding site was validated by performing chIP-RT-qPCR, resulting 
in a 24-fold enrichment over the genomic background, which was comparable to the 
HNF1β binding site in the fibrocystin precursor (Pkhd1) gene that was used as a 
positive control (Figure 2C). Subsequently, luciferase assays were performed on 
HEK293 cells containing the human promoter for the CaSR, including the HNF1β 
binding site. HNF1β overexpression raised promoter activity significantly by 5.8-fold 
(P<0.05) compared to cells that lacked HNF1β expression (Figure 2D). Overexpression of 
the HNF1β p.Lys156Glu mutant that was previously reported in a patient with renal 
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cysts and MODY, abolished the rise in promoter activity.5, 27 No significant changes 
were observed in mock-transfected cells. Luciferase experiments with the alternative 
CaSR promoter 2 did not show HNF1β-induced CaSR transcription (Figure 2E). 
Removal of the HNF1β binding site abolishes any significant HNF1β-induced increase 
in CaSR promoter activity (Figure 2C).
 
siRNA-mediated knockdown of HNF1β downregulates Casr, Cldn14 and 
upregulates Cldn10b transcript levels in vitro
To further elucidate the role of HNF1β in the transcriptional regulation of the CaSR, 
MKTAL cells were transfected with siRNA targeting HNF1β. Real-time quantitative 
PCR (RT-qPCR) analysis revealed a significant decrease of 59±11 % in Hnf1β transcript 
levels compared to non-targeting siRNA-transfected cells (Figure 3A). A similar significant 
Figure 1 |  HNF1β is expressed in the thick ascending limb
Immunohistochemical stainings of mouse kidney sections were co-stained with anti-HNF1β 
(top right, grayscale), anti-uromodulin (lower left, grayscale) and 4’, 6-diamidino-2-phenylindole 
(DAPI) (top left, gray scale). A merged image is shown in the lower right with HNF1β in green, 
uromodulin in red and DAPI in blue. Scale bar: 100 µm
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Figure 2 |  HNF1β increases activation of the Calcium-sensing receptor promoter
A) HNF1β binding profile for the Casr in mpkDCT cells. Below is a linear representation of the 
location of the promoter and HNF1β binding site in relation to the exons of the CaSR for both 
mouse and human. A black rectangle denotes the HNF1β binding site. A black line denotes the 
promoter region. B) Alignment of the HNF1β peak at +16.611 bp from the TSS of several 
different species reveals a highly conserved binding site. C) HNF1β chIP samples of mpkDCT 
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Table 1 |  MKTAL cells are not selective for Na+, Mg2+ or Ca2+
Native cells PNa/PCl PMg/PNa PCa/PNa
MKTAL1 1.14 ± 0.04 1.93 ± 0.03 2.00 ± 0.01
MKTAL2 1.16 ± 0.03 1.93 ± 0.02 2.01 ± 0.04
MKTAL3 1.22 ± 0.03 2.12 ± 0.20 2.15 ± 0.04
siRNA nt PNa/PCl PMg/PNa PCa/PNa
MKTAL1 1.17 ± 0.03 1.99 ± 0.02 1.99 ± 0.03
MKTAL2 1.16 ± 0.05 1.95 ± 0.01 1.95 ± 0.06
MKTAL3 1.20 ± 0.03 1.98 ± 0.04 1.98 ± 0.08
siRNA Hnf1β PNa/PCl PMg/PNa PCa/PNa
MKTAL1 1.18 ± 0.02 1.96 ± 0.03 2.00 ± 0.04
MKTAL2 1.19 ± 0.03 1.95 ± 0.05 2.05 ± 0.06
MKTAL3 1.19 ± 0.03 1.91 ± 0.02 1.91 ± 0.05
Three independent experiments, each containing three separate measurements (N=3) are 
represented. The ‘native cells’ column displays the untransfected MKTAL cells. siRNA nt 
represents the non-targeting siRNA condition, whereas the siRNA Hnf1β column shows cells 
that were transfected with siRNAs targeting Hnf1β mRNA. PNa/PCl, PMg/PNa and PCa/PNa are 
ratios of ion permeability. Data is expressed as Mean ± Standard Deviation (SD).
samples were used to verify the HNF1β binding site in the CaSR promoter. The Pkhd1 binding 
site was used as a positive control. Samples were measured by quantitative RT-PCR. Data 
represent mean ± SEM and are expressed as fold enrichment over background. The cutoff for 
sufficient enrichment of the binding site was set at 10 fold enrichment over background. The 
background signal was determined at genomic coordinates GRCm38 chr15:99578842-
99579015  D) HEK293 cells were transiently transfected with a luciferase construct carrying the 
human CaSR promoter 1, CaSR exon 1a and also containing the HNF1β binding site (black 
square). Luciferase constructs carrying the CaSR promoter lacking the HNF1β binding site and 
an empty vector were added as negative controls. Promoter activity was tested with (white 
bars), without (black bars) or with mutant (striped bars) HNF1β stimulation. E) HEK293 cells 
were transiently transfected with a luciferase construct carrying the human CaSR promoter 2, 
CaSR exon 1B and also containing the HNF1β binding site. An empty vector was added as 
negative control. Promoter activity was tested with (white bars) or without (black bars) HNF1β 
stimulation. Data (n=3) represent mean ± SEM. *, p<0.05, compared to the non-stimulated 
condition
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decrease of 56±18 % was observed for the Casr (Figure 3B). Kcnj16 mRNA levels were 
taken along as a positive control. As expected, Kcnj16 transcript levels were 
significantly decreased by 65±19 % (Figure 3C).11 In addition, mRNA levels of Cldn10b, 
16, 19 and 14 were investigated, as these tight junction proteins are involved in the 
reabsorption of Ca2+ and Mg2+ in the TAL. Transcript levels of Cldn14 were significantly 
downregulated by 48±14 % (Figure 3F). However, no significant changes were found 
Figure 3 |  siRNA mediated knockdown of Hnf1β causes downregulation of the Casr, 
Cldn14, and upregulates Cldn10b expression levels in an immortalized TAL 
cell line
A-G) The mRNA expression levels of Hnf1β (A), Casr (B), Kcnj16 (C), Cldn16 (D), Cldn19  (E), 
Cldn14 (F) and Cldn10b (G) in MKTAL cells treated with either non-targeting (nt) (black bars) or 
Hnf1β targeting (white bars) siRNAs. Samples were measured by quantitative RT-qPCR and 
normalized to GAPDH expression. Data (n=3) represent mean ± SEM, *, p<0.05 and are expressed 
as the fold difference compared to the expression in siRNA nt
Figure 3
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in the abundances of Cldn16, Cldn19, Cldn3 mRNA (Figure 3D, E & H). Interestingly, 
RT-qPCR measurements for Cldn10b revealed a 5-fold (p<0.05) increase in transcript 
levels in Hnf1β deficient cells (Figure 3G). Cldn10a expression levels were not 
detectable in the MKTAL cell line. Ussing chamber experiments were performed to 
assess the consequences of Hnf1β deficiency for Ca2+ and Mg2+ transport in MKTAL 
cells. Measurements in native MKTAL cells displayed no significant changes in Na+, 
Mg2+ and Ca2+ permeability (Table 1). Transfection of MKTAL cells with Hnf1β targeting 
siRNAs resulted in no significant changes in cation permeability (Table 1).
Figure 4 |  Casr and Cldn10b transcripts are reduced, whereas Cldn3 mRNA levels 
were increased in a HNF1β mutant mouse model
A-F) The mRNA expression levels of Hnf1β (A), Cldn14 (B), Cldn16 (C), Cldn19 (D), Cldn10b (E), 
Cldn3 (F) in Ksp-Cre;Hnf1βflox/flox mouse kidneys. The black bars represent Hnf1βfl-/fl- wild-type 
mice, while the white bars represent Hnf1βfl+/fl+ knockout mice. Samples were measured by 
quantitative RT-qPCR and normalized for U6 spliceosome RNA expression. Data (n=3) represent 
mean ± SEM, *, p<0.05 and are expressed as the fold difference when compared to the 
expression in Hnf1βfl-/fl- wild-type mice.
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Expression of Casr, Cldn19 and Cldn3 is regulated by HNF1β in vivo
We confirmed our findings that HNF1β regulates CaSR transcription and thereby 
affects electrolyte reabsorption in the TAL by performing RT-qPCR on RNA isolated 
from kidney-specific (Ksp)-Cre;Hnf1βflox/flox mouse kidneys (n=3). In these mice, 
Ksp-cre induced knockout of Hnf1β ensures that Hnf1β is inactivated in 99 % of all TAL 
segments.28 This specific lack of Hnf1β in the TAL causes a significant (P<0.05) 
decrease of 81±6 % in Casr mRNA abundance (Figure 4A). Cldn14, one of the critical 
downstream targets of the CaSR, was not significantly affected by the decrease in 
Casr abundance (Figure 4B). Similarly, Cldn16 mRNA levels were not significantly 
altered (Figure 4C). Contrary to the in vitro data (Figure 3E & G), Cldn19 and Cldn10b 
were significantly downregulated by 37±6 % and 83±2 %, respectively, in Hnf1β 
mutant mice (Figure 4D and E). Interestingly, Cldn3, a component of the divalent 
cation selective pore in the TAL, exhibited a significant 4.6-fold increase in Hnf1βfl+/fl+ 
mice compared to Hnf1βfl-/fl- mice (Figure 4F). 
Discussion
Our findings provide novel insights into the role of HNF1β in the TAL. HNF1β is 
ubiquitously expressed throughout the kidney.11 It is therefore likely that problems 
with electrolyte homeostasis in ADTKD-HNF1β patients cannot be attributed to only 
one segment of the nephron. We have demonstrated that HNF1β induces the 
expression of the CaSR gene in the TAL. An enriched and conserved binding site of 
HNF1β was found in the second intron of the CaSR gene. Subsequent luciferase assays 
revealed that HNF1β enhances CaSR promoter activity. The absence of the HNF1β 
binding site or overexpression of mutant HNF1β protein was sufficient to abolish this 
stimulatory effect. SiRNA knockdown of HNF1β in MKTAL cells decreased Casr 
expression significantly compared to a non-targeted control siRNA. RT-qPCR analysis 
in Ksp-cre Hnf1β KO mice revealed a similar decrease of CaSR expression in the kidney.
 The CaSR is a G-protein-coupled receptor (GPCR) that is sensitive to extracellular 
Ca2+, and, to a lesser extent, Mg2+ ions.29, 30 The receptor plays a major role in the 
maintenance of the plasma Ca2+ concentration by regulating the circulating levels of 
parathyroid hormone and directly affecting Ca2+ reabsorption in the kidney.31. 
Intracellular signaling is initiated upon Ca2+ binding to the large extracellular domain. 
CaSR-dependent signaling activates phospholipase C activity that results in an 
accumulation of inositol 1,4,5-trisphosphate and a rapid increase of the cytosolic Ca2+ 
concentration.32-34 Although it has been shown that the CaSR promoter is responsive 
to 1,25-dihydroxyvitamin D3, proinflammatory cytokines and the transcription factor 
glial cells missing-2 (GCM2), this is the first report of regulation of the CaSR by 
HNF1β.35
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The CaSR gene has eight exons, of which exons 2 to 7 contain the coding sequence for 
the CaSR protein (GenBank U20759). Interestingly, the gene harbors two alternative 
first exons (1A and 1B) that encode different 5′-UTRs, both splicing to the common 
exon 2.36, 37 The human CaSR gene has two promoters driving the transcription of 
alternative exons 1A and 1B. Our data demonstrated that HNF1β regulates promoter 
1 activity, whereas promoter 2 is unaffected. The CaSR is highly expressed in the 
parathyroid gland and the renal tubular system, including the TAL.38 Northern blot 
analysis of human parathyroid glands shows exclusive exon 1A use.36 Moreover, 
nephrolithiasis is associated with the transcription of promoter 1.39 These data 
suggest that promoter 1-driven exon1A transcription is most important for Ca2+ and 
Mg2+ transport. Therefore, HNF1β-regulated promoter 1 activity may be of particular 
importance for renal electrolyte homeostasis. 
 In TAL, the CaSR has been implicated in the regulation of NKCC2 activity and 
CLDN14 expression.21, 22 Previous studies in mice have shown that extracellular Ca2+ 
increases Cldn14 mRNA levels through CaSR-mediated increases of intracellular Ca2+. 
This reduces the expression of two miRNAs, Mir-9 and Mir-374. As a consequence of 
this downregulation, Cldn14 mRNA levels are decreased.21 In our model, we expected 
to observe a decrease in Cldn14 due to the decreased CaSR activity following 
Hnf1β-mediated downregulation. A decrease in Cldn14 expression was indeed 
observed in our MKTAL cell model, when Hnf1β expression was suppressed. However, 
there was no significant decrease in Cldn14 expression levels in Ksp-Cre;Hnf1βflox/flox 
mouse kidneys. Cldn14 expression is normally low in mice on a normal Ca2+ diet;19, 25 
previous studies have shown that an increase in dietary Ca2+ is required to ensure 
Cldn14 upregulation.19, 25, 40, 41 Our data confirms low basal expression levels of 
Cldn14. Previous research showed that wildtype mice treated with the CaSR agonist 
cinacalcet had increased expression of Cldn14.21 Subjecting HNF1β mutant mice to 
cinacalcet is not possible, as these mice suffer from early postnatal lethality, which 
limits any further investigation.17 
 There are some disparities between the in vitro and in vivo expression levels of 
Cldn10b, Cldn19 and Cldn3 (figure 3EGH and 4DEF). Although these discrepancies 
cannot completely be explained, it is expected that this is a limitation of the MKTAL 
cell model. It has recently been shown that the mosaic claudin expression in the TAL 
results in several types highly organized and spatially separated paracellular 
permeation pathways in vivo.20, 42 This complex physiological organization is not 
mimicked in MKTAL cells, which just express one type of paracellular shunt. Moreover, 
MKTAL cells cannot take into account the compensatory effects of other tubule 
segments affected by a reduction in HNF1β. The ion permeability measurements 
performed in Ussing chambers determined that MKTAL cells are not suitable for 
permeability studies, because the cells were not selective for Na+, Mg2+ or Ca2+ (Table 
1). The PNa/PCl values did not exceed 1.2, whereas cortical TAL and medullary TAL 
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should have at least a PNa/PCl of around 4 and 8 respectively to accurately mimic the 
ion transport selectivity in these segments.42 Furthermore, targeting HNF1β 
expression in MKTAL cells did not elicit the expected decrease in Na+ and increase in 
Mg2+ and Ca2+ permeability. Taken together, our experiments indicate that the MKTAL 
cell line is not a sufficient model to study ion transport. What does remain evident is 
the clear reduction of Casr expression after loss of HNF1β in both in vitro and in vivo 
models,
 Patients that suffer from ADTKD-HNF1β often have kidney cyst formation.8, 43 
A study in mice with rodent nephronophthisis shows that stimulating the CaSR with 
calcimimetics reduced cyst progression.44 A lack of CaSR expression due to a HNF1β 
mutation might contribute to cyst formation. It would therefore be interesting to 
treat ADTKD-HNF1β patients with calcimimetics to induce CaSR activity and reduce 
cyst progression. In some cases ADTKD-HNF1β patients develop nephrolithiasis.45 
Curiously, a single-nucleotide polymorphism (SNP) in the CaSR promoter 1 has been 
associated with nephrolithiasis.39 The SNP was more frequent in stone formers vs 
controls, and homozygous SNP carriers had lower CaSR mRNA levels in the kidney 
medulla.39 Our finding that HNF1β controls CaSR transcription may therefore be of 
clinical interest for reducing cyst and kidney stone formation. However, more 
research is needed to elucidate what effect the loss of HNF1β has on ion transport in 
the TAL and what the consequences are for the ADTKD-HNF1β patient.  
 In conclusion, a HNF1β binding site was identified in the second intron of the 
CaSR gene. Our data indicate that HNF1β positively regulates gene transcription of 
the CaSR in vitro and in vivo. Thereby providing a novel insight into the potential role 
of HNF1β in electrolyte transport that is not only confined to the DCT, but also 
relevant to TAL function.
Materials and Methods
Cell lines 
Human embryonic kidney cells (HEK293) were grown in Dulbecco’s Modified Eagle’s 
Medium (DMEM) (Lonza, Leusden, The Netherlands) containing 10 % (v/v) fetal calf 
serum (FCS) and 2 mM L-glutamine, at 37 °C in a humidity controlled incubator with 
5% (v/v) CO2. The immortalized TAL cell line (MKTAL) was derived from microdissected 
medullary TAL tubules.46 MKTAL cells were cultured in DMEM/HAM-F12 (1:1) (Lonza, 
Leusden, The Netherlands) containing 5% (v/v) FCS and 2 mM L-glutamine, at 37°C in 
a humidity controlled incubator with 5% (v/v) CO2.46 
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Animal experimentation
Renal-specific inactivation of HNF1β was achieved using Cre/LoxP recombination by 
crossing Ksp-cadherin Cre mice with HNF1βflox/flox.17 Cre/LoxP activity varies along 
the nephron and ensured HNF1β inactivation along 27 % of the proximal tubule, 99 % 
of the TAL, 92 % of the DCT/connecting tubule, and 100 % of the collecting duct.28 
Mice were housed in standard cages with bedding material consisting of straw and 
paper in a temperature- and light-controlled room with standard pellet chow and 
deionized drinking water available ad libitum. Animals were sacrificed at postnatal 
day 28. An equal number of male and female mice were used for all procedures. All 
animal procedures were performed in accordance with the guidelines of the 
Institutional Animal Care and Use Committees of the University of Texas Southwestern 
Medical Center and the University of Minnesota Medical School. The animal protocol 
number is 1503-32434.
Immunohistochemistry (IHC)
Immunohistochemistry was performed as previously described.11 In short, stainings 
for HNF1β were achieved on 4 µm sections of mouse kidney samples fixed in formalin 
and embedded in paraffin. Sections were incubated for 1 hour at 4 °C in rabbit 
anti-HNF1β (Santa Cruz Biotechnology, Santa Cruz, CA, USA) at a dilution of 1:1,000 
and mouse anti-Tamm-Horsfall at 1:2,000 (Santa Cruz Biotechnology). For detection, 
samples were incubated with an Alexa 594-conjugated goat anti-mouse antibody 
1:300 (Thermo Scientific, Amsterdam, The Netherlands) and a biotin-conjugated 
swine anti-rabbit antibody 1:2,000. Subsequently, samples were incubated with 
streptavidin-HRP 1:100 and fluorescein-tyramide 1:50 using the TSA Fluorescein 
System (PerkinElmer, Groningen, The Netherlands). Cell nuclei were stained with DA-
PI-Fluoromount-GÒ mounting medium (Southern Biotech, Uithoorn, The Netherlands) 
at room temperature (RT) for 5 minutes. Images were taken with an AxioCam MRm 
camera (Zeiss, Sliedrecht, The Netherlands) at 40x magnification.  Zeiss Zen 2012 
(Zeiss, Sliedrecht, The Netherlands) software was used to acquire the images.
Cloning 
The human CaSR promoter 1 region (-2622 bp, -539 bp upstream) from the transcription 
start site (TSS) and the CaSR promoter 2 region (-972 bp, -242 bp upstream) were amplified 
from a human bacterial artificial chromosome  (BAC) clone (Human RPCI-11.c 79M2; 
chr3: 121,868,424-122,055,369, Source biosciences, Nottingham, UK) using a high 
fidelity DNA polymerase (Phusion, Thermofisher, Amsterdam, The Netherlands). 
The HNF1β binding site region (+16,290 bp to +16,864 bp) was amplified from the 
same human BAC-clone. The CaSR promoter 1 and promoter 2 PCR products were 
digested with restriction enzymes KpnI and NheI, whereas the HNF1β binding region 
was digested with NheI and XhoI (New England Biolabs Ltd, Leiden, The Netherlands). 
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The CaSR promoter sequences were ligated first into the pGL3b vector, followed by 
the HNF1β binding region. Both sequences were cloned upstream of the luciferase 
gene using T4 DNA ligase (New England Biolabs Ltd, Leiden, The Netherlands). Primers 
used for the CaSR promoter 1 region were; forward 5’-TAAAGCTTCTAGCCACAGCG-3’ 
and reverse 5’- CTCATTCTGCAAGACTCAGGTC-3’. The following primers were used for 
the CaSR promoter 2 PCR; forward 5’-TAAGAGTTTGGGCACGCG-3’ and reverse 
5’-GTTCCCCGGTCCTACCTG-3’. For the HNF1β binding region the subsequent primers 
were used; forward 5’- GAAGCACAGATTATTACGGAGATCTC-3’ and reverse 5’-CAT-
GTCCCTGACCTAATTTGAG-3’. Human HNF1β full-length cDNA was amplified by PCR 
from HNF1β pCMV-SPORT6 (clone IRATp970A0421D), ImaGenes), and subcloned into 
the pCINeo IRES GFP expression vector. HNF1β p.Lys156Glu was obtained by 
site-directed mutagenesis (Stratagene, La Jolla, USA).47 
Luciferase assay
Human embryonic kidney 293 (HEK293) cells were transiently transfected with 700 
ng of the promoter firefly luciferase constructs using polyethylenimine cationic 
polymer (PEI) (Invitrogen, Breda, The Netherlands) (ratio 1µg DNA to 6 µl PEI). Cells 
were transfected with either a pGL3b-empty, pGL3b-hCaSR-promoter-1, pGL3b-hCaSR- 
promoter-2, pGL3b-hCaSR-promoter-1 or pGL3b-hCaSR-promoter-2-HNF1β-binding-
region construct. All three conditions were additionally transfected with 50 ng of the 
pCINEO-empty, pCINEO-hHNF1β, or pCINEO-hHNF1β p.Lys156Glu mutant construct. 
In the case of the CaSR promoter 2 experiments only pCINEO-empty and pCINEO- 
hHNF1β constructs were used. For standardization of the transfection efficiency, 20 ng 
of Renilla luciferase plasmid pRL under a human cytomegalovirus promoter (CMV) 
was used as a reference in all conditions. Firefly and Renilla luciferase activities were 
measured with the Dual-Luciferase Reporter Assay (Promega, Fitchburg, MA, USA). 
Real-Time quantitative PCR
MKTAL cells were transiently transfected with 100 pmol of a siRNA smart pool against 
Hnf1β (Dharmacon, Lafayette, USA).48 Cells were transfected using lipofectamine 
2000 (Invitrogen, Breda, The Netherlands) adding 3 µl for each condition. After 48 
hours, Total RNA isolation was performed with TRizol (Invitrogen, Breda, The 
Netherlands). 1.5 µg of RNA was used for reverse transcription using a Moloney 
Murine Leukemia Virus (M-MLV) reverse transcriptase protocol as described by the 
manufacturer (Invitrogen, Breda, The Netherlands). The cDNA was used to determine 
mRNA expression levels by CF96 Real-Time PCR detection system (Bio-Rad, 
Veenendaal, The Netherlands) for target genes of interest and of the housekeeping 
gene glyceraldehyde 3-phosphate dehydrogenase (Gapdh), as an endogenous control. 
RT-qPCR primers are reported in Table 1.
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Real-time qPCR on Ksp-Cre;Hnf1βflox/flox kidneys 
Total RNA from postnatal day 28 adult wild–type or HNF1β mutant mouse kidneys 
was extracted using the RNeasy Mini Kit (Qiagen, Germantown, MD, USA) according 
to the manufacturer’s protocol. RNA was treated with DNAse (Invitrogen, Breda, The 
Netherlands) and cDNA was synthesized using superscript III first strand synthesis kit 
(Invitrogen, Breda, The Netherlands). cDNA was diluted 1:20 and 10 µl was used in the 
RT-qPCR reaction. RT-qPCR was performed with the iTAG Universal SYBER Green 
Supermix (Bio-Rad, Veenendaal, The Netherlands) using the CFX Connect Real-Time 
System (Bio-Rad, Veenendaal, The Netherlands). U6 spliceosomal RNA was used as an 
endogenous control. Real-Time PCR primers are listed in Table 1.
Ussing chamber 
After seeding MKTAL cells on transwell membranes, confluence was monitored by 
measuring TEER (trans epithelial electrical resistance) daily with an EVOM2 chamber 
(World precision instruments, Sarasota, USA). MKTAL cells were transfected with 100 
pmol siRNA for 24 hours, a day before these cells reached their TEER plateau (30-40 
Ω*cm2). Measurements in the Ussing chamber were performed 24 hours after 
transfection of the MKTAL cells. Experimental and control solutions were preheated 
Table 1 |  RT-qPCR primer sequences
Gene Forward Reverse
U6 5’-GTAACCCGTTGAACCCCATT-3’ 5’-CCATCCAATCGGTAGTAGCG-3’
Gapdh 5’-TAACATCAAATGGGGTGAGG-3’ 5’-GGTTCACACCCATCACAAAC-3’
Kcnj16 5’-GACTTCCGACCAAACCATGTG-3’ 5’-GTCATCCTCCCTTCACTGTC-3’
Casr 5’-CTTTCCTATCCATTTTGGAGTAGCA-3’ 5’-GCAAAGATCATGGCTTGTAACCA-3’
Cldn16 5’-GTTGCAGGGACCACATTAC-3’ 5’-GAGGAGCGTTCGACGTAAAC-3’
Cldn19 5’-GGTTCCTTTCTCTGCTGCAC-3’ 5’-CGGGCAACTTAACAACAGG-3’
Cldn10b 5’-GGAGTTCCCCTCCATGCT-3’ 5’-GCAAAAATGGAACCGAAAAA-3’
Cldn14 5’-GTCCAGCTCCTAGGCTTCCT-3’ 5’-CATCCACAGTCCCTTCAGGT-3’
Hnf1β 5’-CATTGCACAGAGCCTCAACACC-3’ 5’-GTTGAGAGAACTGGACGGGCTG-3’
Cldn3 5’-GCACCCACCAAGATCCTCTA-3’ 5’-GTAGTCCTTGCGGTCGTAGG-3’
Pkhd1 (chIP) 5’-AGAAAAATGTAAGCAGCCCTTTC-3’ 5’-GAGTGAAAGTTCACAAATGACCAC-3’
Casr (chIP) 5’-CACAAAGCCCATGATGAATG-3’ 5’-GTGTGGCTTGGGCTAGTCTC-3’
U6, U6 spliceosomal RNA; Gapdh, glyceraldehyde 3-phosphate dehydrogenase; Kcnj16, ATP- 
sensitive inward rectifier potassium channel 16; Kcnj16, ATP-sensitive inward rectifier potassium 
channel 16; Casr; calcium-sensing receptor, Cldn16; Claudin16, Cldn19; Claudin19, Cldn10b; 
Claudin10b, Cldn14; Claudin14, Hnf1β; hepatocyte nuclear factor 1 homeobox β, Cldn3; Claudin3, 
Pkhd1 (chIP); Fibrocystin
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to 37°C before pouring them in liquid reservoirs connected to the Ussing chamber. 
Two additional heaters were interposed between the fluid reservoirs and the 
chamber. The flow rate was approximately 10 mL/min. Transepithelial voltage was 
recorded using agarbridges (2.5 (w/v) agar in 1M KCl and chlorinated silver electrodes 
connected to an Ussing-Amplifier UPG3. A 10 µA current pulse was applied every 10 
s and the resulting voltage reflection was used to calculated transepithelial resistance 
according to Ohm’s law. Paracellular permeability properties were assess similar to 
by generating a NaCl diffusion potential reducing the NaCl concentration to 30 mM 
first at the apical then on the basolateral side and by generating bi-ionic diffusion 
potentials replacing NaCl by either MgCl2 or CaCl2. All three permeability ratios for 
PNa/PCl, PMg/PNa and PCa/PNa were calculated with the Goldman-Hodgkin-Katz 
equation and a simplified Kimizuka-Koketsu equation, respectively. 40, 49 Osmolality 
for all solutions was ~300 mOsm and pH was set at 7.4 using HCl. The composition of 
the solutions used was the following; Ringer’s solution (control solution): 145 mM 
NaCl, 0.4 mM KH2PO4, 1.6 mM KH2PO4, 5 mM glucose, 1 mM MgCl2, 1.3 mM 
Ca-gluconate; Low Na+ solution: 30 mM NaCl, 0.4 mM KH2PO4, 1.6 mM KH2PO4, 5 mM 
glucose, 1 mM MgCl2, 230 mM mannitol, and 1.3 mM Ca-gluconate; Ca2+ solution: 3.6 
mM KCl, 5 mM glucose, 75 mM mannitol, 72.5 mM CaCl2, and 3 mM HEPES; Mg2+ 
solution: 3.6 mM KCl, 5 mM glucose, 72.5 mM MgCl2, 71 mM mannitol, 1.3 mM 
Ca-gluconate, and 3 mM HEPES.
Chromatin-immunoprecipitation and quantative PCR (ChIP-qPCR)
Chromatin was isolated from an immortalized DCT cell line (mpkDCT4a) cells by fixing 
with 1% (v/v) formaldehyde (Ultra-Pure) (Thermo scientific) for 15 min at RT. Cells 
were washed and permeabilized in 0.25% (v/v) triton-X-100 and 0.05% (v/v) SDS. 
Samples were sonicated in a Diagenode bioruptor (Diagenode, Ougrée, Belgium), 50 
times 30 seconds on 30 seconds off at high intensity. Chromatin samples were then 
immunoprecipitated with Protein A/G beads (Santa Cruz Biotechnology, Santa Cruz, 
CA) in 5µg rabbit anti-HNF1β (Santa Cruz Biotechnology, Santa Cruz, CA) for 16 hours 
at 4 °C. Samples were de-crosslinked in 5 M NaCl at 65 °C for 5 hours. De-crosslinked 
samples were then purified with phenol-chloroform. cDNA was synthesized from 
isolated RNA and RT-qPCR was performed as described above. RT-qPCR primers 
targeting the HNF1β bindingsites found in the Casr and Pkhd1 gene are represented 
in Table 1. 
Data analysis
All results presented are based on at least three independent experiments. Values 
are expressed as mean ± SEM. Statistical significance (P<0.05) was determined using 
one-tailed students T-test or one-way ANOVA with Dunnett’s multiple comparison 
procedure. ChIP-seq data can be accessed through NCBI GEO (Accession: GSE77397). 
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Abstract
Mutations in family with sequence similarity 111, member A (FAM111A) cause 
Kenny-Caffey syndrome type 2 (KCS2). KCS2 is characterized by severe proportionate 
short stature, gracile bones dysplasia and other morphological symptoms. Patients 
also suffer from hypoparathyroidism combined with a hypocalcemia and hypo-
magnesemia, which explains the growth retardation and other morphological and 
endocrine symptoms. FAM111A is a protein known for having anti-viral properties 
and a function in cell replication. However, the role of FAM111A in renal electrolyte 
transport and parathyroid hormone (PTH) secretion remains unclear. 
 To elucidate the function of FAM111A that explains its role in electrolyte 
reabsorption. Fam111a was knocked down 50% using siRNAs in an immortalized 
mouse distal convoluted cell line. Transcriptome analysis in these cells culminated in 
a list of 78 upregulated and 39 downregulated genes (Fold change >1.32). Pathway 
analysis of the upregulated genes showed significantly enriched anti-viral pathways. 
Green Fluorescent Protein (GFP)-pulldown experiments confirmed signal transducer 
and activator of transcription 1 (Stat1) as a potential binding partner of FAM111A. 
Stat1 was also upregulated 2.0±0.8 fold after Fam111a knockdown in mpkDCT cells 
and part of the anti-viral pathways established in the KEGG pathway analysis. STAT1 
is known as a transcriptional activator of the calcium sensing receptor (CaSR). The 
CaSR is an important regulator of Ca2+ and Mg2+ reabsorption in the kidney and PTH 
secretion in the parathyroid. 
 It might, therefore, be possible that increased STAT1 expression due to aberrant 
FAM111A functioning could be responsible for the phenotype of the KCS2 patient.
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Introduction
Kenny-Caffey syndrome (KCS, OMIM; #127000, #244460) is a complex disease with a 
wide variety of morphological, neurological and endocrinological manifestations. 
Symptoms shared by all KCS patients are a severe proportionate short stature, gracile 
bones dysplasia, mid-face hypoplasia, delayed closure of the anterior fontanel, 
frontal bossing, eye abnormalities and hypocalcemia owing to hypoparathyroid-
ism.1-4 KCS is classified in two subtypes based on clinical features and inheritance 
pattern. KCS type 1 patients (KCS1, OMIM; #244460) develop mental and prenatal 
growth retardation. Mutations in the tubulin-folding cofactor E (TBCE) gene cause 
KCS1, which follows a recessive inheritance pattern.4, 5 6 Cases with normal intelligence 
and an autosomal dominant inheritance pattern suffer from KCS type 2 (KCS2, OMIM; 
#127000).7 Sequencing of several patients with KCS2 identified that mutations in the 
family with sequence similarity 111, member A (FAM111A) gene are responsible for 
the KCS2 disorder.8 In a Japanese KCS2 cohort, p.Arg569His was established as a 
hotspot mutation.9 Mutations in FAM111A were also identified in five patients 
suffering from osteocraniostenosis (OCS, OMIM; #602361), a similar but more severe 
disorder than KCS2 resulting in early life lethality.8 
 A common feature in KCS2 is the distinct electrolyte deficiencies observed in 
these patients, characterized by hypocalcemia, hypomagnesemia and hypokalemia, 
combined with a hypoparathryoidism.8 Together these symptoms explain the growth 
retardation, gracile bones syndrome and other morphological and endocrine 
symptoms.8-10 The distal convoluted tubule (DCT) and thick ascending limb of Henle’s 
loop (TAL) are segments that are crucial for Ca2+ and Mg2+ reabsorption in the kidney. 
In one patient, Ca2+ and Mg2+ restriction tests were performed which determined 
that the hypomagnesemia was primary to the hypoparathyroidism.9 The role of 
FAM111A in the DCT and TAL segments could, therefore, determine the molecular 
mechanism behind KCS2 syndrome. However, the relation between FAM111A 
function and renal Ca2+ and Mg2+ reabsorption has never been investigated.
 FAM111A encodes a protein of 611 amino acids and has homology with trypsin- 
like peptidases.11 The protein has been identified as an interactor with the large 
T antigen of the SV40 virus indicating that FAM111A has anti-viral properties.11 More 
recent studies concluded that FAM111A is a binding partner of proliferating cell 
nuclear factor antigen 1 (PCNA1).12 Depletion of FAM111A by RNA interference indeed 
decreased PCNA loading onto the chromatin. As a consequence, FAM111A-depleted 
cells start replication significantly slower than control cells.12 In sillico, modeling of 
FAM111A mutations elucidated that the Arg569His hotspot mutation potentially 
disturbs an enzymatic pocket, which could result in FAM111A function loss.8 
 In this study, the role of FAM111A in renal electrolyte handling was investigated. 
FAM111A knockdown in an immortalized mouse distal convoluted cell line (mpkDCT) 
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and subsequent RNA-sequencing (RNA-seq) was used to reveal novel transcriptional 
pathways that explain the physiological role of FAM111A in electrolyte handling in 
the kidney. In addition, an eGFP-pull down experiment was performed to elucidate 
potential binding partners of FAM111A that could further determine its molecular 
function in the context of the KCS2 syndrome. 
Results
Fam111a mRNA is ubiquitously expressed 
Fam111a mRNA levels were measured in various mouse tissues (Figure 1A). Fam111a 
was ubiquitously expressed. The highest expression was present in spleen, lung and 
inguinal fat with differences in mRNA levels of 231 ± 21, 50 ± 6 and 59 ± 28 fold, 
respectively, compared to kidney. Since the DCT segment of the nephron is crucial for 
Mg2+ reabsorption, mouse DCT tubules were acquired by complex object parametric 
analyzer and sorter (COPAS) cell sorter isolation to measure Fam111a expression 
levels. Fam111a mRNA was present in the sorted DCT and unsorted tubules to a 
similar extent (Figure 1B). Trpm6 is exclusively expressed in the DCT and used as a 
positive control (Figure 1C). As expected, Trpm6 expression was significantly increased 
6 ± 2 fold in sorted DCT tubules compared to unsorted tubules.
Knockdown of Fam111a does not change mRNA expression of Ca2+  
and Mg2+ transport genes
To understand the role of Fam111a in electrolyte handling in the kidney, mRNA 
expression levels of various genes involved in Ca2+ and Mg2+ transport were measured. 
To this end, Fam111a was significantly knocked down by 44 ± 13% in mpkDCT using 
siRNAs (Figure 2A). However, Fam111a knockdown did not result in significant 
changes in expression of the epithelial Mg2+ channel Trpm6, basolateral Mg2+ 
transporter Slc41a1 or magnesiotropic gene Cnnm2 (Figure 2A). Neither were 
significant differences observed in mRNA expression levels of pro- epidermal growth 
factor (EGF) or the EGF receptor (EGFR), which are known to enhance Trpm6 channel 
activity (Figure 2A).
 To examine a potential role of FAM111A in TAL, Fam111a was knocked down 
by 68 ± 8% in an immortalized mouse kidney TAL cell line (MKTAL) (Figure 2B). 
The expression of the tight junction proteins Claudin16 (Cldn16), Claudin19 (Cldn19), 
Claudin14 (Cldn14) or the Casr was not significantly affected by knock down of 
Fam111a (Figure 2B). 
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Figure 1 | Fam111a mRNA is ubiquitously expressed 
A) Data displays Fam111a mRNA expression in various mouse tissues relative to kidney. 
Samples were measured in wild-type mice (n=3) by quantitative RT-PCR and normalized for 
Gapdh expression. Data (n=3) represent mean ± SEM and are expressed as the fold difference 
compared to the expression of Fam111a in kidney. B-C) The mRNA expression levels of 
Fam111a B) or Trpm6 C) were measured in unsorted (black bar) or sorted DCT tubules (white 
bar). Samples were measured by RT-qPCR and normalized for Gapdh expression. Data (n=3) 
represent mean ± SEM expressed as the fold difference compared to the expression in unsorted 
tubules.
Figure 1
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Fam111a down regulation activates anti-viral pathways 
As our targeted-approach did not identify genes that are regulated by FAM111A, 
a genome-wide approach was used. An RNA-seq was performed on mpkDCT cells 
to identify which genes in the kidney are regulated by FAM111A and related to ion 
transport. SiRNAs targeting Fam111a decreased endogenous Fam111a expression 
significantly with 58 ± 5% compared to a non-targeting control condition (siRNA nt) 
(Figure 3A). A principal component analysis (PCA) demonstrated that the siRNA 
Fam111a samples form a separate cluster from the siRNA nt samples along the PC1 
axis, which explains most (70%) of the variance observed in the dataset (Figure 3B). 
This indicates higher variance between the siRNA nt and the siRNA Fam111a 
conditions than within the groups. Differential expression of 21,041 genes was 
assessed (Figure 3C), resulting in the identification of 519 up- and 298 significantly 
down-regulated genes (false discovery rate (FDR); p<0.05) (supplemental table 1). 
A >1.3 fold change cut-off was used to select for biologically relevant targets 
culminating in a list of 78 upregulated (Table 1) and 37 downregulated genes (Table 2). 
The genes with the most substantial expression differences were Inmt with a 1.68 fold 
upregulation and, as expected, Fam111a with a 1.95 fold downregulation (Table 1 and 2). 
 KEGG pathway analysis demonstrated that several anti-viral pathways (Herpes 
simplex infection, mmu05168; Hepatitis C, mmu05160; Influenza A, mmu05164) where 
significantly upregulated (Table 3). The affected genes in these pathways were interferon 
regulatory factor 7 (Irf7), interferon-induced protein with tetratricopeptide repeats 1 
(Ifit1), ribonuclease L (2’, 5’-oligoisoadenylate synthetase-dependent) (Rnasel), toll-like 
receptor 3 (Tlr3), transporter 1, ATP-binding cassette, sub-family B (MDR/TAP) (Tap1) 
and signal transducer and activator of transcription 1 (Stat1). KEGG pathway analysis for 
the downregulated genes determined that the p53-signaling (04115) pathway was 
affected. Due to the limited amount of differentially expressed genes this result did not 
reach statistical significance. Stat1 upregulation after Fam111a knockdown was verified 
by RT-qPCR in mouse DCT cells. Fam111a was significantly knocked down by 50 ± 13%, 
while Stat1 expression was significantly upregulated by 2.0 ± 0.8 fold (Figure 3D).
Figure 2 |  Knockdown of Fam111a does not change mRNA expression of Ca2+  
and Mg2+ transport genes
A) The mRNA expression levels of Fam111a, Trpm6, Slc41a1, Cnnm2, Proegf and Egf in mpkDCT 
cells treated with either non-targeting (nt) (black bars) or Fam111a targeting (white bars) 
siRNAs. B) The mRNA expression levels of Fam111a, Casr, Cldn16, Cldn19 and Cldn14 in MKTAL 
cells treated with either non-targeting (nt) (black bars) or Fam111a targeting (white bars) 
siRNAs. Samples were measured by quantitative RT-PCR and normalized for Gapdh expression. 
Data (n=3) represent mean ± SEM, *, P>0.05 and are expressed as the fold difference compared 
to the expression in siRNA nt.
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Figure 3 | Fam111a downregulation activates anti-viral pathways 
A) The mRNA expression levels of Fam111a in mpkDCT cells treated with either non-targeting 
(nt) (black bars) or Fam111a targeting (white bars) siRNAs that were destined for RNA-seq. 
Samples were measured by quantitative RT-PCR and normalized for Gapdh expression. Data 
(n=3) represent mean ± SEM and are expressed as the fold difference compared to the 
expression in siRNA nt. B) The principal component analysis (PCA) plot exhibits the two 
variables that explain most of the variance present in the data. Principal component 1 (PC1) 
explains 70%, whereas PC2 explains 17% of the variance found in all samples (n=3 control 
samples, n=3 siRNA Fam111a samples) of the RNA-seq dataset. Samples are plotted based on 
the amount of variance that both PCs explain in the RNA-seq of that sample. Control samples 
are depicted as white squares, siRNA Fam111a samples are shown as black squares. C) The MA 
plot displays the overall mean expression for every tested gene and the relative differential 
gene expression of the siRNA Fam111a samples compared to the non-targeting control samples 
expressed as a Log2 fold change. The mean expression is expressed as the normalized number 
of reads per gene. Red data points depict genes that are significantly differentially expressed in 
Figure 3
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the siRNA Fam111a condition compared to the control samples (FDR; P<0.05, corrected for 
multiple comparison with Benjamini-Hochberg). D) The mRNA expression levels of Fam111a or 
Stat1 in mpkDCT cells treated with either non-targeting (nt) (black bars) or Fam111a targeting 
(white bars). Data (n=3) represent mean ± SEM and are expressed as the fold difference 
compared to the expression in siRNA nt. Samples were measured by RT-qPCR and normalized 
for Gapdh expression.
Table 1 |  Upregulated genes due to decreased Fam111a expression in mpkDCT cells
Gene name Mean of normalized counts 
across samples
Differential gene expression
(Fold change)
P-value
(FDR, <0.01)
Inmt 271 1.68 1.5E-11
Aqp1 1155 1.67 8.0E-18
Kank4 207 1.66 1.3E-09
Hsd11b2 510 1.60 1.5E-09
Npnt 2715 1.53 1.5E-17
Fras1 658 1.52 2.6E-10
Vnn1 114 1.50 3.4E-05
Nrp2 473 1.50 1.5E-09
Ifit3b 511 1.50 2.0E-07
Ube2l6 355 1.49 1.7E-06
Prr5l 121 1.49 6.6E-05
Kazn 226 1.47 1.8E-05
Dhx58 411 1.47 8.5E-06
Peli3 107 1.47 1.6E-04
Nrip3 73 1.46 2.9E-04
Neurl1b 1933 1.46 8.9E-13
Sema3a 95 1.46 3.2E-04
Ifitm3 1826 1.45 9.9E-09
Tspan13 514 1.45 1.4E-08
Masp1 281 1.44 8.5E-06
Rasgrp2 90 1.44 7.4E-04
Aebp1 430 1.43 1.9E-06
Nup210 1131 1.43 4.4E-11
Lipg 186 1.43 1.9E-04
Irf7 1218 1.42 1.7E-06
Bsnd 320 1.41 1.3E-05
Tmem8 153 1.41 4.4E-04
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Table 1 |  Continued
Gene name Mean of normalized counts 
across samples
Differential gene expression
(Fold change)
P-value
(FDR, <0.01)
Lgals3bp 3528 1.41 3.5E-09
Stard8 370 1.40 6.2E-05
Chchd10 844 1.40 1.6E-05
Dgat2 71 1.39 2.6E-03
Afap1l1 249 1.39 1.6E-04
Fam53b 201 1.39 4.9E-04
Cxcl12 36 1.38 NA
Them6 657 1.38 7.0E-06
Cmpk2 519 1.38 1.9E-04
Crybg1 97 1.37 3.9E-03
Ppargc1b 53 1.37 4.3E-03
Tap1 341 1.37 8.8E-05
Pcsk5 250 1.37 4.3E-04
Lynx1 711 1.36 3.6E-06
Ppargc1a 936 1.36 2.0E-06
Dmd 131 1.36 3.4E-03
Ifit1 1875 1.36 2.3E-03
Fyco1 534 1.36 6.4E-06
Hcn2 296 1.36 4.3E-04
Gpd1l 1019 1.35 8.7E-08
Uap1l1 902 1.35 1.9E-05
Gnai1 378 1.35 9.7E-05
Itgb3 249 1.35 1.1E-03
Oxct1 818 1.35 7.0E-07
Gal3st1 64 1.35 8.6E-03
B3gnt7 60 1.34 1.0E-02
Stat1 549 1.34 2.1E-04
Tlr3 411 1.34 4.3E-04
Ifi27l2a 132 1.34 7.3E-03
Arfgef3 226 1.34 2.0E-03
Usp18 1322 1.34 3.9E-05
Aldh6a1 530 1.34 1.6E-04
Cpped1 820 1.34 2.9E-06
Rhcg 231 1.34 3.9E-03
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Table 2 |  Downregulated genes due to decreased Fam111a expression in mpkDCT cells
Gene name Mean of normalized 
counts across samples
Differential gene expression
(Fold change)
P-value
(FDR, <0.01)
Fam111a 186 1.94 6.1E-16
Sprr1a 97 1.53 2.4E-05
Creb5 285 1.49 1.4E-06
Mettl7b 121 1.48 1.1E-04
Ankrd1 1790 1.47 3.8E-12
Gm38357 158 1.45 1.2E-04
Serpine1 442 1.44 1.4E-06
Col4a2 5009 1.43 1.5E-20
Table 1 |  Continued
Gene name Mean of normalized counts 
across samples
Differential gene expression
(Fold change)
P-value
(FDR, <0.01)
Slc27a6 78 1.33 1.1E-02
Wipf3 30 1.33 NA
Frem2 48 1.33 1.1E-02
Gfra1 99 1.33 1.0E-02
Pltp 290 1.33 2.1E-03
Fam84b 985 1.33 1.4E-06
Slc45a4 682 1.33 1.4E-05
Rnasel 205 1.33 3.7E-03
Iigp1 570 1.33 1.4E-02
Ifi30 731 1.33 1.7E-04
Fam20c 936 1.33 3.4E-06
Arhgdib 491 1.32 1.1E-03
Rsad2 722 1.32 1.4E-02
Me3 108 1.32 1.3E-02
Nptxr 273 1.32 1.6E-03
Bpnt1 767 1.32 2.0E-05
Adora1 369 1.32 7.6E-04
Columns indicate Gene name, list of HGNC gene symbols; mean of normalized counts for all 
samples; differential gene expression between siRNA Fam111a and siRNA non-targeting 
expressed as fold change; P-value, false discovery rate (FDR) p<0.05, and corrected for multiple 
testing with the Benjamini-Hochberg correction.
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Table 2 |  Continued
Gene name Mean of normalized 
counts across samples
Differential gene expression
(Fold change)
P-value
(FDR, <0.01)
Gm42899 61 1.42 9.3E-04
Zdhhc21 549 1.42 3.2E-06
Akap12 10704 1.40 2.1E-11
AC087890.1 120 1.40 2.0E-03
Gm45223 101 1.40 2.2E-03
Ano1 248 1.40 1.4E-04
Zbtb37 860 1.39 3.4E-06
Pmaip1 363 1.37 3.4E-05
Zswim6 413 1.37 5.2E-05
Slc13a2os 87 1.36 5.0E-03
AC160637.1 763 1.36 5.1E-05
A930004J17Rik 192 1.36 1.5E-03
Slc39a3 255 1.36 4.9E-04
AC131586.1 83 1.35 7.2E-03
Gm37420 86 1.35 7.3E-03
Mtm1 149 1.35 3.3E-03
Galnt3 151 1.35 4.6E-03
Amn1 592 1.34 2.5E-04
Gm37472 143 1.34 7.3E-03
Gm37238 169 1.34 6.5E-03
Ctgf 841 1.34 3.4E-05
Tgfbi 41 1.33 NA
Rhob 1545 1.33 1.4E-06
Clock 1300 1.33 2.1E-06
Rbm4 218 1.33 5.6E-03
AC140397.1 63 1.33 1.3E-02
Sbds 532 1.32 4.8E-05
Gm21781 278 1.32 8.0E-03
Mfap3l 3227 1.32 7.0E-12
Gene name, list of HGNC gene symbols; mean of normalized counts for all samples; differential 
gene expression between siRNA Fam111a and siRNA non-targeting expressed as fold change; 
P-value, FDR p<0.05, and corrected for multiple testing with the Benjamini-Hochberg correction.
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FAM111A binds to transcriptional activator STAT1 
eGFP-pull down experiments were performed to determine potential binding partners 
of FAM111A. A HeLa FRT-flp-in cell line was produced that stably expresses eGFP- 
FAM111A or eGFP-FAM111A R569H hotspot mutation to assess whether protein 
interactions are affected by this patient mutation. Proper expression of eGFP-FAM111A 
wildtype and R569H mutant protein was verified on immunoblot at the expected 
height of 100 kD (Figure 4A). A protein sample of cells expressing eGFP only was used 
as a positive control and displays eGFP (27 kD) expression at a height of ~34 kD. 
 An eGFP-pulldown on an ‘eGFP only’ expressing HeLa cell line was used as a 
control for non-specific binding. As expected, FAM111A was demonstrated to be 
significantly bound to itself, acting as a validation of the specificity of the GFP-pull 
down experiment (Figure 4B and C). STAT1 was the only protein that met the minimum 
requirements (FDR; p<0.015, Log2 fold change >6) as a potential interacting partner 
of the FAM111A wild-type protein. The FAM111A R569H mutant did not abolish the 
interaction with STAT1 (Figure 4C). The results of the FAM111A mutant pull down 
identified cysteine and glycine-rich protein 1 (CSRP1) to be significantly more present 
in the negative control compared to the FAM111A mutant (FDR; p<0.015, Log2 fold 
change >6) (Figure 4C). 
 Further examinations into FAM111A binding partners demonstrated five proteins 
(RPL23, RPF2, ELF6, KRT2 and RBM8A) with a higher affinity for binding to the 
FAM111A wildtype compared to the FAM111A mutant protein (FDR; p<0.025, Log2 
fold change >1.6) (Figure 4D). 
Table 3 |  Deregulated pathways in mpkDCT cells with decreased Fam111a expression
KEGG pathways
(upregulated genes)
Count p-value
Herpes simplex infection 6 <0.01
Hepatitis C 5 <0.01
Influenza A 5 0.01
Renin secretion 3 0.05
Chemokine signaling pathway 4 0.08
Toll-like receptor signaling pathway 3 0.09
KEGG pathways
(downregulated genes)
Count P-value
p53 signaling pathway 2 0.07
KEGG pathways analysis with up and downregulated genes P<0.01, Fold change >1.3. Columns indicate 
KEGG pathway, number of genes and P-value. KEGG, Kyoto Encyclopedia of Genes and Genomes.
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Figure 4 | FAM111A binds to transcriptional activator STAT1 
A) Immunoblot of protein lysate from HeLa cells stably expressing eGFP-FAM111A. The blot is 
stained for eGFP detecting ‘eGFP only’ (27 kD), eGFP-FAM111A (97 kD) and eGFP-FAM111A 
R569H (97 kD). Marker (ez-run prestained marker (ThermoScientific, Breda, The Netherlands) 
represents protein size in kilo Dalton (kD). B-D) The volcano plots display proteins that are 
bound to either FAM111A wild-type or FAM111A R569H versus an empty control sample or 
FAM111A wild-type versus FAM111A R569H. All samples are expressed as a Log2 fold change. 
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Discussion
The aim of this study was to elucidate the molecular mechanism explaining the 
disturbed electrolyte balance seen in KCS2 patients. Transcriptome analysis of a 
mouse DCT cell line demonstrated that decreased Fam111a expression upregulates 
several anti-viral pathways. One of the upregulated genes found in these anti-viral 
pathways was Stat1. eGFP-pull down experiments further substantiated that STAT1 is 
a binding partner of FAM111A. These experiments demonstrated that FAM111A 
might be a novel partner for STAT1 functioning, which could be conducive to the 
development of the KCS2 patient phenotype. 
 STAT1 is a key transcription factor that activates genes involved in cell 
proliferation, apoptosis and immunological processes.13, 14 STAT1 activity is regulated 
by the Janus (JAK) kinase family, which is essential for activating interferon (IFN)-α 
induced anti-viral responses.15, 16 In humans, loss-of-function mutations in STAT1 
increased susceptibly to mycobacterial and viral infections.17 This phenotype was 
reflected in a STAT1 knockout (KO) mouse model, which manifested as compromised 
innate immunity to viral disease.18 Fam111a knockdown indeed resulted in the 
upregulation of anti-viral pathways. A co-operating role of FAM111A-STAT1 complexes 
fits with previous literature on FAM111A, as depletion of FAM111A via RNA 
interference in CV-1P cells induced viral gene expression and replication.11 FAM111A 
was actively bound by the viral SV40 large T antigen c-terminus to reduce host range 
restriction activity of FAM111A allowing for increased viral RNA replication.11 It is, 
therefore, plausible that depletion or limited availability of FAM111A can act as a 
signal for the upregulation of other anti-viral genes like STAT1. Indeed, STAT1 
upregulation was confirmed in cells lacking Fam111a (Figure 3D).
 The interaction of FAM111A with STAT1 may also contribute to the electrolyte 
phenotype of KCS2 patients. STAT1 is a transcriptional activator of the CaSR,19 which 
is an important factor in Ca2+ and Mg2+ transport in the TAL by regulating Cldn14 
expression.20 The hypocalcemia found in critically ill patients suffering from burn 
injuries and sepsis is associated with CaSR upregulation activated by the STAT1/STAT3 
pathway in response to Interleukin-6 (IL-6) signaling.21, 22 Indeed, rats that were 
injected with interleukin (IL)-6, activating the STAT1/3 pathway, displayed significant 
decreases in serum PTH, 1,25(OH)2D3 (VitD) and Ca2+ levels.23, 24 These results are in 
line with the KCS2 patient’s hypoparathyroidism, hypocalcemia and hypomagnesemia, 
A positive Log2 fold change represents higher affinity to FAM111A wild-type or R569H versus 
the empty control B-C) or FAM111A R569H D). The statistical significance of the Log2 fold 
change is expressed as –Log10 FDR. The thresholds for binding are set at >6 Log2 fold change, 
FDR p<0.015 B), >6 Log2 fold change, FDR p<0.015 C), >1.6 Log2 fold change, FDR p<0.025 D).
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because increased expression of the Casr reduces Ca2+ and Mg2+ reabsorption in the 
kidney. The CaSR also directly regulates PTH release. Therefore, future studies should 
examine extra-renal effects of FAM111A. CaSR gain-of-function mutations are known 
to reduce PTH release aggravating the loss of Ca2+ and Mg2+ in the kidney and 
reducing Ca2+ resorption in bone.25 It is, therefore, important to investigate the 
function of FAM111A in parathyroid tissue to delineate potential direct effects on 
PTH secretion. 
 Based on our data, siRNA-mediated knockdown of FAM111A did not result in 
increased Casr and Cldn14 expression levels in MKTAL cells (Figure 2B). This could be 
due to insufficient knockdown of Fam111a. However, it cannot be excluded that the 
electrolyte phenotype of KCS2 patients is explained by STAT1-independent effects. 
Patients with heterozygous STAT1 gain-of-function mutations suffer from a different 
phenotype then KCS2, characterized by impaired IL-17 immunity causing chronic 
mucocutaneous candidiasis.17 This shows that STAT1 and FAM111A have different 
functional effects. Careful characterization of a FAM111A KO mouse model may help 
to determine STAT1-dependent and STAT1-independent effects. Furthermore, the 
binding of STAT1 to FAM111A requires confirmation in a co-immunoprecipitation 
(CO-IP) experiment. Other point mutations and deletions found in KCS2 patients 
could subsequently be investigated by CO-IP to determine whether these affect 
STAT1 binding to FAM111A.8, 26 This study focuses mainly on FAM111A functioning in 
the kidney. However, the results from the tissue panel (Figure 1A) indicated that, 
although Fam111a is present in the kidney, there seems to be a vastly increased 
expression of Fam111a in spleen, lung and linguinal fat. For spleen and lung, this is 
likely due to FAM111As’ anti-viral properties. As spleen holds a large reservoir of 
monocytes and both lung and spleen have an important role in combating infections.27, 
28 Despite these high relative expression levels of Fam111 in these tissues, the total 
mRNA level of Fam111a in kidney was detected at 25 PCR cycles by RT-qPCR. Meaning 
that Fam111a is expressed in sufficient quantities to participate in biological processes 
in the kidney. 
 In this study, we identified STAT1 as a new binding partner of FAM111A. Although 
the precise mechanism responsible for this binding is yet unclear, it is apparent that a 
decrease in Fam111a abundance in a mouse DCT cell line increases Stat1 expression 
levels. STAT1 is an important activator of Casr receptor transcription and could affect 
Ca2+ and Mg2+ reabsorption in the kidney and PTH release in the parathyroid. The 
KCS2 patient phenotype could therefore be caused by abnormal STAT1 expression 
and functioning due to mutations and deletions in its binding partner FAM111A. 
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Methods
Cell lines 
Human embryonic kidney cells (HEK293) were grown in Dulbecco’s modified Eagle’s 
medium (Lonza, Leusden, The Netherlands) containing 10% (v/v) fetal calf serum 
(FCS), 2 mM L-glutamine at 37 °C in a humidity controlled incubator with 5% (v/v) CO2. 
HeLa cells were cultured in DMEM (Lonza) containing 10% (v/v) FCS, 2 mM L-glutamine 
and 3 µg/ml blasticidin. MpkDCT4a were cultured as described previously.29 The 
immortalized mouse kidney TAL cell line (MKTAL) was derived from microdissected 
medullary TAL tubules.30 MKTAL cells were cultured in DMEM/HAM-F12 (1:1) (Lonza, 
Leusden, The Netherlands) containing 5% (v/v) FCS and 2 mM L-glutamine, at 37°C in 
a humidity controlled incubator with 5% (v/v) CO2.30 
Tissue panel 
Tissues were harvested from C57BL/6 wildtype mice and homogenized using a tissue 
homogenizer. Total RNA was isolated as described in the Real-Time quantitative PCR 
section (RT-qPCR). Primers for Fam111a are described in Table 4. Tubules were sorted 
with a COPAS Biosort cell sorter (Union biometrica, Geel, Belgium) as described in a 
previous study.31 
Real-Time quantitative PCR
MpkDCT4a and MKTAL cells were transiently transfected with 100 pmol of a siRNA 
smart pool against Fam111a (Dharmacon, Lafayette, USA). Cells were transfected 
using lipofectamine 2000 (Invitrogen, Breda, The Netherlands) adding 3 µl for each 
condition. After 48 hours, Total RNA isolation was performed with TRizol (Invitrogen, 
Breda, The Netherlands). 1.5 µg of RNA was used for reverse transcription using a 
Moloney Murine Leukemia Virus (M-MLV) reverse transcriptase protocol as described 
by the manufacturer (Invitrogen, Breda, The Netherlands). The cDNA was used to 
determine mRNA expression levels by CF96 Real-Time PCR detection system (Bio-Rad, 
Veenendaal, The Netherlands) for target genes of interest and of the housekeeping 
gene glyceraldehyde 3-phosphate dehydrogenase (Gapdh), as an endogenous control. 
RT-qPCR primers are reported in Table 4.
Cloning 
Human FAM111A full-length cDNA was amplified by PCR from human cDNA clone 
(clone IRAUp969C0699D), ImaGenes), and subcloned into the pcDNA/FRT-TAP eGFP 
expression vector using a high fidelity DNA polymerase (Phusion, Thermofisher, 
Amsterdam, The Netherlands). The PCR product was digested with restriction 
enzymes KpnI and XhoI (New England Biolabs Ltd, Leiden, The Netherlands). The 
sequence was than ligated into a pcDNA/FRT-TAP vector behind the eGFP using T4 
521424-L-sub01-bw-Kompatscher
Processed on: 24-7-2018 PDF page: 102
102 | Chapter 4
DNA ligase to create the eGFP-FAM111A fusion protein (New England Biolabs Ltd, 
Leiden, The Netherlands). Primers used were; forward 5’- ATGCCACCAGCTGTA-
AGAAGCAGAGGTC-3’ and reverse 5’- ATCTCGAGTCACAAGTCCTCATCACTCAT-
CATTTC-3’. FAM111A p.Arg569His was obtained by site-directed mutagenesis 
(Stratagene, La Jolla, USA).32 Primers used for mutagenesis were; forward 5’- 
CCAAGATATGAAACTTAAGCTCACACATAGTGAGAATAGTAG-3’ and reverse 5’- 
CTACTATTCTCACTATGTGTGAGCTTAAGTTTCATATCTTGG-3’.
Stable eGFP-FAM111A HeLa cell line
300,000 HeLa flp-in cells were seeded into a 6-well plate. After 12 hrs, the medium 
was changed to HeLa cell medium without blasticidin (Sigma-Aldrich, Zwijndrecht, 
The Netherlands). Cells were transiently transfected with 2 µg of pcDNA5-flp-in 
eGFP-FAM111A or pcDNA5-flp-in eGFP-FAM111A R569H constructs with 200 ng 
pOG44 Flp-recombinase expression vector. 3 µl of lipofectamine 2000 (Invitrogen, 
Breda, The Netherlands) was used for each 1 µg of DNA. After 24 hrs, 100 µg/ml was 
added to the HeLa medium to start the selection procedure. eGFP-FAM111A 
expression was induced by adding 1 µg/ml of tetracycline to the cells. 
Table 4 |  Primer Sequences for RT-qPCR
Forward Reverse
Gapdh 5’-TAACATCAAATGGGGTGAGG-3’ 5’-GGTTCACACCCATCACAAAC-3’
Fam111a 5’-TAACATCAAATGGGGTGAGG-3’ 5’-GGTTCACACCCATCACAAAC-3’
Trpm6 5’-AAAGCCATGCGAGTTATCAGC-3’ 5’-CTTCACAATGAAAACCTGCCC-3’
Slc41a1 5’-CCGCGATTTATCAGAGC-3’ 5’- AGATCCTTGAGGTAGAGGAA-3’
Cnmm2 5’-GCCTTTAAGCAGACGGACAG-3’ 5’-GATGGGCTAAACGCTTCTAC-3’
proEgf 5’-GAGTTGCCCTGACTCTACCG-3’ 5’-CCACCATTGAGGCAGTATCC-3’
Egfr 5’- CAGAACTGGGCTTAGGGAAC-3’ 5’- GGACGATGTCCCTCCACTG-3’
Casr 5’-CTTTCCTATCCATTTTGGAGTAGCA-3’ 5’-GCAAAGATCATGGCTTGTAACCA-3’
Cldn16 5’-GTTGCAGGGACCACATTAC-3’ 5’-GAGGAGCGTTCGACGTAAAC-3’
Cldn19 5’-GGTTCCTTTCTCTGCTGCAC-3’ 5’-CGGGCAACTTAACAACAGG-3’
Cldn14 5’-GTCCAGCTCCTAGGCTTCCT-3’ 5’-CATCCACAGTCCCTTCAGGT-3’
Gapdh, glyceraldehyde 3-phosphate dehydrogenase; Trpm6, transient receptor potential 
cation channel, subfamily M, member 6; Slc41a1, solute carrier family 41 member 1; Cnnm2, 
Cyclin M2; proEgf, epidermal growth factor; Egfr, epidermal growth factor receptor; Casr, cal-
cium-sensing receptor; Cldn16, Claudin16; Cldn19, Claudin19; Cldn14, Claudin14
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Immunoblotting
Cells expressing eGFP-FAM111A, eGFP-FAM111A R569H or ‘eGFP only’ were lysed in 
lysis buffer (50 mM Tris/HCl pH 7.5, 1 mM EDTA, 1 mM EGTA, 1 mM Na-Orthovandate, 
5 mM NaF, 5 mM glycerolphosphate 0.27 M sucrose and 1 tablet of complete protease 
inhibitor cocktail (Roche) containing 1% (v/v) Triton X-100. Protein concentrations 
were measured with a colorimetric Pierce BCA protein assay kit (ThermoFisher 
scientific, Breda, The Netherlands) according to the manufacturer’s protocol. In short, 
samples were loaded on a 96 well plate, incubated for 30 minutes at 37 °C and 
measured at 562 nm with a Biorad Benchmark plus microplate photospectrometer 
(Biorad, Veenendaal, The Netherlands). Samples were set to 1 µg/µl of protein. 
 Protein lysates were denatured in Laemmli containing 100 mM Dithiothreitol 
(DTT) for 5 minutes at 95 °C. Samples were then subjected to SDS-PAGE and 
Immunoblots were incubated with a rabbit polyclonal anti-GFP antibody (ab290, 
1:5,000) (Abcam, Cambridge, UK) in 5% (w/v) milk o/n at 4 °C. Then, immunoblots 
were incubated 45 minutes at RT in 5% (w/v) milk with peroxidase conjugated goat 
anti-rabbit (1:10,000) secondary antibodies (Sigma-Aldrich, Zwijndrecht, The Netherlands). 
RNA-seq
mpkDCT cells were transiently transfected with 100 pmol of a siRNA smart pool 
against FAM111A or a non-targeting control (Dharmacon, Lafayette, USA). Total RNA 
was isolated with the RNeasy micro kit according to the manufacturer’s protocol 
(Qiagen, Venlo, The Netherlands). Fam111a knockdown was confirmed by RT-qPCR. 
RNA quality was assessed on an Experion bioanalyzer (Bio-rad, Veenendaal, The 
Netherlands). RNA integrity numbers (RIN) for all samples were >9. Library preparation 
was performed on 4 control and 4 experimental samples with a KAPA hyper prep kit 
according to the manufacturer’s protocol (Roche, Woerden, The Netherlands). 
 In short, 1 µg of Poly(A) RNA was captured with magnetic oligo-dT beads. Total 
RNA was fragmented for 6 min at 94 ºC. The total RNA is converted to double-stranded 
cDNA by 1st and 2nd strand cDNA synthesis followed by A-tailing. Seperate adapters 
are ligated to the cDNA fragments for each library sample. The libraries were then 
amplified by PCR for 9 cycles. The library was size selected (200-250 bp) on an E-gel 
(Thermo Fisher Scientific, Amsterdam, The Netherlands). No PCR induced bias was found 
using RT-qPCR. Sample quality and size was confirmed on an Experion bioanalyzer. 
Samples were sequenced with paired end (2X 42bp) on an Illumina NexSeq 500 
(Illumina, Eindhoven, The Netherlands). 
 Data analysis was performed as follows. Raw sequencing data was demultiplexed 
with Illumina software to obtain fastq files. Fastq files were mapped on the mm10 
mouse genome with GRCm38 vM16 annotation from gene code using STAR v2.5.3a.33 
The quantMode TranscriptomeSAM GeneCounts option was used to quantify the 
count table containing the number of reads per gene. The gene count table was 
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imported in DESeq2 and analyzed as a pairwise comparison using the default Wald 
statistics to normalize the data and test for significance.34 Results were revised for 
multiple testing using the Benjamini-Hochberg correction.
Label free pulldown
HeLa cells stably expressing eGFP-FAM111A or eGFP-FAM111A R569H were seeded 
in 12 cm ø Petri dishes. Tetracycline (1 µg/ml) was added to the medium at 80-90% 
confluency. After 16 hrs, cells were harvested to achieve optimal protein production. 
Label-free eGFP-pulldowns were performed in triplicate as described in Smits et al.35 
For GFP-pulldowns, 1 mg of nuclear extract was incubated with 7.5ul beads (GFP-TRAP; 
Chromotek, Planegg-Martinsried, Germany) in incubation buffer (300 mM NaCl, 20 mM 
HEPES KOH pH 7.9, 20% v/v glycerol, 2 mM MgCl2, 0.2 mM EDTA, 0.25% v/v NP-40, 
complete protease inhibitors, and 0.5 mM DTT) in the presence of 50 µg/ml ethidium 
bromide (Sigma-Aldrich, Zwijndrecht, The Netherlands) to prevent indirect DNA 
mediated interactions. Beads were washed two times with incubation buffer (0.5% v/v 
NP-40), two times with phosphate-buffered saline (PBS) (0.5% v/v NP-40) and finally 
two times with PBS. Subsequently, the proteins were subjected to on-bead trypsin 
(Promega, Leiden, The Netherlands) digestion and peptides were acidified and desalted 
using C18-Stagetips.35 Protein yield was determined using a Bradford assay (Sigma-
Aldrich, Zwijndrecht, The Netherlands) before moving on to mass spectrometry.
Mass spectrometry and data analysis 
Before mass spectrometry analysis, peptides were eluted from the C-18 stagetips and 
recorded with LC-MS/MS Orbitrap Fusion Tribrid mass spectrometer (ThermoFisher 
Scientific, Breda, The Netherlands) at top speed mode of 3 seconds cycle.36 Raw data 
were analyzed by MaxQuant (1.5.1.0)37 using default settings and searching against 
the Human Uniprot database downloaded on December 2015. Statistical outliers for 
the eGFP-pulldown of the Hela empty WT compared to FAM111A WT or FAM111A 
mutant samples were determined using a two-tailed t-test. A correction for multiple 
testing was applied by using a permutation-based FDR method in Perseus (MaxQuant 
package). Differential proteins between Hela empty WT and FAM111A WT or 
FAM111A mutant samples were presented in a volcano plot with FDR <0.015 and fold 
change >6. Statistical cut-offs were chosen such that no proteins were present as 
outliers on the empty vector control side of the volcano plot. 
Data analysis
All results presented are based on at least three different experiments. Values are 
expressed as mean ± SEM. Statistical significance (P<0.05) was determined using 
one-tailed Students T-test or one-way ANOVA with Holm-Sidak procedure unless 
otherwise specified.
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Abstract
ATP-mediated signaling is an important regulator of electrolyte transport in the kidney. 
The purinergic cation channel P2X6 has been previously localized to the distal 
convoluted tubule (DCT), a nephron segment important for Mg2+ and Na+ reabsorption, 
but its role in ion transport remains unknown. In this study, P2x6 knockout (P2x6-/-) 
mice were generated to investigate the role of P2X6 in renal electrolyte transport. 
The P2x6-/- animals displayed a normal phenotype and did not differ physiologically 
from wild type mice. Differences in serum concentration and 24-hrs urine excretion 
of Na+, K+, Mg2+ and Ca2+ were not detected between P2x6+/+, P2x6+/- and P2x6-/- 
mice. Quantitative PCR was applied to examine potential compensatory changes in 
renal expression levels of other P2x subunits and electrolyte transporters, including 
P2x1-5, P2x7, Trpm6, Ncc, Egf, Cldn16, Scnn1, Slc12a3, Slc41a1, Slc41a3, Cnnm2, Kcnj10 
and Fxyd2. Additionally, protein levels of P2X2 and P2X4 were assessed in P2x6+/+ and 
P2x6-/- mouse kidneys. However, significant changes in expression were not detected. 
Furthermore, no compensatory changes in gene expression could be demonstrated 
in heart material isolated from P2x6-/- mice. Except for a significant (P<0.05) upregulation 
of P2x2 in the heart of P2x6-/- mice compared to the P2x6+/+ mice. Thus, our data 
suggests that purinergic signaling via P2X6 is not significantly involved in the regulation 
of renal electrolyte handling under normal physiological conditions.
Keywords: P2X6, ATP, DCT, Purinergic cation channel, Kidney
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Introduction
Adenosine triphosphate (ATP) is an important mediator of cellular communication. In 
normal physiological conditions, extracellular ATP is involved in a wide variety of cell 
signaling processes including the recruitment of leukocytes and platelets to damaged 
cells and sites of increased cell death.1-3 In the kidney, ATP-mediated purinergic 
signaling has been linked to renal inflammation 4 and fibrosis.5 Purinergic signaling is 
also involved in the regulation of Na+ and water transport 6, which means it is one of 
the factors involved in the onset of hypertension.7-10 
 ATP activates both P2X and P2Y receptors.11 Whereas P2Y receptors are G pro-
tein-coupled receptors, P2X receptors form ATP-sensitive ion channels that are 
expressed at the surface of epithelial cells throughout the body.12-14 P2X subunits 
assemble in homo- or heterotrimers with large extracellular loops forming ATP binding 
sites.12, 15 Activation of P2X receptors by extracellular ATP results in the non-selective 
influx of cations into the cell. The P2X family of receptors consists of seven subtypes 
(P2X1-7).12, 16 Within the kidney, P2X receptors are commonly described as inhibitors of 
ion transport.6 In mouse collecting duct (CD) cells, ATP release inhibits ENaC mediated 
Na+ uptake 9, which has been linked to P2X2, P2X4, P2X2/6 and P2X4/6 activity. P2 
channel activity has also been implicated in the inhibition of water uptake via AQP2.17 
 Recent studies demonstrated that P2X receptors regulate electrolyte reabsorption 
in the distal convoluted tubule (DCT).18, 19 A screening of P2x receptors expression 
levels revealed that P2X4 and P2X6 are the predominant P2X subtypes in the DCT.18 
P2X6 forms heteromers with P2X4.19, 20 Recently, P2X4 homomers were found to 
directly inhibit the apical Mg2+ channel transient receptor potential cation channel 
subfamily M, member 6 (TRPM6). In the DCT, TRPM6 is the main channel for Mg2+ 
reabsorption, and extracellular ATP inhibits Mg2+ uptake by increasing P2X-mediated 
Ca2+ influx.21 However, the role of P2X6 in the regulation of Mg2+ transport is still 
unknown.
 The aim of the present study was, therefore, to determine the function of P2X6 
in renal electrolyte handling. To this end, P2x6-/- mice were generated and functionally 
characterized by measuring serum levels and 24-hour urine excretion of Na+, Mg2+, K+ 
and Ca2+. Potential compensatory mechanisms for loss of P2x6 gene function were 
measured by RT-qPCR analysis. 
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Results
Breeding of P2x6-/- mice 
To assess the function of P2X6 in vivo, P2x6-/- mice were generated (Figure 1A). 
Inactivation of the P2x6 gene was achieved by inserting a LacZ knockout (KO) cassette 
in exon 2 of the gene. The breeding of P2x6+/- mice resulted in a normal Mendelian 
inheritance pattern in offspring. Of a total of 116 mice, 23% were genotyped P2x6+/+, 
49% P2x6+/- and 28% P2x6-/-. All offspring were genotyped for the insertion of the 
knockout cassette and presence of the wild type P2x6 allele (Figure 1B). Mouse heart 
cDNA was used to establish the presence of full-length P2x6 transcripts in P2x6+/+ 
mice and the complete absence of P2x6 expression or potential alternatively spliced 
transcripts in P2x6-/- animals (Figure 1C). The expected PCR products were present in 
P2x6+/+ mice and not detectable in the P2x6-/- animals. 
Normal behavior in P2x6-/- mice
P2x6+/+, P2x6+/- and P2x6-/- mice were subjected to an inspection of behavior and 
phenotype according to the guidelines for assessing the health and condition of mice 22. 
All genotypes had a body condition scoring (BCS) of 3, indicating that all animals 
were in optimal condition. No changes in breathing, grooming and fur quality were 
observed. Mice exhibited no problems with any voluntary movement or with 
supporting their own body weight. Both eyes and ears were normal in all genotypes. 
All mice displayed normal open field behavior. No Fighting wounds could be detected 
after thorough examination and there were no mice with a rectal or vaginal prolapse.
Normal renal electrolyte handling in P2x6-/- mice
To investigate the role of P2X6 in renal electrolyte handling, blood, 24 hrs urine and 
feces were collected using metabolic cages. No significant differences in body weight, 
food and water intake were identified between P2x6+/+, P2x6+/- and P2x6-/- mice 
littermates (Table 1). Furthermore, urine production did not significantly change 
between the three mice groups. A similar trend was observed in the feces production, 
which was not significantly altered. Because P2X6 is localized to the DCT, changes in 
electrolyte handling were expected for Na+ and Mg2+. However, measurements of 
serum (Figure 2A and E) and 24 hrs urinary excretion (Figure 2B and f) showed that all 
groups have similar Na+ or Mg2+ concentrations and excretion rates, respectively. 
Furthermore, serum and 24 hrs urine excretion of Ca2+ and K+ remained unchanged 
regardless of genotype (Figure 2C, D, G and H). 
521424-L-sub01-bw-Kompatscher
Processed on: 24-7-2018 PDF page: 113
P2X6 knockout mice exhibit normal electrolyte homeostasis | 113
Gene expression of renal electrolyte transporters is not altered  
in P2x6-/- mice 
Since P2x6 has been implicated in regulating both Na+ and Mg2+ transport in the 
kidney. The renal expression of several sodium and magnesiotropic genes was 
analyzed in the two mice groups using RT-qPCR (Figure 3). Significant changes in the 
renal transcript levels of the apically expressed magnesium channel Trpm6 were not 
detected, neither where there expression differences for Egf, which regulates Trpm6 
activity (Figure 3A and B) 23. Cldn16 was measured to investigate whether paracellular 
Mg2+ transport in the thick ascending limb of Henle’s loop (TAL) was affected in the 
P2x6-/- mice. However no significant changes in Cldn16 transcript levels were detected 
(Figure 3C). Since the epithelial Na+ channel (ENaC) activity is inhibited by purinergic 
signaling 9, its transcript levels were measured. Scnn1 expression, encoding ENaC was 
the same in P2x6+/+ and P2x6-/- litter mates (Figureure 3E and F). Other Na+ and Mg2+ 
related genes expressed in the DCT cell such as Slc12a3, Cnnm2, Kcnj10, Slc41a1, 
Slc41a3 and Fxyd2 were also analyzed (Figure 4), since P2x6 was localized to this 
nephron segment. Again, there was no marked difference in expression levels 
between the two mice groups. To investigate whether other P2x subunits would 
compensate for the inactivation of P2x6, the genes encoding P2x1-5 and 7 were also 
analyzed for changes in expression, but no quantifiable changes could be found 
(Figure 5). To ensure that the putative binding partners of P2X6, namely P2X2 and 
P2X4, did not compensate for the loss of P2x6 at the protein level, Western blots for 
P2X2 and P2X4 were performed using membrane and cytosol fractions of P2x6+/+ and 
P2x6-/- mouse kidneys. P2X4 was detected in both the membrane and cytosol, 
whereas P2X2 was only detected in the membrane fraction. Both proteins displayed 
a band at the expected height of ~54 kD (Figure 6A). After quantification no significant 
differences were found between P2x6+/+ and P2x6-/- mice (Figure 6B). 
Table 1 |  Metabolic Parameters of P2x6 Mice.
P2x6+/+ P2x6+/- P2x6-/-
Body weight (g) 21.5 ± 0.9 21.9 ± 1.0 21.6 ± 1.0
Water intake (mL) 4.1 ± 0.1 4.8 ± 0.2 4.7 ± 0.2
Food intake (g) 3.4 ± 0.3 3.9 ± 0.1 3.9 ± 0.1
Urine volume (mL) 1.2 ± 0.1 1.2 ± 0.1 1.3 ± 0.1
Feces weight (g) 1.4 ± 0.1 1.6 ± 0.0 1.7 ± 0.1
Body weight, water intake, food intake, urine volume and feces weight was assessed after 
housing the animals for 48 hrs in metabolic cages. Numbers represent the mean ± SEM.
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Figure 1 | Characteristics of the P2x6-/- mouse
A) Targeted insertion of the knockout (KO) cassette. Top: P2x6 locus on chromosome 16. 
Bottom: targeted allele in which the KO cassette is inserted within exon 2. Grey boxes indicate 
exons, arrows depict genotype primers. A-C) SA: Splice acceptor site, IRES: internal ribosome 
entry site, LacZ: ß-galactosidase, NEO: neomycin cassette, pA: polyA.  B) Identification of the 
mouse genotype by PCR analysis of ear-derived DNA. The PCR product size ± 478 bp shows the 
presence of the wild-type allele (+/+), using primers A and C; the PCR product sized ± 800 bp 
shows the KO allele (-/-) using primers B and C. Both alleles are detected in heterozygous 
animals (+/-).  c) cDNA isolated from murine heart samples were used to amplify exons 1-12 of 
P2x6 with PCR. The top agarose gels show the PCR products for exons 1-12 in two P2x6+/+ 
animals. The lower gels represent the PCR products for exons 1-12 in two P2x6-/- animals.
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Figure 2 | Normal renal electrolyte handling in P2x6-/- mice
A) Serum Mg2+ concentrations of wildtype, heterozygous and knockout P2x6 mice.  B) 24 hrs 
urinary Mg2+ excretion of wildtype, heterozygous and knockout P2x6 mice.  C) Serum Ca2+ 
concentrations.  D) 24 hrs urinary Ca2+ excretion.  E) Serum Na+ concentrations.  F) 24 hrs urinary 
Na+ excretion.  G) Serum K+ concentrations.  H) 24 hrs urinary K+ excretion. Values (n=10) are 
presented as means ± SEM.
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Figure 3 |  Gene expression of renal electrolyte transporters was not altered  
in P2x6-/- mice 
A-F) The mRNA expression levels of Trpm6 (A), Egf (B), Cldn16 (C), Cnnm2 (D), Scnn1a   (E), Slc12a3 
(F) in kidney of P2x6+/+ (Black bars), P2x6+/- (Striped bars), P2x6-/- (white bars) mice were 
measured by quantitative RT-PCR and normalized for Gapdh expression. Data (n=10) represent 
mean ± SEM and are expressed as the fold difference when compared to the expression in 
P2x6+/+ mice.
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Figure 4 |  P2x subunit expression in response to the loss of P2x6 function  
in the kidney
A-F) The mRNA expression levels of P2x1 (A), P2x2 (B), P2x3 (C), P2x4 (D), P2x5 (E), P2x7 (F), in 
kidney of P2x6+/+ (Black bars), P2x6+/- (Striped bars), P2x6-/- (white bars) mice were measured by 
quantitative RT-qPCR and normalized for Gapdh expression. Data (n=10) represent mean ± SEM and 
are expressed as the fold difference when compared to the expression in P2x6+/+ mice.
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Figure 5 |  Basolaterally expressed compensatory mechanisms for the loss of  
P2X6 function in the kidney
A-D) The mRNA expression levels of Fxyd2 (A), Kcjn10 (B), Slc41a1 (C), Slc41a3 (D) in kidney 
of P2x6+/+ (Black bars), P2x6+/- (Striped bars), P2x6-/- (white bars) mice were measured by 
quantitative RT-qPCR and normalized for Gapdh expression. Data (n=10) represent mean ± SEM 
and are expressed as the fold difference when compared to the expression in P2x6+/+ mice.
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Figure 6 | Protein abundance of P2X2 and P2X4 in response to the loss of P2X6
A) Western blots of membrane and cytosol fractions of P2x6-/- (KO) and P2x6+/+ (WT) mice. The 
upper blot shows the immune-staining for P2X2 in mouse kidney material. To the right a western 
blot of HEK293 cells transiently transfected with HA-tagged P2X4 (P4) and mock (M) constructs is 
displayed. Middle, two western blots below are immune-stained for P2X4, left depicts P2x6-/- 
(KO) and P2x6+/+ (WT) material stained for P2X4, right represents a P2X4 blot on HEK293 material 
transiently transfected with human P2X4 and a mock construct. Bottom, displays a ß-actin im-
mune-staining used as a loading control. Ladders (ez-run prestained marker (ThermoScientific, 
Breda, The Netherlands) represent protein size in kilo Dalton (kD).  B) Protein expression levels for 
the P2X2 membrane lysate, P2X4 membrane lysate, P2X4 cytosol lysate, ß-actin membrane and 
ß-actin cytosol lysates in P2x6-/- and P2x6+/+ mice. Data (n=3) represents mean ± SEM and are 
expressed as the % of total band intensity.
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Figure 7 | Compensatory mechanisms for the loss of P2X6 function in the heart 
A-H) The mRNA expression levels of P2x1 (A), P2x2 (B), P2x3 (C), P2x4 (D), P2x5 (E), P2x7 (F), Trpm7 
(G), Cnnm2 (H), in heart of P2x6+/+ (Black bars), P2x6+/- (Striped bars), P2x6-/- (white bars) mice 
were measured by quantitative RT-qPCR and normalized for Gapdh expression. Data represent 
mean (n=10) ± SEM and are expressed as the fold difference when compared to the expression in 
P2x6+/+ mice. * P<0.05 indicates a significant difference from P2x6+/+ mice.
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Increased P2x2 expression in P2x6-/- heart 
Since upregulation of P2X6 has been linked to chronic heart disease 24, RT-qPCR 
analysis was performed on heart tissue of P2x6-/- mice. As in the kidney, expression of 
the magnesiotropic genes Trpm7 and Cnnm2 remained unchanged. The P2x2 subunit 
was however significantly upregulated two-fold (P<0.05) in the P2x6-/- heart material 
compared to P2x6+/+ mice. P2x subunits 1, 3-5 & 7 did not show significant differences 
in gene expression (Figure 7). 
Discussion
This study demonstrated that P2X6 knockout mice have a normal phenotype, 
suggesting that P2X6 does not play a significant role in renal electrolyte handling. 
P2x6-/- mice were physiologically similar to their wild-type littermates in terms of 
behavior, weight, food or water intake. No significant changes in serum concentrations 
or urinary excretion were observed for Na+, K+, Ca2+ and Mg2+ in P2x6 null mice. 
Furthermore, loss of P2X6 function did not induce compensatory gene expression of 
any P2X purinergic receptors or other ion transporters that were investigated in the 
kidney. Likewise, no changes in P2X2 and P2X4 protein levels were detected in the 
kidneys of the P2x6 null mice compared to wild type littermates. Together, these 
results suggest that P2X6 is not involved in renal electrolyte handling under normal 
physiological conditions.
 P2X receptors have been established as important negative regulators of ion 
transport in the kidney.25 Specifically, homomers of P2X4 receptors and heteromeric 
complexes of P2X4 and P2X6 have been implicated in the reabsorption of Na+ and 
Mg2+.9, 26 In microdissected tubules of the TAL, extracellular ATP inhibited Na+ 
currents in a P2X-dependent manner.10 P2X4 receptors also result in diminished 
TRPM6-mediated currents when overexpressed in HEK293 cells.18 Moreover, several 
studies showed that P2X4 homomers and P2X4/6 heteromers inhibit ENaC in the CD, 
decreasing Na+ reabsorption.17 26 Although this vast amount of in vitro studies shows 
the importance of ATP in the regulation of renal ion channel activity, the physiological 
consequences remain undecided. In this study, we revealed that loss of P2X6 does 
not impair electrolyte handling in vivo, since renal electrolyte handling is unaffected 
in P2x6-/- mice. Moreover, previous studies demonstrated that P2x4-/- mice also 
displayed normal renal Mg2+ excretion.18 These findings question the in vivo role of 
P2X receptors for renal electrolyte handling.
 There are several explanations for the absence of a renal phenotype in P2x6-/-. 
First, the loss of P2X6 function may be compensated for by other P2x subunits. P2X6 
functions in complexes with P2X2 or P2X4 and their function may counterbalance the 
loss of P2X6. However, our expression profile did not show differences in P2x2 and 
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P2x4 expression at the transcriptional and protein level in P2x6-/- mice. Second, 
P2x6-/- mice might need to be challenged to reveal disturbances in Na+ or Mg2+ 
handling. For instance, in rat cardiomyocytes, P2x6 expression is low under normal 
physiological condition.27, 28 However, studies in patients have shown that P2X6 
expression significantly increases after an ischemic cardiac event.24 This latter study 
demonstrated that when the system is pathologically challenged, P2X6 expression 
can be induced. In our study, compensatory mechanisms, e.g. upregulation of other 
P2x subunits in the heart, were not detected in the P2x6-/- mice, except for a significant 
increase in P2x2 transcript. For now, which pathogenic factors would stimulate renal 
P2X6 expression are unknown. A transcriptome-wide screening, where mice were 
challenged with Mg2+-deficient diets, found no differences in P2x4 and P2x6 
expression in the DCT.29 Third, the mouse may not provide a good model to study the 
role of P2X purinoreceptors in the DCT. Although previous studies have shown that 
P2x6 is the predominantly expressed P2x transcript in the DCT together with P2x4, 
P2X4 protein expression could not be confirmed in the DCT.18 These findings together 
with our results shed doubt on the presence of functional P2X4/P2X6 trimers in the 
DCT.
 Over the last decade, the function of P2X6 has been widely debated.19, 30, 31 
Although recombinant homomeric P2X6 complexes have been reported to reach the 
plasma membrane in transiently transfected HEK293 cells 32, Others have shown that 
P2X6 requires the presence of P2X4 or P2X2 to become functional at the cell 
surface.30, 33-35 This has been attributed to P2X6 lacking charged residues in the 
N-terminus, which prevents trafficking of the protein to the membrane.19 Recent 
studies suggest that P2X6 may function as a nuclear regulator of post-transcriptional 
modifications in neurons.31 However, nuclear localization has not been identified in 
other tissues.36 Further in vitro studies are required to examine the function of P2X6.
 In conclusion, P2x6-/- mice exhibit an apparent normal physiological behavior 
and renal electrolyte handling under normal conditions. Serum Na+, Mg2+, K+ and Ca2+ 
concentrations were not significantly different compared to wild type littermates and 
compensatory expression of relevant electrolyte transporters was absent. Thus, 
P2X6 is likely not significantly involved in the regulation of renal electrolyte handling 
under normal physiological conditions. Our results, therefore, question the essential 
role of P2X6 in normal electrolyte homeostasis.
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Methods
P2X6-/- mice
All experiments were performed in compliance with the Central Animal Laboratory 
Nijmegen and the animal ethics board of the Radboud University Nijmegen (DEC 
#2013-185). P2x6+/- mice (mus musculus), from a mixed background, (B6J-129P2-
P2RX6) were provided by The Mary Lyon Centre, Oxfordshire, UK. The acquired 
P2x6-/- mice were backcrossed once with C57BL/6 wild-type. 6-10 littermates were 
housed in standard cages with bedding material consisting of straw and paper in a 
temperature- and light-controlled room with standard pellet chow and deionized 
drinking water available ad libitum (ARRIVE guidelines). To confirm full loss of P2x6, 
PCR amplification of the complete P2x6 transcript was performed in isolated mouse 
heart cDNA. PCR products were designed to be exon-exon junction spanning and 
amplify several exons in a range of 145-564 bp in ascending order. PCRs were 
performed with Amplitaq Gold 360 mastermix (Invitrogen, Bleiswijk, The Netherlands) 
in a Biometra T3000 (Westburg, Leusden, The Netherlands). Primer sequences are 
described in Table 1. 
Phenotyping
Phenotyping was performed on P2x6+/+, P2x6+/- and P2x6-/- mice to assess differences 
in behavior and phenotype. Body condition scoring (BCS) was performed as described 
previously.22 Mice were checked for abnormal breathing, grooming and fur condition. 
Additionally, mice were closely monitored for the ability to support their own body 
weight and whether they lacked voluntary movement of the fore and hind limbs. Eyes 
and ears were visually inspected for abnormalities. All mice were thoroughly 
investigated for fighting wounds. Furthermore, animals were checked for bearing a 
possible rectal or vaginal prolapse. Activity and curiosity of the animals was verified 
by assessing open-field behavior as described previously.22 
Experimental set-up
The experimental sample size was determined by a power calculation (N≥2σ(Zα+Zβ)2/
δ2), based on an estimated urinary Mg2+ excretion of 65 ± 35 µmol/day.37 A difference 
of 70% (45 µmol/day) (δ) with a standard deviation of 75% (48 µmol/day) (σ) in urinary 
Mg2+ excretion was expected, combined with a power of 80% (β) and a significance 
threshold of 5% (α) this results in a minimum sample size of 10 animals (N) per group. 
For the experiment, 30 adult male mice (10 P2x6-/- (knock-out), 10 P2x6 +/- 
(heterozygous) and 10 P2x6+/+ (wild-type)) were housed individually in mouse 
metabolic cages during the last 48 hrs for urine and feces collection (24 hrs adaptation, 
24 hrs sampling). Littermates were allocated to an experimental group based on 
genotype. Animals were 8-10 weeks old. Blood samples were collected by orbita 
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extraction in isoflurane-anesthetized mice during the day. The primary outcome 
measure was changes in urinary Mg2+ excretion levels between experimental groups. 
Secondary measures were differences in other electrolytes, such as Na+, K+ and Ca2+. 
After being anesthetized with 4% (v/v) isoflurane, all thirty mice were sacrificed. 
Blood samples, kidneys and hearts were collected and the organs were immediately 
frozen in liquid nitrogen.
Table 2 |  Primer Sequences for RT-qPCR
Forward Reverse
Gapdh 5’-TAACATCAAATGGGGTGAGG-3’ 5’-GGTTCACACCCATCACAAAC-3’
P2x1 5’-CCGAAGCCTTGCTGAGAA-3’ 5’-GGTTTGCAGTGCCGTACAT-3’
P2x2 5’-CACCACCACTCGAACTCTCA-3’ 5’-GGTACGCACCTTGTCGAACT-3’
P2x3 5’-GGTGGCTGCCTTCACTTC-3’ 5’-TCAGCCCCTTTGAGGAAA-3’
P2x4 5’-TTGGCTCTGGCTTGGCGCTC-3’ 5’-TCTCCGGAAAGACCCTGCTCG-3’
P2x5 5’-GAGCGAGTTTTACCGAGACAAG-3’ 5’-GATGAACCCTCTCCAGTGGC-3’
P2x7 5’-GGGGGTTTACCCCTACTGTAA-3’ 5’-GCTCGTCGACAAAGGACAC-3’
Trpm6 5’-AAAGCCATGCGAGTTATCAGC-3’ 5’-CTTCACAATGAAAACCTGCCC-3’
Cnnm2 5’-GGAGGATACGAACGACGTG-3’ 5’-TTGATGTTCTGCCCGTACAC-3’
Egf 5’-GAGTTGCCCTGACTCTACCG-3’ 5’-CCACCATTGAGGCAGTATCC-3’
Cldn16 5’-GTTGCAGGGACCACATTAC-3’ 5’-GAGGAGCGTTCGACGTAAAC-3’
Slc12a3 5’-CTTCGGCCACTGGCATTCTG-3’ 5’-GATGGCAAGGTAGGAGATGG-3’
Scnn1a 5’-CATGCCTGGAGTCAACAATG-3’ 5’-CCATAAAAGCAGGCTCATCC-3’
Trpm7 5’-GGTTCCTCCTGTGGTGCCTT-3’ 5’-CCCCATGTCGTCTCTGTCGT-3’
Fxyd2 5’-TCAGCCTTTCTTGTGACTGG-3’ 5’-GGTCTTCCTGTGGCCTCTACT-3 ‘
Kcjn10 5’-CCGCGATTTATCAGAGC-3’ 5’-AGATCCTTGAGGTAGAGGA A-3’
Slc41a1 5’-CATCCCACACGCCTTCCTGC-3’ 5’-CGGCTGGCCTGCACAGCCAC-3 ‘
Slc41a3 5’-TGAAGGGAAACCTGGAAATG-3’ 5’-GGTTGCTGCTGATGATTTTG-3’
Gapdh, glyceraldehyde 3-phosphate dehydrogenase; P2x1-5, 7, P2X purinoreceptors 1-5, 7; 
Trpm6, transient receptor potential cation channel, subfamily M, member 6; Cnnm2, cyclin and 
CBS domain divalent metal cation transport mediator 2; Egf, epidermal growth factor; Cldn16, 
claudin 16; Slc12a3, solute carrier family 12, member 3; Scnn1, Amiloride-sensitive sodium 
channel subunit; Trpm7, transient receptor potential cation channel, subfamily M, member 7; 
Fxyd2, FXYD domain containing ion transport regulator 2; Kcnj10, ATP-sensitive inward rectifier 
potassium channel 10; Slc41a1, solute carrier family 41, member 1; Slc41a3, solute carrier 
family 41, member 3.
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Expression profiling
Total RNA was isolated using TRIzol total RNA isolation agent (Invitrogen, Bleiswijk, 
the Netherlands) according to the manufacturer’s protocol. Obtained RNA was 
treated with DNase (Promega, Fitchburg, WI, USA) to remove genomic DNA. 
Subsequently, reverse transcription of the mRNA by M-MLV reverse transcriptase 
(Invitrogen, Bleiswijk, the Netherlands) was performed for 1 hr at 37 °C. Gene 
expression levels were determined by RT-qPCR on a BioRad (Hercules, CA, USA) 
analyzer using SYBR Green and normalized for glyceraldehyde 3-phosphate 
dehydrogenase (Gapdh) expression levels. Primer sequences are provided in Table 2.
Electrolyte measurements
Serum and urinary total Mg2+ and Ca2+ concentrations were determined using a 
xylidyl blue colorimetric assay kit according to the manufacturer’s protocol (Roche/
Hitachi, Tokyo, Japan). In short, serum Mg2+ and Ca2+ were measured photometrical-
ly via the decrease in xylidyl blue absorbance. 1 M Mg2+ and Ca2+ standards (Sigma 
Aldrich, Zwijndrecht, The Netherlands) were used to generate standard dilution 
curves. The assay was calibrated using a Mg2+ Precinorm (Sigma Aldrich, Zwijndrecht, 
The Netherlands) with a concentration of 0.76 mM Mg2+. Samples were measured on 
a Nanodrop 2000c spectrophotometer (Thermo Scientific, Breda, The Netherlands) 
at 600 nm. 20 µl of urine was acidified by adding 4 µl 1M HCl and diluted 30x with MQ 
before performing the Mg2+ and Ca2+ assays. All feces were dissolved in 5 ml 65 % v/v 
sulfuric acid and incubated for 10 min. at 50 °C and then diluted 50 times in MQ 
before use. Serum and urinary Na+ and K+ concentration were determined by the 
Radboudumc clinical lab on an automated system according to the manufacturer’s 
protocol (Abbott Diagnostics, Belgium).
Isolation of membrane and cytosol fractions
Membrane and cytosol fractions were isolated from kidney tissue of P2x6-/- and 
P2x6+/+ littermates by ultracentrifugation. To this end, half of a mouse kidney was 
first homogenized using a homogenizer (bedrijf) in 1 ml of lysis buffer (50 mM Tris pH 
7.5, 1 mM EDTA, 1 mM EGTA, 1 mM NaOrthovandate, 5 mM NaF, 5 mM glycerolphos-
phate 0.27 M sucrose) containing 1 tablet of complete protease inhibitor cocktail 
(Roche) and 0.1 % b-mercapto-ethanol without detergents. Samples were than 
centrifugated at 3000 g for 10 minutes at 4 °C. The supernatant was then centrifugated 
at 100,000 g for 1 hour at 4 °C in a Sorvall™ WX Floor Ultra Centrifuge (Thermo 
Scientific, Asheville, NC, USA) with a 70.1Ti rotor. The supernatant was taken and 
proteins in the cytosolic fraction were solubilized by adding 1% NP-40. The remaining 
pellet was resuspended in 1 ml lysis buffer without b-mercapto-ethanol and 
centrifuged at 100,000 g for 15 minutes at 4 °C to get rid of all cytosolic parts. The 
remaining pellet consists of the membrane fraction and is subsequently resuspended 
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in 100 µl lysis buffer containing 1% NP-40 and b-mercapto-ethanol. To remove any 
debris, membrane fractions were spun a final time at 12,000 g for 10 minutes at 4 °C. 
The remaining supernatant was used for further experiments.
Cell culture and transfection
Human embryonic kidney cells (HEK293) were grown in Dulbecco’s modified Eagle’s 
medium (Lonza, Leusden, The Netherlands) containing 10% (v/v) fetal calf serum 
(FCS), 2 mM L-glutamine at 37 °C in a humidity controlled incubator with 5% (v/v) CO2. 
The cells were transiently transfected with the respective construct using 
Lipofectamine 2000 (Invitrogen Bleiswijk, The Netherlands) in a 1 µg DNA to 2 µl 
lipofectamine ratio and analyzed on Western blot, 48 hours after transfection. Cell 
samples were lysed in lysis buffer (50 mM Tris pH 7.5, 1 mM EDTA, 1 mM EGTA, 1 mM 
NaOrthovandate, 5 mM NaF, 5 mM glycerolphosphate 0.27 M sucrose and 1 tablet of 
complete protease inhibitor cocktail (Roche)) containing 1% (v/v) Triton X-100.
BCA protein measurements and western blotting
Protein concentrations were measured with a colorimetric Pierce BCA protein assay 
kit (ThermoFisher scientific, Breda, The Netherlands) according to the manufacturer’s 
protocol. In short, samples were loaded on a 96 well plate, incubated for 30 minutes 
at 37 °C and measured at 562 nm with a Bio-rad Benchmark plus microplate photo-
spectrometer (Bio-rad, Veenendaal, The Netherlands). Protein lysates of membrane 
and cytsolic fractions of P2x6-/- and P2x6+/+ mouse kidney samples were denatured in 
Laemmli containing 100 mM DTT for 30 minutes at 37 °C. Samples were then subjected 
to SDS-PAGE and Western blots were incubated with a rabbit anti-mouse P2x2 
antibody (Alomone Labs, Jerusalem, Israel, 1:500) or a rabbit anti-mouse P2x4 (H-40, 
Santa Cruz biotechnology, Santa Cruz CA, USA, 1:500) in 5% milk o/n at 4 °C. Then, 
immunoblots were incubated 45 minutes at RT with peroxidase conjugated goat 
anti-rabbit secondary antibodies (Sigma-Aldrich, Zwijndrecht, The Netherlands, 
1:10,000). β-actin was used as a loading control and samples were stained in 5% milk 
o/n at 4 °C with anti-mouse β-actin (Sigma-Aldrich, Zwijndrecht, The Netherlands, 
1:10,000). HEK293 cells, which were transiently transfected with HA-tagged pCINEO-
hP2X4-IRES-GFP and pCINEO-mock-IRES-GFP constructs, were subjected to the same 
procedure as described above.
Statistical analysis
All results are depicted as mean ± standard error of the mean (SEM). The statistical 
analyses were conducted by one-way ANOVA, followed by a Tukey’s post hoc test 
when comparing the three treatment groups (n=10 for each group). Difference in 
means with P values < 0.05 were considered statistically significant. 
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Introduction
Mineral homeostasis is crucial for many physiological processes in the body like 
enzymatic activity, cell metabolism, bone formation and neuronal excitability. Ca2+ 
and Mg2+ concentrations are therefore tightly regulated by the kidney, parathyroid 
glands, intestine and bone. The kidney determines the final concentration of these 
ions by reabsorbing Ca2+ and Mg2+ from the pro-urine into the blood. This reabsorption 
process is facilitated by paracellular and transcellular epithelial transport in the PT, 
thick ascending limb of Henle’s loop (TAL) and distal convoluted tubule (DCT) of the 
kidney. The capacity to mediate ion transport in these segments depends on the 
amount, availability, composition and activity of membrane transporters, channels 
and tight junctions. Membrane transporters and channels facilitate transcellular 
epithelial transport in the kidney. Endocrine signaling molecules, like parathyroid 
hormone (PTH) and 1,25-dihydroxyvitamin D3 (VitD), regulate the activity of these 
transporters and channels in the whole kidney. Whereas, paracrine signaling 
molecules like ATP, regulate ion transport on a local cellular level. The other 
rate-limiting factor of both transcellular and paracellular ion transport is the amount 
of ion transporters, channels and tight junctions at the plasma membrane. Two key 
mechanisms are: the recruiting and recycling of these elements to the plasma 
membrane via vesicle trafficking, a fast response and the regulation of transcription 
and translation of additional transport proteins to facilitate a change in ion transport 
capacity, a slow response. The aim of this thesis was to elucidate new transcriptional 
networks that regulate Mg2+ and Ca2+ transport in the kidney. In particular, i) in 
chapter 2 a genome-wide dataset of HNF1β binding sites in the DCT was established; 
ii) Kir5.1 was identified as a target of HNF1β elucidating a new regulatory pathway of 
Mg2+ transport in the DCT; iii) chapter 3 investigates the identification of the CaSR 
gene as a new transcriptional target of HNF1β, providing insight in a novel transcrip-
tional mechanism for Ca2+ and Mg2+ reabsorption in the TAL; iv) chapter 4 established 
that FAM111A is a binding partner of transcription factor STAT1, which revealed a 
novel regulatory role for FAM111A in Ca2+ and Mg2+ reabsorption in the body; v) 
additionally, chapter 5 demonstrated that the P2X purinoreceptor subunit P2X6 is not 
involved in renal ion transport based on the characterization of a P2x6 knockout (KO) 
mouse model. 
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P2X6 functioning in and outside the kidney
Inside the kidney
P2X receptors are important regulators of Ca2+ and Mg2+ transport in both TAL and 
DCT. In an initial report by Dai and colleagues, ATP was shown to regulate Mg2+ 
transport via P2X purinoreceptors.1 P2X receptors are ATP-activated ion channels 
with a cation selective pore and are mainly permeable for Ca2+, although monovalent 
cations can also pass through. P2X receptors can form both homotrimers and 
heterotrimers. Expression pattern analysis of mouse P2x subunits 1-7 revealed that 
only P2x4 and P2x6 transcripts are highly expressed in the DCT.2, 3 However, immuno-
histological co-localization analysis of P2X4 with NCC in mouse kidney sections 
revealed that only P2x6 is exclusively expressed in the DCT.3 The exclusive expression 
of P2X6 in DCT made it an interesting candidate to further investigate its potential 
role in the regulation of Mg2+ transport in the DCT. 
 To examine the aforementioned role of P2X6, a P2x6-/- knockout mouse was 
developed and in chapter 5 a detailed characterization of this mouse is presented.4 
Knocking out P2x6 in mice did, however, not result in a measurable electrolyte 
phenotype in serum or urine. Possible compensatory mechanisms were ruled out, as 
none of the common magnesio- or calciotropic genes in the kidney were affected by 
the loss of P2x6. On the functional level, previous work confirmed that co-expression 
of P2X6 with TRPM6, in an in vitro cell model, did not have an effect on TRPM6 activity 
after ATP stimulation. This fits with preceding in vitro studies, which state that P2X6 
cannot form homotrimers and requires P2X2 or P2X4 subunits to reach the plasma 
membrane and become a functional ion channel.5-7 The lack of an effect on electrolyte 
transport and the absence of any transcriptional changes in magnesio- and calciotropic 
genes in the P2x6-/- mouse lead to the conclusion that the P2X6 subunit has no role in 
renal electrolyte transport. The physiological role of P2X6 beyond the kidney remains 
elusive. 
Outside the kidney
Data from the P2x6-/- mouse showed a decrease of P2x2 expression in the heart. 
Indeed P2X6 forms heterotrimers with P2X2 and only then becomes a functional P2X 
receptor at the plasmamembrane.8, 9 Previous research describes that P2X6 and no 
other P2 receptors are upregulated in chronic hear disease. It is argued that increased 
P2X6 activity raises intracellular Ca2+ levels resulting in cell death, which contributes 
to the elevated risk of cardiac arrest.10 Although P2x6-/- mice did not appear to suffer 
from heart problems, P2X2 subunits were significantly upregulated, as a potential 
compensatory mechanism to increase ATP-mediated Ca2+ signaling in the heart. 
Another study showed how P2X6 subunits might have an additional function in brain.11 
They described P2X6 accumulation in hippocampal neurons in an age-dependent 
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way, which then interacts with the splicing factor 3A1 resulting in decreased mRNA 
splicing in these cells.11 It is, therefore, possible that the primary function of P2X6 is 
not related to ATP-mediated Ca2+ signaling, but involved in regulating splicing factor 
3A1s’ function in mRNA splicing. The P2x6-/- mouse model can be used to further 
study the physiological effects of P2X6 loss on hippocampal neuron functioning in an 
age-dependent manner. Subsequently, it is interesting to examine the exact role of 
P2X6 in the heart as well. 
HNF1β: key regulator of renal Mg2+ reabsorption
Mutations and deletion of hepatocyte nuclear factor 1 homeobox β (HNF1β) is one of 
the most common genetic causes for genital tract malformations (CAKUT) and cyst 
formation in the kidney.12-15 Most HNF1β patients tend to additionally develop an 
electrolyte phenotype characterized by hypomagnesemia, hypocalciuria and 
hypokalemic metabolic alkalosis.16-18 HNF1β has been identified as a transcriptional 
regulator of many cystic disease genes.19-22 However, the role of HNF1β in regulating 
electrolyte transport in the kidney has not been thoroughly investigated. HNF1β was 
identified as a transcriptional activator of the FXYD2 gene, encoding the y-subunit of 
the Na+-K+-ATPase, and is essential for the reabsorption of Mg2+ in DCT.23 24 Mutations 
in FXYD2 indeed cause hypomagnesemia and hypocalcemia in patients.25, 26 Close 
investigation of the literature, however, reveals that HNF1β is specifically responsible 
for the regulation of the FXYD2a splice variant of FXYD2.23 FXYD2 gene expression in 
DCT is however limited to the FXYD2b splice variant.27, 28 Consequently, HNF1β 
mediated FYXD2a expression in the DCT cannot be responsible for the lack of Mg2+ 
reabsorption in HNF1β patients.27 
 In chapter 2, all genome-wide binding sites of HNF1β were, for the first time, 
identified in an immortalized DCT cell line (mpkDCT). In DCT, the potassium inwardly- 
rectifying channel, subfamily J, member 16 (KCNJ16 gene), encoding for the Kir5.1 K+ 
channel subunit, was identified and validated as a target for HNF1β-mediated regulation. 
Hnf1β knockdown experiments resulted in a loss of Kcnj16 gene transcription both in 
vitro and in vivo. The potassium inwardly-rectifying channel, subfamily J, member 10 
(KCNJ10) gene coding for the Kir4.1 K+ channel subunit was likewise affected. 
HNF1β chIP-sequencing unravels novel transcriptional networks 
Over the years various studies investigated the complex transcriptional networks of 
HNF1β, slowly elucidating parts of its vast web of target genes in the kidney and other 
organs. In 2004, Gresh et al. identified multiple cystic disease genes, namely Pkhd1, 
Pkd2 and Umod, as HNF1β targets using chIP-qPCR in a kidney specific HNF1β KO 
mouse.19 A related study using chIP-qPCR in a mouse inner medullary collecting duct 
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(IMCD3) cell line argues that HNF1β is not a typical transcription factor. Instead of 
releasing from the chromatin during post-mitotic silencing, HNF1β remains bound to 
certain parts of the chromatin and is postulated to act like a bookmarking factor to 
rapidly reactivate target genes after mitosis.29 Although, this idea has not been 
explored further. 
 The aforementioned findings identified parts of the role of HNF1β in renal cyst 
formation and cell cycle regulation, but there are several big downsides to chIP-qPCR, 
which limits its usefulness for further research: i) ChIP-qPCR is highly labor intensive 
as potential HNF1β sites have to be identified in silico and then tested in vitro or in 
vivo; ii) this severely limits the amount of potential target genes that can be tested for 
HNF1β binding sites; iii) potential HNF1β binding sites outside of the promoter of the 
target gene can be missed; iv) most importantly this approach is highly biased as 
genes of interest have to be chosen a priori. Indeed after genome-wide screening 
methods became available a chIP-chIP for HNF1β in IMCD3 immediately revealed 
cystic disease gene Kif12 as a novel target of HNF1β.22 
 A limitation of chIP-chIP is that it does not cover the whole genome.30 With 
chIP-chIP, immunoprecipitated chromatin was hybridized to promoter tiling arrays that 
cover 1.5 kb of the promoter regions of 26,842 mouse genes.22 This severely limits the 
identification of intronic or intergenic enhancer sites obscuring the identification of 
HNF1β targets. The solution to the problem is chIP-sequencing. This method is truly 
genome-wide and has a much improved signal to noise-ratio compared to chIP-chIP.31 
The first HNF1β chIP-seq was performed in the collecting duct (CD) cell line IMCD3 and 
identified 4,725 mRNAs and 85 miRNAs with HNF1β bindings located in a 50 kb range 
from their respective transcription start sites (TSS). Most HNF1β peaks could be mapped 
close to or within gene bodies.32 Our study in mpkDCT cells revealed a remarkably 
similar set of 4,530 genes containing HNF1β binding sites in a 50 kb range from the TSS 
of which 43.5% were present near transcriptional active genes. Aboudehen et al. 
combined the differentially expressed genes from a RNA-seq of renal epithelial (53A) 
cells expressing mutant HNF1β with HNF1β target genes identified in the chIP-seq.32 
Metabolic pathways were highly regulated by HNF1β and further research showed that 
specifically cholesterol metabolism was affected. A similar approach was used in 
a CD-specific Hnf1β KO mouse. RNA-seq was performed on CD material from the 
CD-specific Hnf1β KO mouse model. This revealed differentially expressed genes related 
to osmoregulation between CD-specific Hnf1β KO and wildtype mice. The chIP-seq data 
from the IMCD3 cells was used to investigate, which of these differentially expressed 
genes from the RNA-seq data contained HNF1β binding sites.33 Such a combined 
analysis could also be used to identify with more specificity the pathways in DCT that 
are directly affected by HNF1β. However, constructing a HNF1β mutant mpkDCT cell 
line is highly challenging. Current innovations in gene knock-in technology, like CRISPR- 
CAS9, could potentially solve this problem. 
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The chIP-seq performed in IMCD3 cells also identified HNF1β binding sites near 
85 miRNAs. A follow-up study determined that HNF1β regulates a long-coding RNA 
containing the mir-200 family.34 Mir-200 is known to coordinate Pkd1 expression, 
which demonstrates another regulatory pathway that connects HNF1β to cyst 
formation.34 It would be of interest to analyze which miRNAs have HNF1β binding 
sites near them in the mpkDCT chIP-seq. This could be combined with a DCT-wide 
screening of differentially expressed miRNAs in mice that are subjected to a low 
versus normal Mg2+ diet. This approach could reveal HNF1β-regulated miRNAs with a 
role in Mg2+ transport regulation. 
 HNF1β also plays an important role in kidney development, especially uretric bud 
branching and in the initiation of nephrogenesis.35, 36 A recent RNA-seq of E15 kidney 
material from HNF1β KO mice identified that HNF1β controls specifically epithelial 
organization and cell polarity during ureteric bud branching and collecting duct 
morphogenesis.37 Loss of cell polarity and epithelial organization are often linked to 
cilia genes like PKHD1 and PKD1&2, which are incidentally cystic disease and HNF1β 
target genes.20, 21, 38 The role of HNF1β in ureteric bud branching and CD 
morphogenesis fits with the fact that loss of HNF1β after birth does not result in 
cystic kidneys anymore.29 Consequently, the regulation of cystic disease genes by 
HNF1β is mainly important during nephrogenesis. Of particular interest was the result 
of a HNF1β chIP-seq performed on E14.5 mouse kidney material, which validates 
HNF1β targets like Kcnj16 found in our chIP-seq data.37 Kcnj16 was also downregulated 
in the aforementioned RNA-seq further confirming the results in chapter 2. Except of 
a list of genes containing HNF1β binding sites; more details on this chIP-seq were not 
available.
HNF1β regulates the Kir5.1 K+ subunit; consequences for Mg2+  
transport in DCT
The results of chapter 2 demonstrate that HNF1β directly regulates Kcnj16 while 
Kcnj10 is indirectly controlled. The consequences for Mg2+ reabsorption in DCT are, 
therefore, as follows. We postulate that the decreased availability of Kir4.1/Kir5.1 K+ 
channels at the basolateral side of DCT diminishes K+ extrusion and subsequently 
decreases Na+-K+-ATPase activity, depolarizing the basolateral membrane. As a 
consequence, this would lead to diminish extrusion of Cl- via the CLC-Kb channel 
(Figure 1). An increase in intracellular Cl- decreases the activity of the WNK-SPAK 
kinase pathway, which in turn reduces phosphorylation of the hydrochlorothia-
zide-sensitive Na+-Cl- co-transporter (NCC) and limits its activity.39 NCC activity is 
required for proper reabsorption of Mg2+ via Mg2+ channel TRPM6 (Figure 1). This is 
illustrated in Gitelman syndrome and SeSAME-EAST syndrome, where patients suffer 
from hypomagnesemia and a hypokalemic metabolic alkalosis due to decreased NCC 
functioning or activity in the DCT.40, 41 42-44 Both Gitelman and SeSAME-EAST syndrome 
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Figure 1 |  A model of HNF1β deficiency and the consequences for Mg2+ 
reabsorption in the DCT
1) In the physiological normal situation HNF1β facilitates expression of Kir5.1, which results in 
normal functioning of the Na+-K+-ATPase. This in turn results in proper extrusion of Cl- from the 
cell. Loss of Cl- autophosphorylates WNK kinases and causes phosphorylation of the SPAK/
OSR1 complex. In turn, SPAK/OSR1 phosphorylates NCC inducing NCC activity. NCC activity 
increases Mg2+ reabsorption via Mg2+ channel TRPM6. 2) Mutations and loss of HNF1β result in 
decreased Kir5.1 expression. This causes hyperpolarization of the basolateral membrane 
reducing Cl- extrusion. Increased intracellular Cl- will bind and inihibit autophosphorylation of 
the WNK kinases, which reduces SPAK/OSR1 activity. Reduced activity of this pathway limits 
NCC phosphorylation and decreases NCC activity. This reduces Mg2+ reabsorption via TRPM6.
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have a comparable electrolyte disorder to ADTKD-HNF1Β patients, alluding to the 
similar mechanism underlying these diseases. 
 Kidney-specific Kir4.1 KO mice mimic to a degree the phenotype observed in 
SeSAME-EAST and ADTKD-HNF1β patients. Mice lacking Kir4.1 expression in the kidney 
suffer from a hypokalemic metabolic alkalosis with urinary Na+, K+, Ca2+ and Mg2+ 
wasting.45 The loss of basolateral K+ extrusion in DCT suppressed the activity of the WNK- 
SPAK kinase, which is an important activator of NCC (Figure 1).46-48 Indeed phosphory- 
lated (active) and total NCC levels were reduced in the Kir4.1 KO mice.45 This fits with 
the decreased NCC mRNA levels observed in the kidney specific Hnf1β KO mice.49 
 ADTKD-HNF1β patients are, therefore, likely to exhibit decreased renal expression 
of Kir4.1/Kir5.1 K+ channels and NCC, which should manifest in a decreased response 
to hydrochlorothiazide (HCTZ). Indeed a recent publication detected a blunted 
response to HCTZ diuretics in HNF1β patients.50 This further strengthens the 
hypothesis that loss of K+ recycling in the DCT is the underlying mechanism behind 
the electrolyte imbalance observed in ADTKD-HNF1β patients. 
 A point of contention in our studies is that a direct regulatory effect of HNF1β on 
Kcnj16 (Kir5.1) was detected and only an indirect effect on Kcnj10 (Kir4.1) gene 
expression.49 Mice that are only Kir5.1 deficient display an inverted phenotype to 
SeSAME-EAST and ADTKD-HNF1β.51 These mice do suffer from a hypokalemia but 
combined with an acidosis rather than an alkalosis, and hypercalciuria instead of 
hypocalciuria. Furthermore, renal NCC activity was increased rather than decreased.51 
In normal conditions, the Kir4.1/Kir5.1 channel is the dominant K+ channel present in 
DCT.51-53 However, in the absence of Kir5.1, the formation of Kir4.1 monomer channels 
increases K+ extrusion at the basolateral membrane resulting in the aforementioned 
Kir5.1 KO mice phenotype.51, 54, 55 Likewise, a study in salt-sensitive (SS) Kir5.1 KO rats 
reported that loss of Kir5.1 increased Kir4.1 mRNA and protein expression.56 However, 
immunohistochemical stainings displayed that most Kir4.1 subunits were retained in 
the cytosol and were not routed to the plasma membrane. Patch-clamp experiments 
confirmed a decrease in K+ conductance in the basolateral membrane of DCT. 
Together, the electrolyte imbalance in Kir5.1 KO SS rats is similar to the phenotype 
seen in SeSAME-EAST and ADTKD-HNF1β patients. It is relevant to investigate not 
only why Kir4.1 expression is decreased in ksp-cre Hnf1β KO mice, but also whether 
Kir4.1 protein trafficking to the plasma membrane is affected. 
 It remains unclear why Kir4.1 mRNA expression in DCT is decreased after HNF1β 
knockdown. No direct HNF1β binding sites were detected in or near the Kcnj10 gene, 
which tends to rule out direct regulation by HNF1β. However, transcription factors 
are not required to bind within a promoter sequence to affect gene transcription. To 
elucidate whether HNF1β binds the Kcnj10 promoter, circularized chromosome 
conformation capture (4C) can be used to map the interacting DNA sites with the 
Kir4.1 target promoter.57, 58 Allowing for the identification of far-off HNF1Β binding 
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sites or HNF1Β binding partners. CHIA-PET is a technique that combines High-through-
put sequencing (Hi-S) and ChIP-seq, allowing for the detection of de novo long-range 
chromatin interactions mediated by a target protein like HNF1β.59 This would also 
allow for the identification of far-off distal HNF1β binding sites and their interacting 
target genes, which is not possible with standard chIP-seq techniques. Further research 
is, therefore, needed to elucidate the long-range enhancer and repressor sites of 
HNF1β to determine which target genes are affected.
HNF1β: key regulator of Ca2+ and Mg2+ transport in the TAL
HNF1β is ubiquitously expressed throughout the kidney. However, research concerned 
with investigating the transcriptional pathways behind the HNF1Β related electrolyte 
imbalance is confined to the DCT. With the exception of a study that identified HNF1β 
as a repressor of parathyroid hormone (PTH) expression, explaining the development 
of hyperparathyroidism in a subpopulation of HNF1β patients.17 The ADTKD-HNF1β 
phenotype remains, however, reminiscent of typical DCT-based electrolyte syndromes 
like SeSAME-EAST and Gitelman syndrome. 
 Although, one aspect of the ADTKD-HNF1β electrolyte disorder, namely the 
hypocalciuria observed in ADTKD-HNF1β patients, is difficult to explain with a strictly 
DCT-based hypothesis. As, Ca2+ is actively reabsorbed downstream from the DCT, 
which is not affected by changes in NCC-mediated transport.41 A plausible explanation 
for the hypocalciuria in ADTKD-HNF1β focuses on compensatory mechanisms in the 
PT, where increased active Na+ reabsorption drives passive Ca2+ reaborption, due to 
decreased NCC activity in the DCT (Figure 2).41 
 Another segment relevant for Ca2+ and Mg2+ reabsorption is the TAL. A significant 
lumen-positive voltage is maintained in the cortical TAL (cTAL) by uptake of Na+ by the 
furosemide-sensitive Na+-K+-2Cl- cotransporter (NKCC2). Passive reabsorption of Na+ 
through Na+ selective Cldn10b tight junctions in the medullary TAL (mTAL) and cTAL 
also contributes to this lumen-positive voltage in the cTAL.60, 61 This process facilitates 
paracellular uptake of Ca2+ and Mg2+ in cTAL.62 Here, reabsorption of Na+, like in the 
DCT, is dependent on proper K+ recycling via the Kir4.1/Kir5.1 K+ channel and the 
Na+-K+-ATPase to maintain a hyperpolarized basolateral membrane. Similarly to DCT, 
a lack of Kir4.1/Kir5.1 K+ channels reduced phosphorylated and total NKCC2 (pNKCC2) 
in Kir4.1 KO mice.45 Subjecting these animals to furosemide did, however, not affect 
Na+ reabsorption in TAL.63 Furosemide treatment in Kir5.1 KO mice identified a 
normal Na+, K+ and Ca2+ response and NKCC2 levels were increased in salt-sensitive 
(SS) Kir5.1 KO rats.51, 56 It seems that loss of Kir4.1/Kir5.1 K+ channels does not affect 
passive reabsorption of Ca2+ and Mg2+ via aberrant Na+ reabsorption in the TAL.45 
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HNF1β regulates expression of the Ca2+-sensing receptor in TAL  
and the parathyroid glands
Chapter 3 describes how HNF1β regulates the expression of the calcium-sensing 
receptor (CaSR), an important regulator of Ca2+ and Mg2+ in the kidney. The CaSR is a 
G-protein coupled receptor (GPCR) and localized along the basolateral membrane of 
TAL and parathyroid gland.64 Intracellular signaling is triggered when Ca2+ binds to 
the large extracellular domains of the CaSR. These extracellular domains have a high 
affinity for Ca2+ in the mM range, and to a lesser degree also respond to Mg2+.64 
Activation of the CaSR elevates levels of intracellular Ca2+, which subsequently 
decreases the uptake of Ca2+ and Mg2+ in TAL.65 In the parathyroid glands, activation 
of the CaSR reduces PTH release, which also lowers the uptake of Ca2+ in the kidney.66
 CaSR gene transcription is known to be responsive to VitD, proinflammatory 
cytokines and the transcription factor glial cells missing-2 (GCM2) however, the 
connection to HNF1Β is novel.67 Two promoters regulate CaSR expression, each 
controlling a separate alternative exon (exon 1A or 1B) coding for a different ‘5 UTR, 
which then splices to a common segment encoded in exon 2 of the coding region.68 
69 In human kidney, the predominant CaSR transcripts are controlled by promoter 1 
and HNF1β specifically regulates the activity of that promoter.68-70 Promoter 
1-controlled CaSR expression is also dominant in the parathyroid meaning that CaSR 
expression in the parathyroid is regulated by HNF1β. Absence or aberrant functioning 
of HNF1β cause a decrease in CaSR transcript availability, weakening the sensitivity 
for extracellular Ca2+ and Mg2+ sensing at the basolateral side of TAL and parathyroid 
glands. 
 In the parathyroid gland, CaSR activity is an important repressor of parathyroid 
horomone (PTH) release. Additionally, it has been shown that HNF1β is a direct 
repressor of PTH expression.17 A loss of HNF1β would, therefore, raise PTH expression 
levels and via the additional loss of CaSR expression would increase PTH release. 
Subsequently, this stimulates reabsorption of Ca2+ in the kidney and facilitates Ca2+ 
release from bone. This could explain the hypocalciuria observed in HNF1β patients. 
Indeed, a subset of ADTKD-HNF1β patients develops hyperparathyroidism and it has 
been reported that PTH levels in HNF1β patients are elevated compared to controls.16, 
17, 71 This can have consequences for both Ca2+ and Mg2+ uptake in the kidney. It is 
known that PTH stimulates the activity of Ca2+ channel transient receptor potential 
vanilloid 5 (TRPV5), increasing Ca2+ reabsorption in the late DCT and connecting 
tubule (CNT).72 Furthermore, it has been shown that PTH also decreases NCC activity, 
which can negatively influence Mg2+ reabsorption in DCT.73
 Potential treatment options for ADTKD-HNF1β patients would be VitD supple-
mentation to suppress PTH expression and to decrease Ca2+ reabsorption in the 
kidney. Administration of calcimimetics, like CaSR agonist cinacalcet, can boost CaSR 
signaling.74, 75 This subsequently decreases PTH release, which in turn could remedy 
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Figure 2 |  A model of HNF1β deficiency and the consequences for Ca2+ and Mg2+ 
reabsorption along the nephron
Loss of HNF1β along the nephron increases reabsorption of Ca2+ and Mg2+ in the thick 
ascending limb of Henle’s loop (TAL). As a consequence uptake of mainly Ca2+ is 
decreased in the PT. This increases the Ca2+ load in the TAL, which increases the 
chance for nephrocalcinosis (yellow plaques). Loss of HNF1β reduces uptake of Mg2+ 
in the DCT. Yellow plagues show Ca2+ oxalate deposits, indicative of nephrocalcinosis.
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the hypocalciuria. VitD will additionally stimulate CaSR expression directly as both 
CaSR promoter 1 and 2 harbor 1,25-dihydroxyvitamin D3 receptor (VDR) responsive 
elements.76, 77 It is, however, unknown whether these VitD responsive elements 
interact with HNF1β. In addition, it also remains unclear whether hyperparathyroid-
ism is a primary or secondary symptom of HNF1β dysfunction. As increased PTH 
levels can be a consequence of direct defects in Ca2+ reabsorption in the kidney. 
HNF1β regulation of the Ca2+-sensing receptor in the TAL; Consequences 
for Ca2+ and Mg2+ reabsorption along the kidney tubule
In chapter 3 we show that loss of HNF1β decreases CaSR transcription in TAL (Figure 3). 
Patients with inactivating mutations in the CaSR suffer from familial hypocalciuric 
hypercalcemia (FHH; OMIM #145980), which is characterized by hypermagnesemia, 
hypercalcemia, hypomagnesiuria and hypocalciuria. ADTKD-HNF1β patients also 
suffer from a hypocalciuria, which could be the consequence of decreased CaSR 
abundance and signaling in the kidney. Previous research identified that CaSR activity 
is causative of Cldn14 upregulation in the tight junctions of TAL.78 This is induced by 
CaSR-mediated repression of two miRNAs, Mir-9 and Mir-374, which subsequently 
upregulate Ca2+ and Mg2+ excretion.78-80 SiRNA-mediated knockdown of HNF1β 
revealed an anticipated decrease in mouse Casr transcript and Cldn14 mRNA levels in 
an immortalized TAL cell line. Cldn14 levels did not change in a kidney-specific Hnf1β 
KO mouse, although a significant reduction of Casr transcript was observed. Cldn14 
mRNA levels were extremely low in both wildtype and Hnf1β KO mice. These 
observations fit with previous research, as mice require a high Ca2+ diet before Cldn14 
mRNA levels become detectable.78, 80-82 Lacking Cldn14, the increased influx of Ca2+ 
and Mg2+ is expected to trigger other compensatory mechanism to decrease divalent 
cation influx. Indeed, in the ksp-cre Hnf1β KO mice, Cldn19 and Cldn10b expression 
was significantly reduced, whereas Cldn3 expression was upregulated. Claudin19 
forms together with Claudin16, the pore that facilitates the paracellular uptake of 
Ca2+ and Mg2+ in cTAL.83 It is, therefore, plausible to assume that in response to 
reduced CaSR signaling, Cldn19 expression is diminshed to avoid Ca2+ precipitations.
 Claudin10b forms monomeric tight junctions in mTAL, which are selective for 
Na+.61 A reduction in Claudin10b tight junctions would decrease Na+ reabsorption in 
the medullary part of the TAL.60 Loss of Cldn10b in ksp-cre Cldn10 KO mice showed 
that these mice suffer from hyperabsorption of Ca2+ and Mg2+.84 Whereas the 
increased reabsorption of Mg2+ in the TAL caused hypermagnesemia, Ca2+ levels were 
unaffected, even causing a slight hypocalcemia. This can be explained by different 
absorption rates for Ca2+ and Mg2+ along the tubule. The bulk of Mg2+ (~70%) is 
reabsorbed in TAL compared to ~20% of Ca2+. Decreasing the reabsorption of Ca2+ in 
the PT can diminish the effects of hyperabsorption of Ca2+ in the TAL. However, this 
subsequently increases the Ca2+ load in TAL resulting in nephrocalcinosis in the mTAL, 
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which has been observed in ksp-cre Cldn10 KO mice.84 Observations in patients with 
CLDN10 mutations confirmed the decrease in Ca2+ and Mg2+ excretion, due to 
insufficient Na+ reabsorption in TAL.85 It seems, therefore, credible that in HNF1β 
patients the lack of CaSR and CLDN10b expression can result in an increased Ca2+ load 
and hyperabsorption of Ca2+ in TAL. Indeed, HNF1β patients are known to develop 
hypocalciuria and reports of HNF1β patients developing nephrolithiasis have been 
Figure 3 |  A model of HNF1β deficiency and the consequences for Ca2+ and Mg2+ 
reabsorption in the TAL
1) Mutations and loss of HNF1β result in decreased CaSR expression. This diminishes 
CaSR activity and reduces intracellular Ca2+ signaling. 2) Reduced intracellular Ca2+ 
signaling increases the expression of miR-9 & miR-374. 3) miR-9&374 bind to the 
CLDN14 mRNA and facilitates breakdown, reducing CLDN14 mRNA translation into 
protein. 4) The decreased availability of Claudin14 protein increases Ca2+ and Mg2+ 
transport through the Claudin3/16/19 tight junction complex.
5’
3’ U
TR
AAA
A
Claudin 14
Ca2+ Mg2+
CaSR Promoter region
HNF1ß binding sites
Ca2+
Mg2+
Ca2+
Claudin 3/16/19
Mg2+
Ca2+
Mg2+
Ca2+
CLDN14 mRNA
3’ UTR AAAA
5’
Ca2+ Mg2+
Ca2+ Ca2+ Mg2+
Na+
K+
K+
Na+
K+
CI-
Na-K-ATPase
ClC-Kb
CaSR
ROMK
CI-
NKCC2
ATP
K+
Kir4.1/Kir5.1
Mg2+
Nucleus
HNF1ß
miR-9/374
miR-9/374
Mg2+Mg2+
Ca2+ Mg
2+ Ca2+
1
2
34
521424-L-sub01-bw-Kompatscher
Processed on: 24-7-2018 PDF page: 145
General discussion and summary | 145
documented, which is a common consequence of nephrocalcinosis (Figure 2).71 
Patients suffering from inactivating mutations in the CaSR are also prone to develop 
nephrolithiasis. A study in stone formers versus control patients revealed that a SNP 
in promoter 1 of the CaSR is highly associated with nephrolithiasis, the exact promoter 
whose activity is regulated by HNF1β.86 
 Although a plausible hypothesis has been established on how loss of HNF1β 
causes hypocalciuria due to aberrant Ca2+ transport in TAL. It remains unclear how an 
increase in reabsorption of Mg2+ in the TAL results in hypomagnesemia in HNF1β 
patients. More detailed investigations are required to elucidate how Mg2+ reabsorption 
is affected by the loss of HNF1β in TAL.
HNF1β: models to study electrolyte transport in ADTKD-HNF1β
A distinct problem arises when comparing the electrolyte disorder observed in HNF1β 
patients with purely tubular nephropathies like Gitelman syndrome, SeSAME-EAST or 
TAL electrolyte disorders. HNF1β patients suffer from a highly heterogeneous disease, 
which entails the regular occurrence of cysts and or developmental problems in the 
kidney. These complications can be the cause of secondary symptoms like the 
electrolyte imbalance observed in ADTKD-HNF1β patients. 
HNF1β mouse models 
Current mouse models, in which HNF1β has been knocked out along the nephron, are 
not sufficient to exclude cyst progression as a cause for the electrolyte disorder. Cyst 
formation is extremely aggressive in the ksp-cre Hnf1β KO mice causing 75% lethality 
after day 21.19 The high early life lethality in these mice prevents the accurate 
measurement of urine electrolyte excretion. Knocking out Hnf1β in a specific nephron 
segment, like the collecting duct, established that cyst progression can be delayed 
significantly, starting at p28, and mice can be monitored for 2 years.33 It is, therefore, 
necessary to develop TAL and DCT–specific Hnf1β KO mouse models to disentangle 
the effect of cyst progression from the electrolyte phenotype in ADTKD-HNF1β. This 
is, however, highly challenging since TAL or DCT-cre specific mice are not yet available. 
Another option would be an inducible Hnf1β KO model. Indeed, induction after 
postnatal day 10 avoids the cystic phenotype and Hnf1β KO mice develop normally.29 
It would be of great interest to measure electrolytes in these latter mice to investigate 
whether the typical HNF1β electrolyte disorder is persistent in a non-cystic model. 
HNF1β in vitro models
An alternative to avoid the high amount of co-morbidity in HNF1β-related diseases 
would be to study HNF1β-mediated transcriptional regulation in in vitro models for 
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TAL or DCT. In our research, both MKTAL and mpkDCT cell lines were used. The MKTAL 
cell line was derived from mouse thick ascending limb tubules, specifically from the 
inner strip of the outer medulla.87 This cell line sufficiently expresses the CaSR and all 
Cldns important for Ca2+, Mg2+ and Na+ transport at the transcript level. However, 
immunohistochemical data (Kompatscher et al., unpublished data) revealed that 
MKTAL cells, grown either on glass coverslips or polarized in transwell plates, had a 
distinct lack of Claudin16 and Claudin10b staining. As nearly all tight junctions were 
exclusively occupied by Claudin19 and Claudin3. Furthermore, these cells lacked 
Slc12a1 (NKCC2) expression. Although, previous work in MKTAL cells did reveal 
Slc12a1 expression at the mRNA level.87 Measurements of MKTAL cells in an Ussing 
chamber indeed displayed a Na+ permeability that was not sensitive to furosemide 
and was not selective for Ca2+, Mg2+ or Na+.88 This makes MKTAL cells unsuited to 
study functional electrolyte transport. Effects of extracellular Ca2+ on Cldn14, Mir-9 
and Mir-374 expression levels have, however, been measured in MKTAL cells.78 The 
MKTAL cell model is, therefore, a useful tool to study Ca2+-mediated transcriptional 
pathways regulating Cldn expression in TAL. 
 There are several cell models available to investigate DCT cells in vitro. The initial 
immortalized murine DCT cell line (mDCT) was frequently used to study Na+, Ca2+ and 
Mg2+ influx.89, 90 Although these cells express NCC, genes directly involved in Mg2+ 
transport, like TRPM6, are poorly expressed and it turned out to be difficult to 
measure Mg2+ influx in these cells. As an alternative, Vandewalle and colleagues 
established an immortalized DCT cell line derived from microdissected mouse DCT, 
named the mpkDCT cell line.91 Several studies reported thiazide-sensitive NCC- 
mediated Na+ transport in this cell line.92-94 A recent subclone, the mDCT15 cell line 
more closely resembles the native DCT condition with intact WNK-SPAK, PTH and 
insulin signaling.73, 95-97 Both latter cell lines seem good models to study, for example, 
HNF1β-mediated regulation of NCC activity. The lack of native NCC protein expression 
in the mpkDCT cell and mDCT15 subclone (Kompatscher et al., unpublished), however, 
severely limits the study of HNF1Βs’ effect on NCC activity. It remains, therefore, 
necessary to develop an in vitro model that more closely resembles the native DCT 
cell state containing all relevant transporters and channels to study Mg2+ transport in 
the absence of HNF1β.
The role of FAM111A in Ca2+ and Mg2+ reabsorption
Mutations in FAM111A are responsible for the autosomal dominant Kenny-Caffey 
syndrome type 2.98 Patients suffer from severe short stature, gracile bones, hypo-
parathyroidism, hypocalcemia and hypomagnesemia.99, 100 A previous study shows 
that the hypomagnesemia could be the primary symptom in the KCS2 syndrome.101 
521424-L-sub01-bw-Kompatscher
Processed on: 24-7-2018 PDF page: 147
General discussion and summary | 147
Both the DCT and TAL segments of the kidney are crucial for Mg2+ reabsorption. The 
aim of chapter 4 was therefore to investigate the role of FAM111A in the kidney. 
RNA-seq analysis of an immortalized DCT cell line revealed that transcription factor 
Stat1 was upregulated in the absence of Fam111a. This was later confirmed by 
RT-qPCR in Fam111a knockdown experiments. Furthermore, STAT1 was identified as 
a potential binding partner of FAM111A. 
 As of yet the function of FAM111A remains quite elusive. An earlier study 
determined that FAM111A has anti-viral properties.102 Pathway analysis, performed 
on the RNA-seq data of chapter 4, indeed confirmed enrichment in several anti-viral 
pathways, including the upregulation of the Stat1 gene. It was however surprising to 
find that STAT1 was the only confirmed FAM111A binding partner. As a recent study 
concluded that FAM111A was an important binding partner of proliferating cell 
nuclear factor antigen 1 (PCNA1).103 Cells that were lacking FAM111A displayed low 
levels of chromatin-bound PCNA and impaired replication. GFP-tagged FAM111A also 
co-localized with PCNA on replication sites and GST-pulldown experiments displayed 
FAM111A directly interacting with PCNA.103 However, PCNA was not identified as a 
binding partner of FAM111A in our eGFP-pulldown experiments and it remained 
unclear why PCNA binding was not observed. Despite these discrepant results, the 
binding of STAT1 to FAM111A remains of high interest for further investigation.
 Transcription factor STAT1 is known as a transcriptional activator of the CaSR,68 
and could conceivably contribute to the KCS2 syndrome. A first clue can be found in 
patients suffering from severe burns and sepsis, which are prone to develop 
hypocalcemia due to CaSR upregulation induced by the STAT1/STAT3 pathway in 
response to Interleukin-6 (IL-6) signaling.104, 105 Increased expression of STAT1 due to 
aberrant FAM111A functioning could therefore induce a similar response in KCS2 
patients by increasing CaSR expression in the TAL. Activating mutations in the CaSR 
are well known to cause autosomal dominant hypocalcemia (ADH: OMIM 601198) 
together with hypomagnesemia and hypoparathyroidism.106 A phenotype that 
closely resembles the electrolyte disorder seen in KCS2 patients. As increased CaSR 
signaling decreases PTH release from the parathyroid, which subsequently reduces 
Ca2+ and Mg2+ reabsorption in the kidney and resorption in bone. 
 First, it is crucial to establish whether STAT1 is an actual binding partner of 
FAM111A by performing co-immunoprecipitation experiments.98, 107 Additionally, 
this provides the means to assess the effect on STAT1 binding of other point mutation 
and deletions found in KCS2 patients. The eGFP-pulldown experiment in chapter 4 
determined that the FAM111A R569H hotspot mutation did not affect binding of 
STAT1 to FAM111A. However, the mutation could still affect FAM111A-STAT1 
functioning. Overexpressing the R569H mutant in a cell model could elucidate the 
effect of the FAM111A mutant on STAT1 expression and activity. The MKTAL cell 
model would be ideal as CaSR expression levels could also be determined. However, 
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this cell line is notoriously difficult to transfect (Kompatscher et al. unpublished data). 
Furthermore, knockdown of Fam111a in the MKTAL cell line did not increase Casr 
expression. This could mean that FAM111A does not affect CaSR expression. However, 
an in vitro cell model like the MKTAL cell line has limitations. Especially when it comes 
to assessing ion transport in these cells. Since it was not possible to measure changes 
in ion selectivity and permeability in the MKTAL cells using an Ussing chamber 
setup.88 To fully elucidate the role of FAM111A in Ca2+ and Mg2+ handling a KO mouse 
model is required.  
 Careful phenotyping of a FAM111A KO mouse model will be crucial to determine 
whether serum Ca2+, Mg2+ and PTH levels mimic the situation in KCS2 patients. To 
assess whether there is a renal defect, 24-hour urine should be collected to determine 
potential renal Ca2+ and Mg2+ wasting. As a renal defect would confirm that the loss 
of Ca2+ and Mg2+ in KCS2 originates from the kidney. Stat1 and Casr levels can also be 
easily determined in FAM111A KO mice, which should be significantly increased. 
Parathyroid tissue can also be harvested to assess Stat1 and Casr mRNA levels. Rescue 
experiments with CaSR anatagonists like NPS-2143 could establish whether the low 
Ca2+ and Mg2+ symptoms are fully STAT1-CaSR dependent or whether there are other 
mechanisms involved.108 Additional transcriptome analysis of parathyroid and kidney 
tissue would provide an overview of additional pathways that might be affected by 
the complete loss of FAM111A in mice. There is a risk that the FAM111A KO mice will 
suffer from early life lethality. This was observed in patients with osteocraniosteno-
sis, which have more pronounced defects in FAM111A.98 In this case, heterozygous 
FAM111A KO mice should be assessed to investigate whether these mice develop a 
mild KCS2 phenotype.
 Nonetheless, a first step has been taken to understand FAM111As’ role in KCS2 
syndrome. Further in vitro experiments are required to validate the novel interaction 
with STAT1. Additionally, a FAM111A KO mouse model is necessary to discern the 
effects of FAM111A loss on Ca2+ and Mg2+ uptake in the intestines, reabsorption in 
the kidney and regulation from the parathyroid.
Future perspectives
Ion transport in the nephron is highly dependent on the activity and availability of ion 
channels and transporters. Much is known about the factors regulating the activity of 
these channels. In contrast, little research is directed towards elucidating the tran-
scriptional networks that regulate the expression of ion channels and transporters in 
the kidney. The studies reported in this thesis give insight into these transcriptional 
mechanisms. This thesis focused on elucidating novel transcriptional targets of 
HNF1β. A chIP-seq for HNF1β on immortalized DCT material allowed for the 
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identification of two novel targets that are key regulators of Ca2+ and Mg2+ transport 
in both the DCT and TAL, respectively. Firmly establishing HNF1β as a master regulator 
of electrolyte transport in these segments. The next step would be to further 
elucidate these mechanisms and show that loss of HNF1β indeed causes a reduction 
in NCC activity and transcription. It is further relevant to investigate how transcription 
of the Kir4.1 subunit is affected due to loss of HNF1β, since direct regulation can be 
excluded. Accurate in vitro models for the DCT will be key in elucidating these 
pathways. Except for indirect regulation via transcription factor HNF1β, it is unknown 
what other transcription factors or miRNAs regulate directly the transcription and 
translation of key transporters and channels like NCC or TRPM6 in DCT. Powerful new 
sequencing technologies have been developed like 4C-seq that are able to determine 
all interacting regions of the genome with a certain target sequence. This allows for 
the identification of novel transcription factors and regulatory proteins that interact 
with this target sequence. This can be combined with reverse chIP-seq experiments 
were for example proteins interacting with the TRPM6 promoter sequence are pulled 
down and identified by mass-spectrometry.109 These findings could enhance our 
understanding of the transcriptional mechanisms regulating these key ion transporters 
and channels. 
 In the TAL, our findings show that HNF1β regulates CaSR transcription. It is, 
however, unclear what the effect is on ion transport in TAL. Injecting HNF1β KO mice 
with CaSR agonist cinacalcet and measuring Ca2+ and Mg2+ values in blood and urine, 
might provide more insight in how the loss of HNF1β affects CaSR signaling and what 
effect this has on Cldn expression and tight junction formation. Although as discussed 
previously HNF1β KO models develop a severe cystic phenotype and early lethality, 
which hampers this type of study. An alternative would be to investigate the effect of 
HNF1β loss on CaSR signaling and paracellular transport in an in vitro model. However 
as of yet, an in vitro model to measure changes in paracellular Na+ and Mg2+ selectivity 
is not available. 
 In conclusion, elucidating the transcriptional networks that regulate Ca2+ and 
Mg2+ reabsorption in the kidney is key to understanding how and by which 
transcription factors, transporters and channels are regulated at the transcriptional 
level. This provides new targets and insights in treating highly heterogeneous and 
complex inherited diseases like ADTKD-HNF1β.  
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Inleiding
Een adequate Ca2+ en Mg2+ balans in het lichaam is essentieel voor het functioneren 
van verschillende intra- en extracellulaire processen, zoals enzymatische activiteit, 
metabolisme, botformatie en neuronale excitatie. Hierbij zijn de darmen verantwoor-
delijk voor de opname van Ca2+ en Mg2+ uit het voedsel, fungeert het bot als een reservoir 
voor de opslag van deze mineralen en bepalen de nieren hoeveel Ca2+ en Mg2+ 
uitgescheiden wordt via de urine. De bijschildklier dirigeert de afgifte van hormonen 
die opname en excretie van Ca2+ en Mg2+ reguleren uit het bot en de nieren. 
 In de nier wordt bloed gefiltreerd in de glomerulus waardoor Ca2+ en Mg2+ terecht- 
komen in de voorurine in de nierbuis. Deze nierbuis is opgedeeld in verscheidene 
segmenten, die op verschillende manieren ionen resorberen. Het overgrote deel 
van het Ca2+ en Mg2+ wordt tussen de cellen door (paracellulair) geresorbeerd in de 
proximale tubulus en het stijgende deel van de lis van Henle (TAL). Hierna wordt de 
definitieve uitscheiding van het Ca2+ en Mg2+ bepaald door deze ionen actief door het 
epitheel te transporteren (transcellulair). Voor Mg2+ vindt dit exclusief plaats in het 
distaal convoluut (DCT), terwijl Ca2+ transcellulair wordt geresorbeerd in de verbin-
dingsbuis (CNT). De capaciteit voor iontransport van deze niersegmenten is afhankelijk 
van de hoeveelheid, samenstelling en activiteit van membraan transporteurs, ion- 
kanalen en ‘tight junction’ eiwitten. Membraantransporteurs en ionkanalen zijn 
 verantwoordelijk voor het transcellulaire transport van Ca2+ en Mg2+. Terwijl het 
paracellulaire transport gereguleerd wordt door verschillende ‘tight junction’ 
eiwitten, die tussen de cellen een buisje vormen dat selectief is voor de opname van 
Na+ of Ca2+ en Mg2+. De activiteit van membraantransporteurs en ionkanalen wordt 
nauwkeurig gereguleerd door signaalmoleculen, zoals paraathormoon (PTH) en 
1,25-dihydroxyvitamine D3 (VitD). Daarnaast worden lokaal moleculen zoals 
adenosine triphosphaat (ATP) afgegeven om het iontransport te stimuleren. Een 
bepalende factor in zowel het transcellulair als paracellulair iontransport is het aantal 
beschikbare membraantransporteurs, kanalen en ‘tight junction’ eiwitten in de 
plasmamembraan. De twee belangrijkste mechanismen om dit te reguleren zijn het 
rekruteren en recyclen van de eerder genoemde eiwitten naar de plasmamembraan 
uit een reservoir van eiwitten in het cytoplasma. Dit is een snelle response. Of het 
verhogen danwel verlagen van de productie van membraantransporteurs, ionkanalen 
en ‘tight junction’ eiwitten. Dit is een relatief trage response. 
 Het doel van dit proefschrift is om te onderzoeken hoe de productie van de 
eiwitten die bijdragen aan Ca2+ en Mg2+ transport in de nier, gereguleerd wordt. 
Eiwitten die verantwoordelijk zijn voor de aanmaak (transcriptie) van membraan-
transporteurs en ionkanalen worden transcriptiefactoren genoemd. Een transcriptie-
factor bindt het DNA op de promotorsequentie van genen om zo de transcriptie in 
gang te zetten. In dit proefschrift ligt de nadruk vooral op de transcriptiefactor HNF1β, 
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aangezien patiënten met HNF1β deleties of mutaties lijden aan een verlaagde bloed 
Mg2+ spiegel. Het onderzoek is als volgt opgebouwd; i) In hoofdstuk 2 worden alle 
potentiële doelwitten van HNF1β beschreven in het genoom; ii) Het K+-kanaal KCNJ16 
(Kir5.1), een belangrijke speler in Mg2+ transport in het DCT, werd geïdentificeerd als 
een doelwit van de transcriptiefactor. Deze bevinding verklaart hoe HNF1β Mg2+ 
transport in het DCT reguleert; iii) in hoofdstuk 3 werd het calcium-sensor receptor 
gen (CaSR) geïdentificeerd als een doelwit van HNF1β. Dit gaf nieuwe inzichten in het 
mechanisme waarop Ca2+ en Mg2+ geresorbeerd worden in de TAL; iv) in hoofdstuk 4 
werd de transcriptiefactor STAT1 geïdentificeerd als een potentiële bindingspartner 
van FAM111A. Deze bevinding geeft een nieuwe kijk op de functie van FAM111A met 
betrekking tot Ca2+ en Mg2+ resorptie in de nier; v) hoofdstuk 5 toont aan dat het 
ATP-gevoelige P2X receptor kationkanaal P2X6 niet betrokken is bij iontransport in de 
nier. Een P2x6 knock-out (KO) muismodel werd gebruikt om de gevolgen van een 
P2X6 tekort op het transport van Ca2+ en Mg2+  in de nier te onderzoeken. 
Het ATP-gevoelige P2X6 kationkanaal is niet betrokken bij Ca2+ en Mg2+ 
resorptie in de nier
In hoofdstuk 4 werd de fysiologische rol van het ATP-gevoelige P2X6 kationkanaal 
onderzocht met betrekking tot Mg2+ transport in het DCT van de nier. Uit eerder 
onderzoek is bekend dat P2X6 in de nier exclusief wordt aangemaakt in het DCT. P2x6 
komt eveneens verhoogt tot expressie in muizen op een laag Mg2+ dieet. Deze 
resultaten maken het plausibel dat P2X6 een bijdrage levert aan iontransport in het 
DCT. Het verlies van P2X6 in de muis had echter geen verlaging van bloed Ca2+ en 
Mg2+ waarden tot gevolg. Er werd ook geen significant verlies van Ca2+ en Mg2+ 
waargenomen in de urine. Daarbij was de productie van Ca2+- en Mg2+-gevoelige 
genen niet significant verschillend tussen de P2x6 wildtype (WT) en P2x6 KO muis. Op 
basis van deze studie kon een effect van P2X6 op de Ca2+ en Mg2+ transport in de nier 
worden uitgesloten. Wel werd er een verhoging van P2x2 mRNA, een interactiepart-
ner van P2X6, waargenomen in het hart. In hoeverre deze verhoging van P2x2 mRNA 
compenseert voor het verlies van P2X6 en wat de functie van P2X6 is in het hart dient 
nog verder te worden uitgezocht. De eerder genoemde P2x6 KO muis kan hier een 
bijdrage aan leveren.  
De regulatie van Ca2+ en Mg2+ transport door transcriptiefactor HNF1β 
in het distaal convoluut van de nier
Patiënten met mutaties en deleties in transcriptiefactor HNF1β lijden aan het 
ADTKD-HNF1β syndroom. ADTKD-HNF1β patiënten hebben een bijzonder heterogeen 
fenotype bestaande uit de volgende symptomen;  cystenieren, een overerfelijke 
vorm van diabetes, en in ~50% van de gevallen, verminderde bloed Mg2+ en K+ 
waarden. Verder is er ook regelmatig sprake van verminderde uitscheiding van Ca2+ 
521424-L-sub01-bw-Kompatscher
Processed on: 24-7-2018 PDF page: 161
Nederlandse samenvatting | 161
in de urine. De rol van HNF1β in de vorming van cystenieren is veelvuldig onderzocht. 
Cystenieren in ADTKD-HNF1β patiënten ontstaan doordat HNF1β mutaties de 
transcriptie van genen als PKHD1, PKD2 en UMOD verstoren. Er is echter nog maar 
weinig bekend over hoe HNF1β het transport van, in het bijzonder Mg2+, reguleert en 
waarom in ~50% van de HNF1β patiënten er een Mg2+ tekort in het bloed ontstaat. 
Het Mg2+ en K+ tekort in ADTKD-HNF1β patiënten lijkt op het Gitelman syndroom; een 
aandoening die wordt veroorzaakt door een defect in de Na+-Cl- cotransporteur 
(NCC), die specifiek werkzaam is in het DCT. 
 In hoofdstuk 2 werd HNF1β functie onderzocht in een DCT cellijn. Door een 
chromatine immunoprecipitatie (chIP) zijn alle plaatsen op het genoom waar HNF1β 
bindt geïsoleerd en geanalyseerd. In totaal zijn ~7,500 bindingsplaatsen van HNF1β 
geïdentificeerd, waarvan 4,530 in de nabijheid van de transcriptiestartlocatie (TSS) 
van genen op het genoom. De belangrijkste bevinding was de identificatie van een 
HNF1β-bindingsplaats in de promotor van het K+-kanaal KCNJ16, dat codeert voor het 
eiwit Kir5.1. Om aan te tonen dat HNF1β de transcriptie van KCNJ16 reguleert, werd 
HNF1β eiwitproductie verstoord door het inbrengen van ‘korte translatie verstorende 
RNAs’ (siRNAs) in DCT cellen. De reductie van HNF1β expressie verminderde inderdaad 
de KCNJ16 transcriptie in deze cellen. KCNJ16 transcriptie was eveneens sterker 
verlaagd in een nierspecifieke HNF1β KO muis dan in HNF1β WT controle muizen.
 Transcriptie van het verwante Kir4.1 K+-kanaal was eveneens verstoord in zowel 
de siRNA behandelde DCT cellijn als de HNF1β KO muis. Kir4.1 vormt samen met 
Kir5.1 het functionele K+-kanaal aan de bloedzijde (basolaterale kant) van het DCT. 
Een verminderde aanwezigheid van het K+-kanaal leidt tot gereduceerde uitscheiding 
van K+ aan de basolaterale zijde van het DCT. Voorgaand onderzoek wijst uit dat 
verminderde K+- uitscheiding leidt tot verstoorde activiteit van de Na+-Cl- 
cotransporteur (NCC) aan de voorurine zijde (apicale membraan) van de DCT cel. Uit 
observaties in Gitelmansyndroom patiënten is bekend dat verminderde activiteit van 
NCC resulteert in een gereduceerde resorptie van Mg2+ via het Mg2+-kanaal TRPM6. 
Het is daarom waarschijnlijk dat het Mg2+ en K+ tekort in ADTKD-HNF1β patiënten 
veroorzaakt wordt door verlaagde transcriptie van Kir4.1/Kir5.1 K+-kanalen. Onze 
resultaten wijzen uit dat HNF1β direct bind aan de Kir5.1 promotor en transcriptie 
van het kanaal stimuleert. Het is vooralsnog onbekend op welke wijze HNF1β de 
transcriptie van Kir4.1 reguleert. 
De regulatie van Ca2+ en Mg2+ door de transcriptie factor HNF1β in de 
opstijgende lus van Henle (TAL)
ADTKD-HNF1β patiënten lijden, behalve aan verlaagde Mg2+ en K+ bloed waarden, 
ook aan de vorming van Ca2+ afzettingen in de nierbuis (nefrocalcinose) doordat 
minder Ca2+ wordt uitgescheiden. Deze verstoring in Ca2+ resorptie kan niet volledig 
vanuit een defect in het DCT verklaard worden. Verder is HNF1β ook vertegenwoor-
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digd in alle segmenten van de nierbuis. De TAL is het niersegment waar 70% van Mg2+ 
en 20% van Ca2+ wordt geresorbeerd. Verlies van HNF1β in de TAL zou kunnen leiden 
tot problemen met Ca2+ en Mg2+ resorptie, die symptomen als nefrocalcinosis kan 
verklaren. 
 In hoofdstuk 3 werd het eerdere overzicht van HNF1β bindingsplaatsen in de 
DCT gebruikt om nieuwe genen die door HNF1β gereguleerd worden te identificeren. 
De meest veelbelovende bevinding was de identificatie van een HNF1β-bindings-
plaats In het tweede intron van het calcium-sensor receptor (CaSR) gen. De CaSR 
functioneert als een sensor voor Ca2+ en Mg2+ aan de basolaterale zijde van de TAL. 
Als Ca2+ of Mg2+ bindt aan de CaSR wordt er een intracellulaire cascade in gang gezet 
die paracelullaire opname van Ca2+ en Mg2+ verlaagd. CaSR activiteit verhoogt de 
aanmaak van Claudine 14 (Cldn14), waardoor de affiniteit voor paracellulaire Na+ 
resorptie in de TAL toeneemt. Dit gaat ten koste van het Ca2+ en Mg2+ transport in de 
TAL. Op deze manier reguleert de CaSR de resorptie van Ca2+ en Mg2+ in het bloed. 
 HNF1β werd tot overexpressie gebracht in humane niercellen om aan te tonen 
dat HNF1β de transcriptie van de CaSR activeert. Alleen in de aanwezigheid van de 
HNF1β-bindingsplaats in de promotor van de CaSR was er verhoogde promotoractiviteit 
waarneembaar. De toevoeging van een HNF1β mutant die niet aan de HNF1β- 
bindingsplaats kon hechten, zorgde voor een significante vermindering in CaSR pro-
motoractiviteit. 
 Deze resultaten werden bevestigd door de productie van het HNF1β eiwit te 
verstoren met siRNAs in een muis TAL cellijn, wat leidde tot de verwachtte daling in 
Casr mRNA. De afwezigheid van HNF1β zorgde ook voor een afname in Cldn14 
transcriptie in deze cellen. Om CaSR reductie te bevestigen in vivo werden 
experimenten in een nierspecifieke HNF1β KO muis uitgevoerd. Inderdaad CaSR 
transcriptie was aanzienlijk lager in de nier-specifieke HNF1β KO muis dan in de 
controle dieren. Cldn14 mRNA liet echter geen afname zien, hoewel dit overeenkomt 
met eerder onderzoek. Alleen muizen met veel Ca2+ in hun dieet maken Cldn14 aan 
om overmatige Ca2+ resorptie te remmen. 
 Afgezien van deze verschillen in claudine transcriptie tussen in vitro en in vivo 
experimenten is het duidelijk dat HNF1β bindt in het CaSR gen en zo de transcriptie 
van dit gen activeert. In ADTKD-HNF1β patiënten zou dit betekenen dat de CaSR 
verminderd aanwezig is in de TAL. Wat zou leiden tot een verhoogde opname van 
Ca2+ en Mg2+ in de TAL. Deze resultaten passen bij de verlaagde Ca2+ uitscheiding die 
wordt waargenomen in ADTKD-HNF1β patiënten. 
 Patiënten met ADTKD-HNF1β hebben last van nefrocalcinose. Eerder onderzoek 
wijst uit dat dragers van kleine genomische variaties (SNPs) in de promotorsequentie 
van de CaSR een verhoogde kans hebben op het ontwikkelen van nefrocalcinose, 
hetgeen wordt veroorzaakt door de verminderde aanmaak van het CaSR eiwit. Dit 
lijkt sterk op wat er gebeurd in ADTKD-HNF1β patiënten. Er is echter meer onderzoek 
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nodig naar de rol van HNF1β in Ca2+ en Mg2+ resorptie in de TAL. Hierdoor kunnen 
nieuwe behandelmethoden ontwikkeld worden voor ADTKD-HNF1β patiënten door 
bijvoorbeeld CaSR activiteit te remmen.
FAM111A is een potentiële regulator van de Ca2+ en Mg2+ resorptie in de nier
Patiënten met mutaties in FAM111A lijden aan het autosomaal dominant erfelijk 
Kenny-Caffey syndroom type 2 (KCS2). De meest voorkomende symptomen in deze 
patiënten zijn ernstige groeistoornissen, botdysplasie en sterk verminderde bloed 
Ca2+, Mg2+ en paraathormoon waarden. De rol van FAM111A in het KCS2 syndroom is 
echter onbekend. Verstoorde resorptie van Ca2+ en Mg2+ in de nier kunnen de lage 
paraathormoon waarden, groeistoornissen en botdysplasie in KCS2 patiënten 
verklaren. Inderdaad Ca2+ en Mg2+ restrictie experimenten in patiënten tonen aan 
dat het Mg2+ tekort tot de primaire stoornis behoort in KCS2. Het onderliggende 
mechanisme achter dit tekort is echter nog onbekend. 
 In hoofdstuk 5 werd daarom een transcriptoom analyse uitgevoerd op muis DCT 
cellen die behandeld waren met siRNAs tegen Fam111a. Deze verlaging in Fam111a 
leidde tot verhoogde expressie van verschillende antivirale genen waaronder tran-
scriptiefactor Stat1, een eiwit die eveneens een rol heeft in de regulatie van het 
iontransport. Complementair aan de voorgaande studie werd een eiwit interactie-
analyse uitgevoerd om interactiepartners van FAM111A in kaart te brengen. STAT1 
kwam hier naar voren als een sterke FAM111A bindingspartner. In voorgaand 
onderzoek werd STAT1 geïdentificeerd als een activator van CaSR expressie. De 
verlaagde Ca2+ en Mg2+  waardes in het bloed van KCS2 patiënten zou daarom 
verklaard kunnen worden door verhoogde CaSR expressie ten gevolge van 
verminderde FAM111A functie. De CaSR speelt eveneens een belangrijke rol bij het 
uitscheiden van paraathormoon vanuit de bijschildklier. Een hormoon dat cruciaal is 
bij het reguleren van de excretie van Ca2+ en Mg2+ in de nieren en de opname van 
deze ionen in het bot. Deze mogelijke connectie tussen FAM111A en de CaSR zal 
echter experimenteel bewezen moeten worden voordat conclusies getrokken kunnen 
worden over de rol van FAM111A bij Ca2+ en Mg2+ resorptie.  
 Vervolgonderzoek zal moeten uitwijzen of FAM111A inderdaad bindt aan STAT1 
en of de FAM111A mutaties deze verbinding verstoren. Verder zal onderzocht moeten 
worden of verhoogde STAT1 expressie inderdaad TAL transport van Ca2+ en Mg2+ 
beïnvloed en of dit via regulatie van de CaSR gebeurt. Een FAM111A KO muismodel 
kan meer inzicht verschaffen in de gevolgen van FAM111A deficiëntie voor ionresorptie 
in de nier. Transcriptoom analyse in de nier en bijschildklier van de FAM111A KO muis 
zou eveneens mechanismen kunnen blootleggen waarmee de rol van FAM111A in 
Ca2+ en Mg2+ resorptie verklaard kan worden. 
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Toekomstperspectieven 
Dit proefschrift geeft nieuwe inzichten in de wijze waarop Ca2+ en Mg2+ resorptie 
gereguleerd wordt op transcriptioneel niveau in zowel de TAL als het DCT. Een 
gedetailleerde analyse in een muis DCT cellijn van alle bindingsplaatsen voor HNF1β, 
identificeerde twee nieuwe genen die gereguleerd worden door deze transcriptiefac-
tor. Het Kir5.1 K+-kanaal is belangrijk voor de adequate resorptie van Mg2+ in het DCT, 
terwijl de CaSR cruciaal is voor het reguleren van de paracellulaire opname van Ca2+ 
en Mg2+ in de TAL. In vervolgonderzoek is het belangrijk om de consequenties voor 
Ca2+ en Mg2+ resorptie verder te analyseren om zo meer inzicht te krijgen in het 
ziektebeeld van ADTKD-HNF1β patiënten. 
 Een volgende stap zou zijn om causaal te kunnen aantonen dat een tekort aan 
HNF1β inderdaad een verlaging van NCC activiteit en transcriptie veroorzaakt in de 
patiënten. Dit zou uitgevoerd kunnen worden door urine te verzamelen van deze 
patiënten. Om vervolgens uit deze urine de zogenaamde ‘exosoom’ membraanblaas-
jes te isoleren. Hierin kan dan de hoeveelheid NCC eiwit gemeten worden. De 
verwachting is dat ADTKD-HNF1β patiënten minder NCC bezitten door het tekort aan 
goedfunctionerend HNF1β in deze patiënten. Een tekort aan NCC verklaart de 
verminderde Mg2+ resorptie in deze patiënten in het DCT. 
 Verder is het zeer relevant om te onderzoeken hoe de transcriptie van het Kir4.1 
K+-kanaal beïnvloed wordt door HNF1β. Uit onderzoek in dit proefschrift blijkt dat 
directe regulatie via HNF1β kan worden uitgesloten. Een nieuwe techniek op het 
gebied van genoom-sequencing en massaspectrometrie ‘reverse ChIP’ (een 
omgekeerde chromatine-immunoprecipitatie) is in staat om alle eiwitten die aan een 
specifieke DNA sequentie binden te identificeren. Andere transcriptiefactoren die 
belangrijk zijn voor Kir4.1 transcriptie kunnen zo in kaart worden gebracht, waaronder 
mogelijke interactiepartners van HNF1β. Het is eveneens onbekend welke transcrip-
tiefactoren de expressie van belangrijke DCT eiwitten zoals NCC en Mg2+-kanaal 
TRPM6 reguleren. Met technieken als ‘reverse ChIP’ kan men de identiteit van deze 
factoren ophelderen om zo de mechanismen achter Ca2+ en Mg2+ resorptie in de nier 
te onthullen. 
 In het TAL segment van de nier, werd aangetoond dat HNF1β de transcriptie van 
de CaSR reguleert. Het is echter onduidelijk wat het effect is op Ca2+ en Mg2+ resorptie 
in de TAL. Hiervoor is het belangrijk om nauwkeurig te bepalen welke claudines in hun 
productie door HNF1β, direct of indirect, worden gereguleerd. Aangezien de claudines 
verantwoordelijk zijn voor het paracellulaire iontransport in de TAL. Het behandelen 
van HNF1β KO muizen met de CaSR agonist cinacalcet zou hier meer inzicht in kunnen 
geven. Door CaSR activiteit te stimuleren met deze agonist kan men het verlies van 
CaSR transcriptie door HNF1β herstellen en zo aantonen welke claudines nu worden 
beïnvloed door de CaSR en wat het effect is op Ca2+ en Mg2+ resorptie in de nier. Dit 
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soort dierstudies bestrijken lange periodes. Een probleem in de huidige HNF1β KO 
muismodellen is de vroege ontwikkeling van cystenieren, en als gevolg daarvan, 
vroege sterfte van deze dieren. Een alternatief zou een studie zijn in een bruikbaar 
TAL celmodel waar paracellulair iontransport gemeten kan worden. Dit celmodel 
moet nog ontwikkeld worden, waardoor deze iontransport studies nog niet mogelijk 
zijn. De ontwikkeling van nieuwe HNF1β KO muismodellen en bruikbare celmodellen 
is daarom noodzakelijk om het effect van transcriptiefactoren, zoals HNF1β, op 
iontransport verder te kunnen onderzoeken. 
 Het is noodzakelijk om complexe netwerken van transcriptie van membraan-
transporteurs en kanalen verder te onderzoeken. Toekomstig onderzoek zal op deze 
wijze nieuwe mechanismen van genregulatie kunnen onthullen hetgeen inzicht geeft 
in de behandeling van zeer heterogene en complexe erfelijke aandoeningen als 
ADTKD-HNF1β en KCS2.
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List of abbreviations 
1,25(OH)2D3 1,25-dihydroxyvitamin D3
18S 18S ribosomal RNA 
ADH Autosomal dominant hypocalcemia
ADTKD Autosomal dominant tubulo-interstitial kidney disease
ANOVA Analysis of variance
ATP Adenosine triphosphate
ATPase Adenosine triphosphatase
BAC Bacterial artificial chromosome
BCS Body condition scoring 
Bp Base pair 
Ca2+ Calcium ion
CaSR The calcium-sensing receptor
CAKUT Genital tract malformation
CD Collecting duct
CEAS Cis-regulatory element annotation system
cDNA  Complementary DNA
CDK5 Cyclin-dependent kinase 5
ChIP-seq Chromatin immunoprecipitation and sequencing
CKD Chronic kidney disease
Cl- Chloride ion
ClC-Kb Voltage-gated chloride channel
Cldn Claudin
CLDN3 Gene encoding claudin 3
CLDN16 Gene encoding claudin 16
CLDN19 Gene encoding claudin 19
CLDN14 Gene encoding claudin 14
CLDN10a Gene encoding claudin 10a
CLDN10b Gene encoding claudin 10b
CMV Cytomegalovirus
CNNM2 Cyclin M2
CNT Connecting tubule
CO-IP Coimmunoprecipitation
COPAS Complex object parametric analyzer and sorter
CSRP1 Cysteine and glycine-rich protein 1 
cTAL Cortical thick ascending limb of Henle’s loop
DAPI 4’, 6-diamidino-2-phenylindole
DCT  Distal convoluted tubule  
DMEM Dulbecco’s modified eagle’s medium
DNA Deoxyribonucleic acid 
DTT Dithiothreitol
EAST Epilepsy, ataxia, sensorineuronal deafness and renal tubulopathy 
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EDTA Ethylene diamine tetraacetic acid 
eGFP Enhanced green fluorescent protein
EGF Epidermal growth factor
EGTA Egtazic acid
EFGR Epidermal growth factor receptor
eGFP Enhanced green fluorescent protein
EGTA Ethylene glycol tetraacetic acid
EIF6 Eukaryotic translation initiation factor 6
ENaC Epithelial Na+ channel
ER Endoplasmatic reticulum
ERK Extracellular signal-regulated kinase
FAM111A Family with sequence similarity 111, member A
FCS Fetal calf serum
FDR False discovery rate
FHH Familial hypocalciuric hypercalcemia
FHHNC Familial hypomagnesemia with hypocalcuria and nephrocalcinosis
FXYD2a FXYD domain containing ion transport regulator 2 variant a
FXYD2b FXYD domain containing ion transport regulator 2 variant b
GAPDH Glyceraldehyde 3-phosphate dehydrogenase
GCPR G-protein coupled receptor
GCM2 Transcription factor glial cells missing-2
GEO Gene expression omnibus
GFP Green fluorescent protein
GFR Glomerular filtration rate
GO Gene ontology
HA Human influenza hemaglutinin 
H3K4me3 Histone H3 protein trimethylation of lysine 4
HAM-F12 HAM’s F12 nutrient mixture
HCl Hydrogen chloride 
HEK293 Human embryonic kidney cells (293)
HeLa Henrietta Lacks cervical tumor cells
HGNC HUGO Gene Nomenclature Committee  
HNF1α Hepatocyte nuclear factor 1 homeobox alpha
HNF1β Hepatocyte nuclear factor 1 homeobox beta
HSH Severe hypomagnesemia and secondary hypocalcemia
HRP Horseradish peroxide
IDH Isolated dominant hypomagnesemia
IHC Immunohistochemistry
IL-6 Interleukin 6
IR Insulin receptor
IRES Internal ribosome entry site
IRF7 Interferon regulatory factor 7
IFIT1 Interferon-induced protein with tetratricopeptide repeats 1
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IFN-α Interferon alpha 
IRH Isolated autosomal recessive hypomagnesemia
JAK Janus kinase 
K+ Potassium ion
Kb Kilobase
KCl Potassium chloride 
KCNJ10 ATP-sensitive inward rectifier potassium channel 10
KCNJ16 ATP-sensitive inward rectifier potassium channel 16
KCS Kenny-Caffey syndrome
KCS2 Kenny-Caffey syndrome type 2
kD Kilo Dalton
KEGG Kyoto Encyclopedia of Genes and Genomes
Keratin 2A KRT2 
Kif12 Kinesin family member 12
Kir4.1 Inward rectifying K+ channel subunit 4.1
Kir5.1 Inward rectifying K+ channel subunit 5.1
KO Knock-out
KOH Potassium hydroxide
Ksp-cre Ksp-cadherin cre recombinase 
Kv1.1 Potassium voltage-gated channel subfamily A member 1
LacZ β-galactosidase
LC-MS Liquid chromatography–mass spectrometry
LT Large T antigen
MA Bland-Altman plot
mDCT Mouse distal convoluted tubule
MDR/TAP ATP-binding cassette, sub-family B
miR microRNA 
Mg2+ Magnesium ion
MKTAL Immortalized mouse medullary thick ascending limb cell line
mL Milliliter
M-MLV Moloney murine leukemia virus reverse transcriptase
mpkDCT(4a) Immortalized mouse DCT cell line
MODY Maturity onset diabetes of the young
MODY5 Maturity onset diabetes of the young type 5
mRNA Messenger ribonucleic acid 
mTAL Medullary thick ascending limb of Henle’s loop
MsigDB Molecular Signature Database
mV Millivolt 
MS Mass spectrometry
MQ Milli-Q water 
Na+ Sodium ion
NaCl Sodium chloride
NaF Sodium fluoride   
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Na+-K+-ATPase Na+-K+-adenosine triphosphatase pump
NCBI National Center for Biotechnology Information
NCC  The thiazide-sensitive NaCl cotransporter
NCX1 The Na+-Ca2+ exchanger
NEO Neomycin resistance gene
NFAT Nuclear factor of activated T-cells 
NKCC2 The furosemide-sensitive Na+-K+-2Cl- co-transporter
NP-40 Nonidet 40
Nt Non-targeting
OMIM Online mendelian inheritance in man
OCS Osteocraniostenosis
P Probability value
pA polyA
PT Proximal tubule
PC Principal component
PCA Principal component analysis
PCR Polymerase chain reaction
PCBD1 Pterin-4a-carbinolamine dehydratase/dimerization factor
PCNA1 Proliferating cell nuclear antigen 1
PEI Polyethylenimine cationic polymer
pGL3b Luciferase reporter vector
PKD2 Polycystin-2
PKHD1 Fibrocystin
PMCA1b Ca2+-ATPase 
POUH Atypical POU homeodomain
POUS POU-specific domain
pNCC Phosphorylated thiazide-sensitive NaCl cotransporter
PVDF Polyvinylidene difluoride
P2X ATP-regulated purinoreceptor cation channel
RL Renilla luciferase
RNA Ribonucleic acid
RNasel Ribonuclease L
ROMK The renal outer medullary potassium channel
RPF2 Ribosome production factor 2 homolog 
RPL23 60S ribosomal protein L23 
RT Reverse transcriptase
RT-qPCR Real-time quantitative PCR
RBM8A RNA-binding protein 8A
SD  Standard deviation
SEM Standard error of the mean
SeSAME  Seizures, sensorineural deafness, ataxia, mental retardation and electrolyte 
imbalance or epilepsy, ataxia, sensorineural deafness, tubulopathy
SCNN1a α subunit of the epithelial sodium channel 
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SDS-PAGE Sodium dodecyl sulfate polyacrylamide gel electrophoresis
SD Standard deviation
SEM Standard error of the mean
siRNA Silencing RNA
SLC12A1 Solute carrier family 12 type 1
SLC12A3 Solute carrier family 12 type 3
SLC41A1 Solute carrier family 41 member 1
SLC41A3 Solute carrier family 41 member 3
SNP Single-nucleotide polymorphism
STAT1 Signal transducer and activator of transcription 1
STAT3 Signal transducer and activator of transcription 3
SV40 Simian virus 40
TAL Thick ascending limb of Henle’s loop
TBCE Tubulin-folding cofactor E
TEER Trans epithelial electrical resistance
TF Transcription factor
TLR3 Toll-like receptor 3
TRIS Trisaminomethane
TRPM6 Transient receptor potential melastatin member 6
TRPM7 Transient receptor potential melastatin member 7
TRPV5 Transient receptor potential vanilloid 5
TSS Transcription startsite
U6 U6 spliceosome
UCSC University of California, Santa Cruz genome browser
UMOD  Uromodulin
UTR Untranslated region
WT Wildtype
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Curriculum vitae 
Andreas Kompatscher was born in Bolzano, Italy, on 9 February 
1988. After graduating from high school in 2006 at Erfgooiers 
College in Huizen, The Netherlands, he studied Psychobiology 
from 2006-2010 at the University Of Amsterdam, obtaining his 
Bachelor’s degree in 2010. From 2010-2012 he enrolled in the 
research Master Brain and Cognitive Sciences (Cognitive Science 
Center Amsterdam), at the University of Amsterdam, focusing 
on the Neuroscience track. For his first Master internship, he 
performed an internship at the department of Astrocyte Biology & Neurodegeneration 
at the Netherlands institute for Neuroscience under the supervision of Prof. dr. Elly 
Hol. During this internship, he investigated the role of the GFAP-delta splice variant 
as a marker for neuronal regeneration in astrocytes. His second Master internship, 
he performed in 2012 at the department of Functional Genomics in the Secretory 
Vesicle Trafficking and Recycling group under supervision of Prof. Dr. Matthijs Verhage 
and Dr. Heidi de Wit at the Free University in Amsterdam. Here he studied the role 
of Munc18 in modulating cortical F-actin and how this affects vesicle docking in 
chromaffin cells. In 2012, he obtained his Master’s degree Cum laude. After his studies, 
Andreas joined the department of Physiology of the Radboud university medical center 
(Radboudumc) in 2013 as a technician working on elucidating the binding sites of 
transcription factor HNF1B before being extended in 2014 to a PhD position. Under 
the supervision of Prof. dr. René J.M. Bindels, Prof. dr. Joost G.J. Hoenderop and 
Dr. Jeroen H.F. de Baaij, he continued his studies, investigating the role of transcription 
factor HNF1B in renal magnesium handling. During his PhD period, Andreas attended 
and held oral and poster presentations at several (inter)national conferences including 
the Experimental Biology (EB) Meeting, Chicago, USA for which he was awarded a RIMLS 
travel award; Dutch Nephrology days, Veldhoven; Dutch Federation of Nephrology 
(NfN) day, and Radboud New Frontiers Symposia. Additionally, he successfully followed 
the PhD training program of the Radboud Institute for Molecular Life Sciences (RIMLS) 
and supervised 10 students from Biomedical Sciences, Medicine and Medical Biology, 
Bachelor’s and Master’s studies.
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Research data management 
The data obtained during my PhD at the Radboud University medical center 
(Radboudumc) are archived according to the Findable, Accessible, Interoperable and 
Reusable (FAIR) principles.1 The generated primary and secondary data were have 
been stored on Labguru, a digital lab book client which is centrally stored and daily 
backed-up on the local Radboudumc server. Data was additionally backed-up on 
university servers belonging to the department. All data archives (view only) are 
stored on Labguru and accessible by the associated senior staff members. Mouse 
studies described in Chapter 2, 3 and 5 were approved by the Central Animal 
Laboratory and the Animal Ethics Board of the associated universities. Published data 
generated or analyzed in this thesis are part of published articles and its additional 
files are available from the associated corresponding authors on request. All raw and 
processed chIP-seq data described in Chapter 2 is available through the public 
functional genomics data repository GEO (gene expression omnibus). The RNA-seq 
data displayed in Chapter 4 will be available in GEO after publication. To ensure 
general accessibility of the data, all filenames, primary and secondary data, metadata, 
descriptive files and program code and scripts used to provide the final results are 
documented according to the protocol of the department of Physiology. 
1.  Wilkinson MD, Dumontier M, Aalbersberg IJ, et al. The FAIR Guiding Principles for 
scientific data management and stewardship. Sci Data 2016; 3: 160018.
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-    RIMLS Seminars
-    RIMLS Spotlights / Kidney Theme Meetings
-    RIMLS Technical Forums
c)  (Inter)national Symposia & Congresses
-    RIMLS Radboud New Frontiers
-    RIMLS PhD retreat *#
-    RIMLS Radboud New Frontiers #
-    NfN Najaarssymposium *
-    Dutch Nephrology Days *
-    Radboud Science Day *
-    Experimental Biology Meeting * #
2014
2014
2014
2015
2015
2014-2018
2014-2018
2014-2017
2014-2018
2014
2014-2017
2015-2017
2016
2016
2016 
2017
2
1
2
1
1
1
1
1
0.5
0.5
3
2.5
1
1.5
0.5
1
TEACHING ACTIVITIES
e)  Lecturing
-    Teaching Medical course: Practicum Water en Zouthuishouding Q3
-    Teaching Medical course: Vrije Keuzeruimte
f)   Students
-    Supervision Bas Olde Dubbelink
-    Supervision Enna Offerman
-    Supervision Kelly Warmink
-    Supervision Aline de Nooijer
-     Supervision Tom van Haaren, Steffi Bressers, Henrieke van Elst & 
Babette de Geest
-    Supervision Eline Visser
-    Supervision Lex van Son
-    Supervision Markus Bösch
2016, 2017
2016, 2017
2014
2014, 2015
2015
2015, 2016
2015
2016
2016, 2017
2017
0.4
0.4
1.3
1.5
1.3
1.5
1
2.6
2
1.5
TOTAL 34
Oral and poster presentation are indicated with a * and # after the name of the activity, respectively
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Wel het is volbracht. Met wat gepaste trots ben ik ontzettend blij met mijn proefschrift. 
In mijn tijd bij fysiologie heb ik enorm veel geleerd en ben ik menig persoon grote dank 
verschuldigd. In dit hoofdstuk wil ik dan ook graag mijn promotoren, collaborateurs, 
collega’s, vrienden en familie bedanken, die mij gemotiveerd, geholpen en gesteund 
hebben en zo, op hun eigen manier, een bijdrage hebben geleverd aan dit proefschrift.
Uiteraard wil ik eerst graag mijn promoteren Prof. dr. Joost Hoenderop, Prof dr. René 
Bindels en mijn co-promoter Dr. Jeroen de Baaij bedanken voor hun begeleiding, steun en 
vertrouwen gedurende mijn 5 jaar bij fysiologie. Joost, jouw aanstekelijke enthousiasme 
en drive werkten altijd zeer motiverend. Ik ben verder ook heel blij en dankbaar voor 
het vertrouwen die je gedurende al die jaren in mij gestoken hebt. De enorm gezellige 
bbqs bij jouw thuis zal ik me altijd herinneren al was het maar om die ene keer dat ik 
een nat pak haalde in je vijver. Ik hoop niet dat je nu eerst een rol afzetlint gaat kopen 
voor je aan de volgende lab bbq begint. René, jouw scherpe blik en oog voor detail 
hielden mij op het goede spoor. Ik heb veel geleerd van je gedisciplineerde manier 
van werken en veel respect voor de manier waarop je de afdeling en het RIMLS richting 
geeft. Jij ook bedankt voor al je vertrouwen in mij.
 Tja, Jeroen, jij bent de originele aanstichter van mijn hele traject bij fysiologie. 
Ik zal (je) nooit vergeven vergeten dat je tijdens mijn sollicitatiegesprek vroeg waarom 
ik een 6 voor celbiologie had en ook nooit begrepen waarom je me daarna hebt aan- 
genomen. Ik zal er wel goed omheen gezwetst hebben. Ik ben begonnen bij fysiologie 
als je persoonlijke technician. In die rol heb je direct veel vertrouwen in mij gestoken 
en kreeg ik al vrij snel een student en project om mee aan de slag te gaan. Dat project 
is mede dankzij jouw begeleiding uitgegroeid tot alles wat erin dit proefschrift staat. 
Jouw passie voor wetenschap, tomeloze energie (behalve in de ochtend) en wilde 
maar toch ook soms briljante ideeën waren een enorme inspiratie voor mij en ik heb 
dan ook veel van je kunnen leren. Ik ben ook erg blij dat ik je ook persoonlijk goed heb 
leren kennen. Van het broodnodige ‘bullshitten’ in het lab tot aan onze lange en 
vooral late drank- en discussie sessies in de Kluizenaar. Ik heb het bovenal toch erg 
gezellig gehad en ik hoop dat we elkaar nog geregeld blijven zien.
None of the research in this thesis would have been possible without the great 
collaborations I have had with various laboratories around the world. I am incredibly 
grateful to them for all their contributions to this thesis.
De bereidwillige samenwerking met Prof. Dr. Gertjan Veenstra maakte het mogelijk 
om de verschillende NGS technieken die in dit proefschrift gebruikt zijn op te zetten 
en uit te voeren. Gertjan, ik ben dan ook ontzettend dankbaar voor alle tijd en hulp 
die je in mijn project hebt gestoken. Wat me altijd is bijgebleven is dat je het ook geen 
probleem vond om meerder uren van de dag met mij achter de computer te gaan 
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zitten om met mij de data door te nemen. Dat werkte ontzettend motiverend en heeft 
heel veel geholpen bij de data interpretatie. I also want to thank George Georgiou, 
Dr. Saartje Hontelez and Matteo Perino from the Veenstra lab that helped with the 
data analysis and prep work in chapter 2 and 4. I want to give special commendations 
to Matteo, since despite being up to your eyeballs in work finishing your own PhD, 
you still managed to help met out big time with the RNA-seq work in chapter 4. 
I would like to sincerely thank Prof. dr. Peter Igarashi for our collaborations in chapter 2 
and 3. The results from the HNF1B KO mouse was essential for both papers to elevate 
my findings and further substantiate my conclusions. To this end, extensive qPCR and 
staining work has also been performed by Dr. Karam Aboudehen, Dr. Svetlana Avdulov 
and Dr. Shayan Farahani. Thank you all so much for your valuable contributions!
Dankzij de samenwerking met Prof. Dr. Michiel Vermeulen was het mogelijk om het 
proteomics gedeelte in hoofdstuk 4 uit te voeren. Heel erg bedankt voor de suggesties 
en hulp om deze experimenten tot een succesvol resultaat te brengen. Pascal Janssen 
en Marijke Baltissen hebben hier eveneens veel aan bijgedragen. Door jullie hulp 
verliepen deze experimenten vrijwel vlekkeloos! Iets wat ik zelf zelden meemaak en 
wat een zeer welkome ervaring was. 
Ich möchte Prof. Dr. Markus Bleich danken für seine Zusammenarbeit an Kapitel 4. 
Vielleicht waren die Ergebnisse nicht wie wir sie gewünscht haben, aber unsere 
Diskussionen waren für  mich von großen Wert und ich habe daraus viel gelernt. Mein 
Dank gilt auch Dr. Susanne Milatz und Dr. Nina Himmerkus die substanziell an den 
Ergebnissen beigetragen haben. Danke Nina für das gemütliche Dinner und dass du 
dich so rührend um Lex gekümmert hast. Es war eine gute Zeit in Kiel!
Verder heb ik gedurende deze jaren het geluk gehad om te mogen samenwerken met 
een grote groep zeer fijne collega’s, die mijn onderzoek en leven op hun eigen manier 
verrijkt hebben. 
Mark Hess, het was geweldig om met jouw een unit te delen. Je aanstekelijke lach en 
gevoel voor humor zorgden ervoor dat ik slechte resultaten vergat en menigmaal 
krom lag van het lachen. Vooral jouw discussies met Robert over Mg2+-standaarden 
hebben inmiddels mythische vormen aangenomen op het lab en mij vooral ontzettend 
veel plezier opgeleverd. Jij hebt enorm bijgedragen aan mijn leuke tijd bij fysiologie 
en ik was dan ook zeer vereerd om jouw paranimf te zijn. ik hoop dat we elkaar snel 
weer eens zien. Robert, you were one of the original gangsters in my unit. We had 
some real fun times together and you always managed to make me laugh either 
intentionally or not. I still cherish the 1L Mg2+-standard you made. It should become 
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a physiology museum piece to preserve it for posterity. Maxime, you were the level- 
headed bald guy in our unit/insane asylum and a welcome breath of sanity. Luckiley 
you survived the literal shitstorm in 2014, which hopefully did not result in any 
longterm averse effects. Despite all the silliness we had fun together and I very much 
appreciated your sensible and intelligent contributions to the lab and especially our 
unit. Marla en  Femke L., jullie waren van af het begin af mijn mede-technicians. 
Ik herinner me nog goed hoe wij drieën 1 bureau en 1 laptop moesten delen. Heel erg 
bedankt voor alle hulp door de jaren heen en Femke L. nog extra bedankt voor die 
enorme berg HEK293 kweek die je voor me hebt doorgezet gedurende de jaren. 
Sjoerd, jij had altijd een neus voor goede ideeën en je was ook altijd bereid om dat 
talent te delen met je collega’s. Ik heb in ieder geval enorm genoten van onze weten-
schappelijke discussies en ook veel gehad aan je welkome bijdragen. Verder kon ik 
ook altijd goed een biertje met je drinken en die gezelligheid was me eigenlijk nog 
dierbaarder. Bedankt voor al je hulp en hopelijk zien we mekaar snel weer eens. Paco, 
eeh Spanish guy!, We had a lot of fun together, whether it was playing football after 
work or you introducing this dutch barbarian to the glories of Spanish culture in the 
Spanish cultural centre. Although, we had to burn our clothes afterwards, it was great 
fun. I also feel especifically privileged to be one of the few that actually witnessed the 
existence of your thesis in book form. I am putting it here in writing; it does exist! 
Thanks for all the good times and your friendship. Jenny, jouw nuchtere houding en 
intelligente bijdragen aan het Mg2+-team en mijn onderzoek werden door mij zeer 
gewaardeerd. Gelukkig heb je ook een goed gevoel voor humor en ben je niet snel op 
je tenen getrapt…of toch wel ;-). Ellen, Hee Ellie! Of het nu spelletjesavonden of BBQs 
waren, jij was altijd in voor gezelligheid. Ik mis onze zang sessies in de celkweek. 
Misschien moeten we toch maar eens die dubbel cd ‘songs for in the cell culture’ gaan 
opnemen. 
 
Steef, STOOF! Het lot plaatste je samen met mij in een unit en de rest is geschiedenis. 
Onze voorliefde voor zwaar metaal en slechte grappen maakte jouw praktisch voor- 
bestemd als mijn goede vriend en dus ook paranimf. Buiten al het grappen en grollen 
heb ik veel respect voor je diepe nierkennis en vlijmscherpe kritische blik. Ik ga je 
gelukkig nog vaak zien aangezien we al een hoop concertjes op de planning hebben 
staan en ik hoop ook zeker dat we dat in de toekomst gewoon blijven doen. Veel 
succes in ieder geval met het afronden van de laatste loodjes nog een paar maanden 
en dan ben jij er ook Dokter Steefe!  
Anique, PE-- ! Aah laat ik maar niet beginnen met al je bijnamen opnoemen. Bedankt 
Anique dat je altijd zo een gewillige slachtoffer was voor mijn grappen. Dat was altijd 
bijzonder therapeutisch voor mij en een welkome afleiding. Gelukkig heb je niet een 
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te grote hekel aan mij gekregen en kon je er zelf ook altijd wel om lachen, waarvoor 
hulde!
 Caro, Jij hebt zo vaak je heksenhoed voor mij op moeten zetten om mijn anti- 
lichamen aan de praat te krijgen. Daarom Bossie bedankt! Voor al je hulp met de 
kleuringen, FAM muizen en natuurlijk alle gezelligheid.
 Lisanne, Buurman bedankt! Het was ontzettend fijn om gedurende mijn laatste 
jaar jouw buurman te zijn. Zet em nog maar eens op standje 5 als je me begint te missen. 
We moeten ook snel weer eens aan de whisky met de Huubster en JdeB.
Omar, Mijn andere buurman! Ook jij bedankt voor alle gezelligheid zo in mijn laatste 
jaar. Je karakteristieke lach en goede humeur werkten aanstekelijk op mij wat zorgde 
voor een goede sfeer aan onze kant. Sami, your dry sense of humor made it a joy to 
work with you. Thanks as well for your help with the RNA-seq stuff. It was very much 
appreciated.  Eric, Boxmé-r! Jij bedankt voor alle goede lunchgesprekken. Het was fijn 
om eens een politieke medestander te hebben. Frans, Ik heb zeer genoten van de 
regelmatige bordspelavondjes bij jouw thuis en ook op het lab was je altijd wel in voor 
een goede flauwe grap. Ik hoop dan ook dat je snel weer terugkomt van Frakantie ;-). 
Marjolein, jij ook bedankt voor alle supergezellige spelletjesavonden bij jouw thuis. Ik 
hoop dat we die traditie blijven voortzetten. Jojanneke, Bedankt voor de gezellige tijd 
zowel in het lab als in de concertzaal ;-p. 
 Irene, jouw wil ik toch speciaal bedanken voor al je inzet om het lab draaiend 
te  houden en al die irritante bestellingen van mij in goede banen te leiden. Het is 
eigenlijk jammer dat we elkaar pas aan het eind van mijn PhD eens een keer uitgebreid 
hebben gesproken. Ik vond ons fijne gesprek tijdens de ‘science day’ namelijk ontzettend 
leuk!
Verder wil ik ook alle collega’s bedanken die tijdens mijn PhD hebben bijgedragen aan 
mijn fantastische tijd op het lab: Anke L., Liz, Laurianne, Silvia, Ramon, Jitske, Theun, 
Annemiete, Eline van der H., Wilco, Sabina, Marco, Luke, Mohammed, Claudia, 
Dennis, Peter, Sjoeli, Rachael, Femke van der H., Lotte, Gijs, Chao, Hacene, Mark 
van G., Juan, Sara, Nikki, Niky, Valentina, Margo, Kim, Anke van M. en alle collega’s 
van integratieve fysiologie. 
Tijdens mijn promotie heb ik ook goede hulp gehad van veel studenten. Zij hebben 
allemaal een flinke bijdrage geleverd aan mijn onderzoek en daar ben ik ze zeer 
dankbaar voor.
 Anke H., jij hebt zoveel hard werk gestoken in het uitvoeren en optimaliseren van 
de chIP-seq wat de basis was voor een groot deel van de mooiste verhalen in dit 
proefschrift. Super bedankt voor al je hulp en inzet! Bas, Het was erg gezellig met 
jouw in het team. Heel veel succes met je opleiding tot leraar Biologie! Kelly, Ik ken 
521424-L-sub01-bw-Kompatscher
Processed on: 24-7-2018 PDF page: 189
Dankwoord – Acknowledgments – Danksagung | 189
maar weinig studenten die zo moeiteloos hun experimenten opzetten en uitvoeren. 
Heel erg bedankt voor al je bijdragen aan hoofdstuk 2. Enna en Aline, Al waren jullie 
niet voltijd in het lab. Toch hebben jullie je vol ingezet!, zowel bij mij in Nijmegen als 
op jullie succesvolle stages in de USA. Heel erg bedankt! Eline, jij hebt ook hard werk 
verzet waarvoor heel veel dank! Ik zal ook nooit je fantastische zelfgemaakte afsche-
idscadeau vergeten. Al weet ik niet helemaal precies waarom je het spel ‘Secret 
Hitler’ bij mij vond passen. Ik was hopelijk toch niet zo streng ;-p. Lex, Sommigen op 
het lab vonden je misschien een blaaskaak maar jij was toch mijn favoriete toeteraar. 
Jij ook bedankt voor al je inzet en je bijdragen aan hoofdstuk 3 en 4. Markus, Na het 
vertrek van Mark H. kon ik mijn hart niet op met het verschijnen van een nieuwe 
Duitser op het lab. Je hebt het fantastisch gedaan en het was bovenal ook weer erg 
gezellig. 
 Cas, Julia en Daan, Jullie waren dan wel niet officieel mijn studenten, maar we 
hebben samen wel een hoop lol gehad. En Daan jij hebt nog bergen qPCRs gedraaid 
voor hoofdstuk 5 waarvoor heel veel dank. Ik hoop dat we mekaar blijven zien voor 
een biertje in de Kluizenaar! 
Dan wil ik ook graag mijn vrienden en familie bedanken voor alle steun en afleiding de 
afgelopen jaren. Marco, Gerhard, Robert, David, Maarten en Sebastiaan, ik ben heel 
blij dat we elkaar door de jaren toch regelmatig zien. Ondanks het feit dat we 
inmiddels door heel Nederland wonen. Gelukkig delen we een aantal passies 
waaronder goed bier, slechte muziek en harde humor. Onze proefavondjes zijn dan 
ook altijd combinaties van die drie ingrediënten en een welkome afleiding van het 
werk. Bedankt voor alle goede tijden en dat we dit nog lang mogen voortzetten!
Liebe Oma und Verwandten aus Südtirol, leider habe ich wenig Zeit in Südtirol 
verbringen können, aber die wenige Zeit in Südtirol bei euch war mir lieb und teuer. 
Danke dafür und hoffentlich sehn wir uns bald wieder.
 Reini, auch Dir möchte ich danken dass du Zeit gefunden hast und mit mir so 
manche Bergwanderung gemacht hast. Ich hoffe dass du jetzt eine Idee hast über 
welchen Transport ich gesprochen habe. Danke für die gute Zeit beim Bergwandern.
Karin, mijn lieve zus, Het was altijd fijn om elkaar zo nu en dan eens te zien. Al was het 
maar zodat ik een beetje bij kon praten en dat jij weer eens vis kon eten ;-). Het is ook 
altijd fijn dat ik jaarlijks in december bij jouw en Joris terecht kan om te slapen en uit 
te brakken. En dat ik nog steeds welkom ben, ondanks het feit dat ik midden in de 
nacht bijna je kat heb laten ontsnappen ;-). Bedankt voor al je steun. Nog even en dan 
ben jij ook aan de beurt!
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Pa en Ma, jullie ben ik natuurlijk ook veel dank verschuldigd voor al jullie steun en 
hulp door de jaren. Het is altijd fijn om even in Almere Hout te kunnen toeven in jullie 
fijne tuin en door te spreken welke verbouwingen jullie nu weer gestart zijn. Jullie rust 
en kalmte stel ik altijd erg op prijs. Bedankt ook voor de fijne tijd in Süd-Tirol en dat ik 
zo nu en dan met jullie kon meeliften om Oma te bezoeken. 
Lieve Elja, we hebben elkaar natuurlijk twee jaar geleden leren kennen op het lab. 
Geen idee of het zo cheesy was als liefde op het eerste gezicht, maar ik ben zo blij dat 
ik de tweede helft van mijn PhD samen met jouw heb mogen doorbrengen. Je bent 
een immense steun voor mij, zeker de laatste maand van mijn PhD waar de laatste 
loodjes me erg zwaar vielen, heb ik het mede door jouw liefde en zorg toch goed 
kunnen afronden. Wat de toekomst ook mag brengen ik ben blij dat ik die met jouw 
mag delen. Ik hou van je. 
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